var title_f34_7_34928="Calculator: Nasal Canula Oxygen Fractional Inspired O2 (FIO2) Estimate";
var content_f34_7_34928=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"NasalO2FIO2_form\" name=\"NasalO2FIO2_form\" onkeydown=\"clrResults();\" onkeyup=\"NasalO2FIO2_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Nasal Canula Oxygen Fractional Inspired O2 (FIO2) Estimate",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         FIO2 = 21 + (NasalO2 * 3)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Nasal O2",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Nasal_O2_param\" onblur=\"NasalO2FIO2_fx(); minMaxCheck();\" onchange=\"NasalO2FIO2_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Nasal_O2_unit\" onchange=\"NasalO2FIO2_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|L/min\">",
"              L/min",
"             </option>",
"             <option value=\"60|0|L/sec\">",
"              L/sec",
"             </option>",
"             <option value=\"1.666666667e-05|0|mL/hr\">",
"              mL/hr",
"             </option>",
"             <option value=\"0.001|0|mL/min\">",
"              mL/min",
"             </option>",
"             <option value=\"0.06|0|mL/sec\">",
"              mL/sec",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             FIO2",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"FIO2_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"FIO2_unit\" onchange=\"NasalO2FIO2_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|%\">",
"               %",
"              </option>",
"              <option value=\"100|0|fraction\">",
"               fraction",
"              </option>",
"              <option value=\"100|0|ratio\">",
"               ratio",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"NasalO2FIO2_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34928=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function NasalO2FIO2_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.NasalO2FIO2_form){",
"",
"",
"doCalc = true;",
"if (Nasal_O2_param.value.indexOf(',') >= 0){ Nasal_O2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Nasal_O2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Nasal_O2_unit.options[Nasal_O2_unit.selectedIndex].value.split('|');",
"Nasal_O2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"FIO2 =  21 + (Nasal_O2 * 3);",
"",
"unit_parts = FIO2_unit.options[FIO2_unit.selectedIndex].value.split('|');",
"if (doCalc) FIO2_param.value = fixDP((FIO2 - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.NasalO2FIO2_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.NasalO2FIO2_form){",
"",
"FIO2_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f34_7_34928=null;
var title_f34_7_34929="Serum sickness hands feet";
var content_f34_7_34929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serum sickness of the hands and feet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2uBUmRUl644xxk05JTFIkcznHRXz19jT9JjWRSckgcYPatSbT4po9r85H5VwHrSkluQqR/ESRngAU90DruLcduP0qvbE28uy4GVIwJPX0BrUEalQSeevrigmTsVQi5wcKRzzSkxgZ6nuRVkwIVPTpzSCAbuM7SOnYUE8yK68nC5z61JHbk8E4PtVtYgDxjNPCke/rTsS6nYhjt1HGBz1NSGJeQAM1IAAvUVBcSqik9PTFFkQm5Mm2qAMDJqJ5UjzkiqL3EjqcMVHPJFVnjdx8z8EgHHJpXLVPuX2uUyB69KjNxkDB5PIqAREkqpHPpT2hYKBtHrSNFFIUSuWYdumaRJtwAJJwOoNIYn2dB9RSfZ3UjnihBoTZUoCAQfrT1baGLbt1VGhmC/KwHcU7c6j52ye5AoCxZ84gDPQUn2jjg556GqrEuvt69KniQMNrDB7Ci4uVCPLK5PPXnpSorN1due1OWLpnIGccVKIsHODmgG0iAQ5IO9s9OT1pRF8x+9nHUmrYjGPX1PrSkcjjGKCeczprTzcgqAR045qo8U8O4RnKk5xjpitrGQCPWo2X5ehyTzSLjUM6aRpPCfiEupXFtKP/ACGa/PRTg5r9FdZTy/CevNnINpMf/IZr4F8I6BLr+qx265WHPzvj9PrXdS+BHlYmLqVrQ3ZXg0ie6sjcwjd1O0dTWYQQSCMEdjX0hZ+E47WxCRQRqFTBZjnGK808SeD2vBcXljGyyA5OB8kn+BqueLeh1Vcrk4c1LVrdHnsETTzJHGMs7BRX2L8FvCa6Np9tKsQ8xkxIMevP868Q+B/hJrzxLKdUiSIRgBBNxk57Z619iaDpp060SEfMFHBx0FU9I27nDTg4JqSsaCrsC7QDkcinA4OMZPr6UZLZwAPrSsMnjIHesyhg3LkZyRyDRnPYk9wOop/A6YPPU0/cMk46dwOtADFHAw2TS5IYDAz3pVIP3TgUrfKhIPPqaYAxO/GC2Oagkkz0HB6jtSySNs9Aw60g+XJI47/WhsCN8uc44H8NKRkemOMU4HaDtGM9/WiNSqNnrjvSEIxyQOntThJ82MHYKcoPl4xk+woiUMmSTupgOdixYdsZphk6ZxjFKWByvUmmsF4x06fWgQpYZ5AppYAkqCGpeDjHT0pGYZyev8qAGu3ygEZI9ajZ+T3J7Upbhh2Pf0pmPnG305NIYqAIvIyx5p+e386TdjtSHkdfxoAXIBBxmm8bsk4pD6D86M5GP50Aed+HfiB4dubUGW7+xSKPmjuE2tn2PQ10UPirQJEBGtWXI43SgH8q+c5bXzZt5RmBYZUcYFMa0jaQoWBz0GM45rDlifRTw93ufSra1otzE0Y1OxZOgxMOv50y11uxtWEU2oWhQ/dbzlwfavnM6eWQhVG0dM9M+tKun4k8t+SeenBqXFdxLDPY+mDr+hRoC2r2KKeeZlqCfxd4bgGH1qy3Z+6rhj+Qr5w/sSdkBaNiG56Y+n/6qtL4fnGDnPGB8uSaTcV1JWCb7nuknxF8Mxtta8lz6+S359KkT4heFSONWQH0Mbf4V4rFoV0wBeUhT2PUVYj0GWNeWIIAxj/D0qPaRRp9QT2PY5fHPh3aSmpRt/wFv8KonxroVxnbqCYHHzKRzXmtvoRWPLrlgc4Pf60r6DkYTKg9gMCpdSLGsHynqMGu6VPgRatZkkY5cCtiGaxbBF7bM3XiQc14z/wjzxqoxnPcnqKmg0DlAIhuPOal1Ei/qXN1ses3/iLRtPUm4vYmY/wRfOc/hWPJ4+0xF3R2V9IMddgWuVtdIbaF8shfUVaTSgckqzDoD0wah1hrBU1u2zdT4h2ARTJp18in+6Af61LD8QfDzTiKeW5tSeA8sJ24+orn/wCy8JuA7AEEdqoX2lb4yEQADJ5FCrdweBpvY9EHifw8zEDV7Q4GT89RS+KfDw3B9XszjHIfpXkp05ISVC/Kepx3qSKwRgsbQ4z2I61XtkNZb15j1OHVtKvmC2Gq2U5HVFmBP5VookvGwqc985xXjkmgQmQOkKbmOcheuKVbFogBHLPE/Yo5GPpR7VA8C+jPbI4m2gMTnPX0q0FIGSK8N+3a9ZbWs9WulXsGfcD9QajvfFnix0B/tJ8A42pEFOPUmrjNGE8vqN7o94wccc1Q1HUbOwi83ULy3to+7SyBR+tfPN1rmuEl7vVr8xMTu2ueR+HaqEjW0sbytMZjjhZWyc/jQ5mlPLL/ABSPdz498NNK8NtqIu51HMdupc4rT0/xBZ3pUhJoEY7VaYBQSeg+tfKUNzJZ6zDd2Z8qeFskDgEd6+mfBUCatpOn6rKoELDzY485O7+8T7c8UXb2JxWEp4eN22dF4hiZ/COuIv3ms5wPr5Zr5p+HOiHSbG1jRVXzMNIWH3nHcE19P6l82g6kPWCT/wBANfPukPHCke887sISOpP8q6+a1NI4MJS55yl1NzVEnuINqS+WikeZheT61DpscV/E/wAu2A/KvHXFaMf723KsMFzgf/Xp1rbGKRtmAvUDtmubmPUStGw1tAs5IEQwrjHynHenW1vqli2bHUryONeAnmlgPzrbtZRtHmAk4wRjvUpZclQOOm30HrVpnFKTvZq5DD4j8QQgYuIrgDqJYxz+IrSt/G92o/0qwikHrGxH86zJEiZhj5c96q3FhIB8pJ+ho55LqR7KlL4lY7K38ZaY6g3CTW591yPzFbVpqNhdgG2vIZD6Bufyrx65ilH31wo9OoqFCd67Xx3yetVGs+pM8BFq8We44+ftn9DQRyMjIHWvGbHxDqWmviC6by8/dfkH8DXYeH/iDpd7L9kv5Fs70DkclX9xWsaikcVXCVKeu52mCQpPNDLkLz26U23lilTMEyS8clWBqZgdn3cHrirOZ6DCd7cg7cYxSLnJySB1Ap4Uqp4GT+tBwPx/SmIQc5OCMdhT2Ix06ikdsA8896jL8cj5cUANIbdu79qCecHGKUkYAYHFIvDe2PxoADkjavXpmm4GMcj1qTJHJ/iNNBO3/DtSAhZSeT+VG04zxj0p7ZwMnNB4UHnPoKAuMOAeelAHXil/3sZ9qUZAJb9KAGMvfpjrTRnuKXJ5yMH0oGc4NAHzHFbu+5QdoGdvufWnrpzkhNu4DDMSePeultrNRHwgXdyVIycVqRWqIoIhy3YDkmvOdY+39gc1b6RLKgCAKp6A8Z9a04tKEKKGTr/dP61uxwbSflIHT6VLFbbnK7enHSsnUbDlSM2OzCAlcHB9+aTaySkbc7ew5/CteUSIAoTB9fX3p9jZmNw8iBmY43dMVm5FKyV2YjwXBJeSMNnn5e9W7ZGlVTt+btkV08VshJQgdCSapG0wwHbPAxU3ZKqxloNW1yg+7uAxxVyC0UIGkwSOBx+lXbWziUBmJAHarJjRlygyM9OxpNs451leyKC2isoZFBzx04qZbNQRlMZ6GnvehWww2qOoApJdRiKDadw6AD1pXJvUeyFSDYCPLw2e/ekliUksAPTB4pFvkxhDz6+1U5LxmkUH7w55HUUmxxhNssLInCrtOO56Gql1IpwiJy2c1Kl9GnG1cY9MYNVri5Eah84c8D6U0awg09iq9rDAMlCSCDhhUJEbxbWTAAz9aivbzMXz5zzgelMtryMou4EcYBPY07HWk7XY5rqIIN4wQMMcVCl1BNCpQDfjGMUXssS/Kw3cck9ao2c8caGMkEA4GKRrGCcbkl0eCXQFQATg8/Ss+6UMSIz371pS3CJn5NwOeT2rMu7lFtxtAAOe9O5pCN+hSkhaQDCDywMDjIrMvdNhkk2zRAjOQRxXSW9xugjCqFAGcY6+9RTiBtvG4rknPHPbFUptFumn0PNtV0m4idlsyzKBltw6Z/nXtnwq8faTcaLaaLcqNL1C0jESwzN8suO6sep9q5NI4G2kx5/vZ6jmqWqaHZX6uGxk88D9a1Vbuc+JwEa0eVnv09zHP4d1V4XDKsEnI5/gNfOZlItxJO/z7eUBGSa9H+EFhLpvgDxRDPO80QMhTc2do8rpXkc6pMwQ42Jxnrx2rvj70EzxMPT9jXqU30sdVomrSyqkJcksRkjnaPWume7EZVCcqT8zD2rjPDSJbgqJFbd1BBJA966SWJp2Gw5TPBBxWUlY7JKM5dkdDYMpYZlBVemTg1eVFYEtJk/3s4Ncmbh4WWNdzsCAO34+3pV+SeYsVjXMoA49KSZzVMO77m2roriN1zu43elTNkKSSGAPGK5pbomULIzhs9e2K0TK8rAQyBR6k9aFIxnQszQuLdJIwzkZxxxzn0rDvotjEKu0YORjAq/EzI7hmLEH+LoPpUc8+6QJNGMHI6/19aTY4RcXpqcrrLyKm4IoRehHIrhdJ8ybxGJt3yB+W9K9O1uyZtNk8uPCkcLnPHqK4zQ/DkkIEzblX/a7GqUuU9ClGEqbbN221G5gmMiSyxgHAZGK8fStuHxVqVsivDfz9cEMc/zrm7jTpnZFZip6Fj3/AMKsRQP9kAbacHLOOtLmZlLDU2rs73TPiLNGwW/iSZe7L8rf4V12n+LNJv4wRP5LZ+7KMV4oLMyOQOQcZwOB75qRUaNTtOSnXPpWkaskcVbL6T+HRnv6SxypvjZZFP8AEpzmmn614hpOtzxBTbTyQuP7rcfSux0zxrdRYGoQrcR92X5WA/ka1VVPc82rgKkNjvyAwG3v60ueDwKz9H1zTtVUC1nXzDz5bcN+XetJh82OMVonc45RcXZiH7pP6U0ggn07nvTjyOvSkwdvPFMRGwA4A9yaVh823pT1+7nOPemtk8nj3oEM45Jox6DJpS2B7UigjJ6YoGMcHtyaO2Mc07tjHGaXGc9vekB47ZSo6rt5J7EYqym4SKDnHJrx3SfG09nOqSksikDK8/l7V6lpeo/boVmtzkHGcjp/9evFnBxP0Ve9sb8ETyA8qEB59qsAiFyNoy2BmsyKWVXCpnkdOpNOvJp2QeWCB6+lSc0qbcrdDQMymcgqCDxnHSrEd3HHjaOemAea54RzlgS+R3A4q2sJAbL8CkTOjHZmpFdLufrgdiakaZQVLckc89qyFEkbkEKwPcHNTtNtwCn49aLGTpLoabXhCZY4DdCDSi7JHyEc9M1Q83y1+dQST196Qz7gMYHXPFLVkeyXYtXcscjBgCCT25H41nqyrIFZz14OOtONwEAQ5Jx1x0qteSIYgxQeYPUYyaVrmsI8qsaCnhtjZx+GRVZ7mJdpfPBxuxWcdR8okOwGPlLCoZNTtWyDLENvqR/Wq5ClHUv3V0oQDbuz3HbFVJrotg44C/dBrPvNTtUUlrmJV93HFc3qfi/R7IBmvfPkH8MPzk/0FVGDZei3Oi1W/SK3AYgk/wCelZEviS2MSoXEOBwWYAk/jXFz63reu3Hl6NZMiN0dhlhnv6Ct7w98PbSNTPrhe6un5IJO0f41pypbjv2NiHXra4k8oyRNNgEgOCT9OakW5ILMqgZ6e1R3Hg/QYQxNhCh7EE9fX2rEvPDLwo0mmavdWuP4Xbevt1qbRZrCTS2Oma7DRqGI59+RxVK7uoo7cgFSRk9ePpXNf2V4mUMyXtpcJ/trtz71Sm0vxY7sqQWy5HJzkY/GmoruPnSV7Hb2d3HJbw4YqxGRmkbynLsepP3W/pXP6TpGu2Vqy3csF2gHyx5wfoDSPr1pDd+VdobaZTjbMMc/XpUuOuhrCpobcakMW8tlc881SkvMPIC2CTnGcZoi1OC6UgTLKDwNrdKzdTAKEZCs5A64KjvU8p1RqJ7nrXw1l3/DvxQ/PCzZyf8ApjXh0d2QVJG7Hp1r2L4XyIvwu8XuGJRVn5P/AFxrwOG4XjJ5J55617FCP7pHylWcVi6vqvyO50W5EhY/KrEks3QkV1MOoRNCvlcqBzjivNLO+EakKMPkHcD1rQj1TZh8/MT93Oc0pU7muvQ76PUg2xyu4dCPb/GrlteIxB3ksMkr24rgrbVmGCoAXcCQTnFW7TWdjsxChjwAD2z1NZumDTsd156Tqv3SrAkhhgj8KeXAtxsUcHrn0rkY9dUDBUEc859PSp4fEMYjXaOD2HUGpcGQos6UTt5iytghOxqdyNw8w4x27muai1ImbzQQ6KoMmP6e9JL4gCT7ZFIbllGMkjtU8rK5G3odMZo5QyBQqquA5Oce1Fr5DSGJ+pwOc4z2xXJ2usYuDIW3K5+4RjFaV3fW0ke6OXbJ7HBzSaaH7PobNxDsYsVCsiEKM53HNVxYhWjmZiquMfMOp9sVycOs3Vjdhpx5qqTs39DTk8Ryw/NIwMLksnolBosLU6M7STTUlAKl+ByDx3rOvtOwWMYAY9ST2qK28SRkCS6YMAOQBtB4ODU8mrQGKMrIpQZBLHk56Yo0MVSrQeph3MRjuoxGAm44/wD11evpp7e1zGu5wOTjIPvVkQwvKZ8qoPG3rk5rUubGMxgb8LjoelCKqTV0mjzqbWLuECRJWiljO4FTgg+v0ruNF+Iuppaxma6ErFc5kUGuQ1vR5DKDaDzVf5Sd3UjsPwFZX2OYQsqZ2pwyk4NUpWN54SlWV2ezWPxIlcjzrWJh3wcH8K6Kz8babOR9oWSDj+IZH6V4HEPOmiV3ZGThlJ/nV1rsxsIzMdw4GeM1SqyXU4auU038J9E2mp2N4o+z3UT+27B/KrkmQMHnI6Cvm6DUWVxGHZcnIc/yrp7DxLqmm+W8d3I0Q7N8ykVoq3c4KuVyjsz2Y5wB1PTihhgc9TXG6H49tLlli1ALC/A81fu/iO1dgjrIqyRsrowyGU5B/GtYyUtjzatGdJ2mgP4cUmOMg59qkZTnFRuMnt+FMzPhTU4prO7/AH+Axwcrxkf0r0rwtqaCzi8qcENjAB5B9DXI+LbQKpZmG77pAH5VY8K+Ibey0+3ghsjLfoSoC/xH1rz5Lc+9jK0tT2KyuJp3yMhAPvsOfyqebV7S1k23t5GG7Kxxn8K5bSIdW1SzEt5d+WZDnZCMbR9TU6aPFbAMMs4zmRvmZj7muayvZs6JRT6G6fFmj2xUKsj55IijLA+9VZPGUDzKltZ3Em8dXAQfrWe8lqEbfnA6kNwPUVhahqsDIYoo1Z8gs5xgVcKal0OacYx1Ovj1yeYnzoY4JAcAbw2avJqG6MbgNy9h2rzaJlVjIHbf94D0rUjv5Io8yOWOOCSKqVLsQpK2p3SXXnRho2+QcY75p63SqV344FctpupPJCBIQuf1q8sxKkknHr/9esXGxSVzcluVf/V4IA+8B0+tROzMhJwV6gY71mJMcHy+QeuTUhueRvK9egpWBqxFfzFUfYilm545x9a4nWtBjvEYFnN5cuBuJ+4PYV1d3cPtyiDPbnt60mnws1wJWILjqf8ACrTaLsupzb/Cm2ji+a+Y7lyCe1TaP8PrC0+a5lMrKc8jAI9K6jW9ftNLtGur+ZI4EGST3PtXgXjnx7qniW9kjsHmtdMBwsaEqX/2mI/lWtKM6nocGKxUMLHVXb2S3PpHT4Le1iENuiRqBgYWmXAYRMUGBnHWvnDwh4d8a6vhtFGqtETjfHIyp+ZOK7V/AvxOEQQy378HO26/+vTlh7P4jKjmHMryg19x6DqE6jLSEgY6kiuZ1XxJplpbuZL2AOvBXcCcfQd65NPhf47v2Au7e4w3H7+44H610Wj/AAB1eRlOqalaW0X8Sx5kbH8qFRS3ZrLMZW92NvVkNr470a5nMQuJIg3AZ0Kj/wCtXQ6d4gtbrbFb3lu8ik4VJASR7Cuw0H4NeEdOjX7VaTajN3eeTA/75FT33wg8GXDrLHYXNq4OcwTFaHCL2IjmEk/eVzk1uHLqOq9sd6rTQR3VwwniiliOBtdc10mofDjUbZ9/h7WfMjH/AC7aim7P0cc/nWFqEOsaWmNS0K8Ucky2w8+Mn/gPOPqKydKS2PRp46lPS9vUwtS8JaZdDfbBrWT+/A20flXN6l4Xvi6qupyvkhQrk5xXUSeILKEbBOI2A3FZ0ZDx7EVmX2u6UZo5RfI8pbkJzj8qEpXNr0mtWej/AA80t9C+DPjMSzNNuink3Yx/yxr5dsdW2KVc8bieecjNfXHw+tX1z4U+JbS0dZDdrNDGS3GTGB/WvHrT9nLXnX9/f2asewJ+UV6+Gf7pXPisxnKli58hwNjrcbhi5PynG7rWoL1dyAPhW5Ga6y4/Zy8QQn/R9RtZT1yuVGPxrI1D4M+NLMESQJMfuqI34IrayYU8fOKtJFNb/d8occdRup6XeOj8diDWdc+BvF1vP9nl0a98wAMBHHyfUU1PDniBJxjStUJz2gbaPrjrQ6R1QzJX1NZbtk4Vh+PNTJfuFOGwTxz6ViTaXrsaNu028Vh/fgYEH04HSqEk1zbzYnjZCud25CAaXsjRY6J18erSRqQGKqOoHepDqbXToFfZjkE9yex/xrg31ZJdsTNjfwDnuexq1Y37RwxIXV5Jc7uRwe2fpUukaQx0HKx2f26UTHa5JH8Q9fSkbUZlcZY+/v61xtnqVx/a9wgYtCYtw7Y7datT6oifLnBBxnk1HsjaONg4nYjU/tDL55DDvzg1ajvYZokidiq5x8orhbXVUmchVKuACFPcetXIL/kbeDnGKl0TenjIvZnaB7dFdgScEBQfSrVrqEHnqJTtUevY/wCFcaL5s43c9MGnLdbwT94njnr9azdE3WIUtGz0I+IYl5gHKnqR0+nrWiniGF7ctJIoCkFQD3/GvMFvWSLbkgjoaja7YjaD0/h6UvZEyVNo7u+1GzuiVaVkXh045yevTpzVIl7RY2ZhIxIC7nycd81xElyIkDZYd60o9ZEkKhgGZTkZGfzqJU2jrpOHwpnUW13HPnEWWLbwcZJ74/rVgQ/a0Z7i3eJsjCsPve9YOn65HFIrTRpx3Bxjp/hXQP4ssHhZZIix3blYjPXoP0rOzCopRfuIiltJ4IiwQ5GNvHSrVnfPKAZgqoOOeoplr4nsVSQRkjK5VJOhPcVThvILlpPJEYYkFiOgNGxMqcpp80fmad7PDFIrIArd/pW74S8azaXMke4SWrY3Q7unuPQ1g+Vb3Fuyu4MkfUbu1crPEsOo7zKPKHIPWqi7HJLCwqxcZH1TpOqWmq2X2ixkDo3XnlT6EVbxnFfP/g7xDPpl7GYJcrkBh1DDuDXuml38Gp2UdzbElH6jupHUV1RldHzOKwzoTt0PmLXrC1uoSkhG45AK9R9K81ZZtI1ddpJ2vkMe9egxpdXMZeNRyclW61zHiWKRLhJZY8lSN/v+Fcb1R9fOnrc9g8L6it7pMUwCgOPuYxg1D4h1m00yB5pZVXy+CMZz+Febab4qs9Dsne5uS5Jykajk/Qdq4LxP4sutcu97KI4FJ2Rg/qfU1McM5Sv0McVmtHDRs373Y6XU/Etxe3Mjq3lREkhB3+vrTrTV9zR73EYA+6vUn61wA1Bx1GW9c1LFqTjAEZY+1b+ymjzY5xRk9T1q2vofmbepJ44rc0mKa8VXKEZPGT0rzvwjpXijWCP7I0p3jb/lpL8qfrXtnhfwLryQA6rqlvACPuQR7iD9TWc1od9PFQlrr91ij9gaGJsq2089cg/hWbf6ta2D5nuBABzyeM+4r1G18I2aIDPeXV1tHSRwo/IYqZPCmjlyRptucnhmXcT+dYqPcp4uPRHkMfiXSlQMuq2xHpvx+GKq3PjrR4TgztKR/cy2PpXstz4M0G6RxLpdsc/3YwOKzk+GnhX5t+mQ5J5wOn0o5Y9TN4t2/r/M8Xn+JlqhZbXTrmU9t0gUH9DUP/Cf67qCiLSNLEbuSOA0rZ9sCvoCz+Hnhe2YMmkwEDuVrprLTNP04D7DZ28BAz+7QCnyw7GE8ZO/xfgl/mfMmn/C3xp4uu1udYV4EI4e7bAUeyV6t4P+Cfh/Rik+qsdSuVOdrjEYP07/AI16dJLhMyMFUHqTUcE6zBtjBwMjIOR9Krm6HK5Sd2v6+ZZt4IbeJYIYo4oVACogCqv0AqUIuMA59zVbzAAMkDAyead9oG3HJI56daRi4sc0RIUn/Io2c7lzjpiiOUHjqT+lTZGDng/yoBtohwwYAKOnNKHKjHXn86e45GASP51COhyDx1+tALUfgHAIyKcoHXAGTxkVESw4BAHoaVnYsQOPWgdhtxbW0xbzoIJAODvjBqGPStMj/wBXp1kp68QKP6VKJGGCWGenNOWXac/L7gCi7DlZe0m2gtbK4+zQwwh2Zm8tAoJwOTikQfMSuDnq1S2LeZp8xx/e/lUO75FB6E8iu6n8CPNrfG7jyMMCSPwqQAlsYHHrUXAIIIAqUDjA7dDVGYrkFgrDDHknFOBC/LxtAwQBSA5JBwQOc0/K5GQAT3FAXI1SNUCgKF9MZIqrNpNhcYN1Y2sxPG54gSau4XzAR1p5AMg2ng9jQFzkNQ8AeF9Sjmjv9BsGVhgeXEFOPYjvXE3f7P8A4LuPOMVve2zMPl2zE7foK9kYEMewxTGUh8j7p796rmYrJ7nzbL+zZHM5a21+eJF4Cyx5YDvQ37ONwYlNp4ll3RnK+bGMZr6RP3hx/wACpzFFYcHJHbpT55C5UfJt78DvFNuwezFjfsnVo2Me8HtWbN8M/HMIG/w87M2MJFOGIPr7V9hfIpAAAB5wBwaAFjHyDGT09aftWaxqzjsz4tuvDuv2DOLvQNUSUHJAi3gD6issztCNsqSwsOMSxspB98ivucbYx125PQ1Tn0+xkDCe1t5EY5w8YJ/WjnXVG8cXUR8QSXSjIjlRj04cZqtNqG1S20qA2C1fYV18NvCFxJLJcaHaO0nLPtwa5i9+BPhCd3+z/a7dZMttjkJA98GqUoFfXZs+WG1UNfxoGIiVSxGep7Vdj1BWjwCVIAPyjnNexav+zfc+e503XY5IyMATRbSoHTkV5/rfwr8T+GruSG+sJLi3Y8XFsd6kevqKfLGWzKpY2cXq9zDOpooDMCpB71E2sqnVWb26Y+tQ3tjLbsftZELrxtmUqfbr/Oqv2OF3eS5vLcRnGcOOfwpeyR1vMKqXus0YdZ3su1DtatrSZZZuVcQRMRln7D6U7wda+Fbjb9q1OJb1TgROSiAdsMeK6W98MT/aHezUPAx3KUOVHsKynGC0Oihj6s9JTIjpcrGN4dUR8HgY4+mM1VvtMfzXNvqFrKuMncShJ7jFWV0W6VsMrxhf4gMVYTRHGGCNMCD1GK53BHoQxjjrzahotrqNqVItQ6nujAgV6r8JNTu11/VtNnV1gMaTorDGGxg4rg9Js5rPkBljByTIcBfrXbeE9Ua71aGPRAl7dIMO2fkRe+W7/SrgrPQ8fMK3tE+axxMEMX2TzoygAJBx04461w3jF48gswMn8Xv6c13UEUdrpcNuh/dxLg+Yf515342eNZQkf3WOR61w09Wz6atJRiea6qu2/mA6E5FV0jZyMd6v3sYfUnB7HH6U+3hXHODg9xXoOfLE+FlhXVryfS7HWOl+dIqBWlcnG1Rnmvcvht8IBcGO71mPZHwwhI6j3rivhzeW1jqQWSJTIxwrntX0z4YvRcxqEYFDjrWE5O17ns06EKEfcjqaOnaHbabarBaIqKowPapfsbp91uSefpWuiAjPB9qGiLYPpzWL1M/bO+pmJbOuee4zn0qUIy46YAI49auNHgZwPfBoCZ28kE9PegHUuVFUxrkkDHGPWnRhQ4x9/HXHSpmQJzjp60zDsTk8c4BGPypWDmuRM5yNuSSO/GacOPm3fMR1pXXDbjgkeop6gkAgdR3pWBsrmztbh907NJ0G1jxx7VbCQhAioFHYKMYoWPIAbP0xUgQDB9vSqSJlK/UrNFFtPoOOBnNAj2ggfKD0OOQKnLbSMDbzwKST7uGIHtSsHMypCNknzHgcDNWYpuMhjz6ioZohIiqxx6471C1oQpMOQM5zk5x7elFinZ7msh3E8847VHtY9CD35rPDTgH5snHQdvxqSOS4Krk455xzTI5Gi2Y5CQV24PWoZImJGR+PpTxcyKCWXOR2pftOG2lffinYS5kQMjBSNpOfw4pEc87h9BjpVkueu35cd+9NZwRnb15GO9JlJs0NM/5Bs3P97+VVo23D1x39atWLZ02c4x97jHtVIEDofc4rup/Ajy6/8RkowVJyMgfl7VPG2Y1BOB7VWYqnykjbnAJp0I2LtGB6AnrVGRaOcDC0bsgAY574qBHwx25YgYb2+lJFvLkS8r3X0/GkMtKFIwASadnpg8j1qJZMnLAAdjShhnBGc9cUCJCDgkcHqCaGwMk5OfXmmswbgHoc4oLYXqTnqKYCqvB4yR2pe/qMcVExwM5I9gacuQo/umkAmdx59acgDAjHHX3pAePl7c0ofKllALCgBzbWBGM4FMI3DBxx0JoGc7mBJ7AcUY5yeB2oAbIiuME8g5BPOKVlzgBsHrRnMnA+UfrSAnJAGO4oGDBiny4Djmk2l4zkAkjoelKRlxilJbIxyKEFzH1jwxoutIG1TS7a5cDALoMj8a5e7+D/AIKvY1M2kLlegRyv6V6E2Qy85Ujt60YOQOg9apSkuotDgLX4Q+CIIwp0WOYYxiRiQKr6l8ItBki/4k9zf6O4/wCfSY7f++a9HHBIP504+3fijml3BO2qPE7z4X+MYIv+Jb4sjfti4gVuPfis6L4b/EeUhJ/EVlEg43JEoP14Fe+47A5OO9NOAc96fN5L7ivaT/mZ5BY/BxrpoJvE+v3t9JGctEh2o31r03S9KsdKtRBp9rFbxL/Ci4rSPrxUZODgnrScmxXb1bueVah8LdcmjxBe6aGzzu38j8q429+A/iWe4aVrzSHf+El5MD8Nte9C8mBIMpJ7c017ucnHmPk+h6Vyx9nHZHtyxOKno5I+Zm/Zw8YO25r7R9xJJPmPyT/wGnj9nPxcMAXukY/66P8A/E19HPNcyuUW4mBxnhyKxdRXVVykOoXajnB8wmqc4PdHNChVT0kjxS2/Z+8Y21xHLHeaTuU5/wBa/wD8TXp/g7wJ4o0hD9un0+Q9wkrYP6Vj6xqHiWxY41W+JXkHzTirehfEi+jZYNdlYKeBcxjj/gQ/qKpKDjZGzWIju0ep21hdLEFl8nOOdrH/AAqQWVx1zGPxNZdhq1xcQLLDMJomGQwOQfoasC9kclvNlQg44PFTywMHGr5F37DMR8wjPPrR9jnyfufnVf7bcKnEm49ulRG+uTw8pVh1IAo5YC5ankWjY3BPAXHbnmojp91xgAkcj5qi/tG6jADS71/vKoJ/GpEv7naCZdw7HaMGlyQ8xr2q7AthdA/cXHu2acLG5IGUUevz8Ui31y7ZWQbSOPlHNSfbp8D5xk8AbRRyQ8wbq+QxbO6ycxDJ/wBulNlcsACgH/A6cb+cAAsuTxnbTkvbgnkr/wB80+SHmK9XyGiwm6MgP/AqPsVxu+4NoHA3CpDfTKPmCH8DSNqEoxwn5GjkgK9XyIo7GdesYz/vCj7DOAR5f6ilGpXIUkrGfoD0oXUp9mT5XPT5T/jRyUx/vfIQ2U4XiI5PXkUG0nGQIfxyOaUanOeFEZJ/2TTv7QuNwGIvcYP+NHJTF+98ivJZTnA8l8euRxTDaXC/dhkOf85q0up3G4gpGR2xmnnUZgcGNOvYGjkpjvW8iqtvcK3+qkwPala3nb/lkwJ9qvLeyH+FKeLtz/Av54o9nB9SHOr5EdtE6afOpVgx3EDHPQdqzo45mZ1W3mVlOMlcA/Stu7maGymmRcskZYA+oGa5VfFN7v5tbcqenzEGuhJJWOSbcpXZfKTs2PJmMi9ipA/OnSwSvGpKS5XsFOarx+JLh8YtoyT/ALRxU6eIJSBvtlX33f8A1qNBco9ormT5SrouMHCndmrCJJDGqqrlsckg01dYYgZhTJGcB/8A61NbW2V1Btsg9w//ANajQOUmklKbT5bN6jHNJLL5Ks7bkTr06Vm6n4qWyi3i0L84H7zH9KafFh+yxzfYGy/8Pmjj9KLILF/fICWPyqe7CnopZg5JOOM4qUaqvy5hIz/tClfUwq5ELHPT5qNAsMcxx5JJdjyBUDT/AL3JB5GSc8D61X1vxTFpNqJZbWR2Y7VQMAWNZdv4+hnfaNOmAx18wEUtAUG9jbEmCGEpJJ6AVI0zFhjCr069axLXx1bz3ZgisJ+BywYYFbC6/EWx9llxjOePypXRXs5E3mEH5CR9aGcgZUZJ65PSkGswkn9zJgd+P8aYmv2zceVMD6YH+NF0LkY8yEY2ruY+tSK2MdyR0qNdatm6RTEEf3R/jSNrlopGY5ef9kcfrT0FyMlU8c9OuKcvJ4HHv3qkfEdgE3mOXHT7g/xoTxFp7HCxy8HH3B/jRdD9nIvjnp2owT0qi/iHT0xlJf8AvgcVCvirTSxURz5HB/dj/GjQPZyNbI/Cg4wAelZZ8UaYoJKTDjP+rpr+K9KQjIm9eI6LoPZSNfjbzTD2x0rCbxxoiHaxnB7jyTxVW4+InhuFws0k4Pb9waaV9hOnJHUHlcZxUT54IOGHbHWuaPxI8LAc3MvP/TB/8KjvPiV4RtoQ1xeSgMwUDyHJJPToKfKw5GbkkW4llO1sdKruJFzwN3X2NXEY7Rnk+tMdVdcHdXE1c9SMmtGVYwC2/oakYIyncBmmsu1uPpTQTtIzx2zUmm+pm31hHcMQUyhGTmuL1zwxG6t5cfzEnkV6EZFkG0hgewPeqtzsRfLIGT/eoV1sbxk9meQ2b6t4duXfTJ2iQnmF+Y2/Dt+Fd54Z8dWOpSpbakqaffH5VWQ/JKf9lv6GrN9pEc4JdB07jOK43WPD0LFh0OOhGa0U0/iCVNS2PW8gY3A5JxjtTvUE4HrXj+la9r3h0xoh+32I/wCWExyf+At1H48V3mieOND1NVjmuPsNyTjybr5Tn2PQ1Vuxzyi47nRGNcgYA9CpwaeIwR159+9KCGUNEyOp5BB7VImMcmkQ2J5WGGAcDjinbV6EDJ9KbvbeB6+lSdQNw56ZFMTuR4XqwIOaXOOV7/pS9vUChsIueh6/WkAZ578ehpCAV5HXnPpThyTyPrSk4U5zimIhC5B2kADtQV746VKdpGAOvpRx/Fnp0pDuRjCj5cY55o6DCk57VJtTaB0BoVcOWXoaYXBVPFOOP/1UdcE9u9BwR05zQSOAIP8AkU7JGea5/wAY+I4fDOjm6ZfNuZW8u3hz99z/AEHU14//AMLU8S6HqjrqX2bUbJZSHQJscDP8JHHHvRdI1pYadZNxPoa6k8zSLssekbjj6VyNmF2KHAyOc55+la2h67Y+I/Bk2paVJ5lvLG4APDK2OVPoRWDYAqAhzz3at1qkebOPLNpmoAdpYgeuMdKk2AooUEE9hUX3vLILA981LGZN5IO5e/tSEIic5AHHU9KeeJGKjj9KV3OwsykJ1ApkZHDqzHPT6UAc94n+W2JBIG7GatRxj+yISBxgKcjiq3ihT9kQEEDduPHQVp6Ykj+H03clsHFPoLqa0Y220YIyQo4zSTSrGrSO22NAWYt0A9asAAhSMEAdK4vxnfmec6VbHCn5rlweAOy5/nSGlfY5vVdTm1rUXujuW1A2W6/7P978anjc2lihKYlkbCr/AHjTIQiHnIRTgelaWiwtqOoC6K/uE4hU9/ek2bJJaGn4d0/7PCGcHzW5b/Ct45VCy8juvekRVjVeBgDr70Bwpw3A9ugrPVjZBcyZUNuz04HemRs5JDAZ7n0pZ0QRYVh1yfXGaXYSPlySMceopiFDMu0jkE9e1MkO4ENtBz8v/wBepJWUBduBjsO1MUGRMNg5607isZFxcEKyggNn0q/Y7XgBxg+uazr6JJJtqKSeuB2NaUH7mAFyM/3AOlDK0sVLxizbUbA9/WqEUGJ3HmfeOck8Va375pMgkZwc/wBKbB8+ccKDwSOtItKwXO2O3Ctjp0NZE8+7cF/H2q9rTkRKSjE9Of8ACqEMW5RvOc84IpjXQpshKl2xya5rXIHkmV4P4T0zwRXbvbrwAAfX1rHu7BtrkgA8EEdxTjKzuOSujmXQJAzIMsACAfWsK+P2nxboFoQzNJch3T/YUZ6fWuqvk2Ic4XJxycce3vXLaPB5/wAUrYRksttavKxHOM8DNdEJJsxqpxg2fTNrKHUd889atDnPOfauO0m9ZE2rJtY85I4rqrdgYg2QxI5Irzk+h3VadtR0igA8/pmqgxLh1DDJ7jFaGR1Xmo3TJJPU02iYzsZs7+VICNuSfSkkXzIwQoJPQntVi4twYyppkaKuD8w96g3UlbQgUBWBI69aSezglQ+Zb5J7f1q2YlOWVuvTFLErFcPlv60WDm6o5ifw9EzHaQEJzisLWPDVvJAwjRTg4O7nNejSQqqHcCQetZGoGIOEkV2UEdFzinqi41OY8vt01HRZj/Zd9NbbTkx53R4/3TxW7Y/EPVLMquqWEN1Gf+WkB2HH06GtXUdNhuFMlucMoyUfjPtWTPp9rNADLGIm6Bl6A1an3CVOMjqtN8deH75QGuWtHx924Ur+vSuotZ4biIPDNHJGwyrKwIIrxW60lkJLwiRCcZHP41BHbRwoWsZbi1lzgGKQjH4VV0ZOg2e7dKcoz1NeO6f4h8S6dFldQh1CHHCTx5I/EYNdLpHxDtXjWPWbaW0kPBkT54/8RTRlKjKJ3oQA5HFI49cke1UdL1vS9Ux/Z9/bznptVxu/I81fYHBFMy1vqRgjsfwNKygDOKQpuAyM445pVjxxkgntSKGsc44OKVAM9fwpwU5yOv8ASnbMrgjOKBNiKDk88HpTtoJBGaztZ1nT9FtjNqNykS9l6sfYCvOte+K6qzQ6TCIQQQbidS+36Kv9TQXClOp8KKXxMvhd+MGtjho7OJYkycgSNySR9MVma3otpe6FKYkUzwpn0D+prkLm3fUNSW9stQub2e6JM0q5Bdye46Cs3W9ee1gtf7JDw3NozxXB8zcsxPXd+VZSi5u6Pbow9jBRPcfgNEIPhjqickC8n4x/sLW5CFeTIX5icAHoawfgNMLj4U6hKwwrXU55PJ+VetdBpyqI85ZfxziuuPwo+bxn+8Tt3L0edrMwJK8ccU5GUDdkjPH0pJARGroTuAO4DuKI2JZVHzL3yOfxoOcmnwsQIyVA6ntVfmNFlUbl3YIx096skRt8gO0njk9fpVGwb/TJbVs+WBlc9fpQBm+KzutEBIHOR2yP8K3dDI/suFcEjbjNc74kytiY2O54TjnqRXSeHFJ0+E5AG3Ptim9g6kHiXV49F0ZpyFNyT5cEf95/8BXBRyFEaSUlpHbc7f3mJ5z7VHrmrnWtflnVc21uTFAOyrnlvxNVZJjKx/55Ahd399vb2qJdjopwS1ZZRvttwIRuCkZIUdveuw0xVgWNBlABgAjFY2l2jQJlSGb7zVrtdpJFsjGJExnPIrNyua8tjVQkE7eVI5zTHdfNAx8pqKByVUknGO3enFlOFYk8ce3tQjKwSOomH7vc20ZCihtxJGNpHvilCKv3Tgn8cVDcTPEFZhxnBqrkpDbuRdhAGGz3pDMsdvkj5sZ5qG3jaZyzAc8nPaoNauDEFXOWI6AUXKUbuwmn/vZTMc7icDtx7VevAVt+mPpUVpCYbaME/MWyBSatKWXCjcQOpoTBq7MouWcx/wAR5yPStLSo43LZzgDqDWdYqZjIVbLdM+lbOnxKF2lRx8o9KY2UNZKMw789/wDPWqkttGYEMgyy8g1d1IqZsFQf5VVy27lxt2/dA71Ny0rIjA3FSOfeortEwQwwcc1biXAYocA9TWVrNz5UTM2fQY44oLjG5xXiS5MW4ecmI8nceAMe1Ufg5ZSXi6nrk28Ney+VF7opxx9Tms7xfa3OoIlpaktfalOsMSqOVQ/eb2AGea9e0PR7fRtLtbS2CiG2jWJAB1IHJrojpEwxDu1Htqad5psiqzwrlh/DVjRtSGVglJDjjB/lV9ZMRKvJz39K5+/g2vvU7cNyw7159z1UrqzO1jkDDjjPSpFO4gY61zui3UjxhJmBPOD04rdgYEglu9O5zThylgxBwePoaquNrFMEelaAOFDA5z27VXlUdR1q5IxhLXUqqeVGOPanSjaAyDOPzxUgQkcEUPEcY3dR0xUpM15lchlu1RB5nfpVN5w53KQSfUVPFDltw5J4qRLcAvgd+lGrLXLEzi8csgjuY0LHoSP0rNvdLNofMijDWrHLqOdh9R7VuT2QdTt+Vs9QKW3LhGin+YdM0ylLqjmrnSUcqygrg9jWVqegPcLvhZVdeoxyfyrs/KELeW/KHoTzn61HJEF5WPeegPTFI0UzzVbKSJhHERvydyScc/WmSQmaIpLGyEc/d5rudRtoZ87/AJWJxwKyv7DaP94ly4Y9F6g/hTuWnc85utN3XBlgysufllQ7TWnpnivxDpBCR37SxqPuXA3/AKnn9a6W6e0Z/suq24jD8eZ0wfUGs670aW3keH91eWxXMbk4LD0z61op9yXBPRmvYfE+42IbnS45iR1hk25/A1rwfErTmkCT2N7G+OeFYfnmvNBpdsGU+dNasCSA6nb+Bp02lzBQ0N1bzx45OQpp3XQl0IvoeoL8RdMJIjtLvI6FgoB/HNZ2qeO9Tlj2aTa2qTOSFDOZCB/eJ4Ary+WK6km8uOWKMr8jSFsha6KztfD1lp6xXeprK7D5yXwpP0FROVuprTwsHrylTV7vShcLP4gvnvdRJ3OPvBT6YHAAq5YX2h3tmY7R4VbH3eARV6Hw9p8qK1u8EkUgyoUg5FZ194W0vTbh7mWEyW7/AOsRDtYe4rnbUup6UFGGlgkiTS7J77S5/IMRJZAAVbjk4NeH63Osl7M8SfNPuCoD1Ynr/Ouk8Ta8tvey22m+ZDp7ggRyybmJ65Y9q4K4vt91mJNyZyW7t/gK6sPSa1ZyY3EQgrbP8T6w/Z5Mb/CG6RSWVbmZCR3O1a62CE7AEOASOoznFU/hVo2n6T8K7WPS5Hmt7qI3LMx5LOBn8sY/CtCCLgFWKk8+1b9D5yq71ZNj8usoZcELxx2pwfnft6n7uPvVYgRjHtIBOODUhiCq3G0g8GkQUZZxuDnBGeBjpVG6dotQQg/vPvo3qO4NWdTTZGzxg7duGX1+lYTTbpom5YIuzj36GmgLnjExtYpcxD74GSOfzrm9Z8RztYQ6TpzEBk/fuvGQe2ewq7q+pmLT5dOMfmPI3yHso7nFYENioztJOeWc9PxpN2VjSnC7uyO0gDosUIPAyCewHUn+la+lwh5d23CqMIp7nu1VFjVwtvakeTkbyT8zn6+lbLSxW8GcgOBhlPFYTmd1Om7F9rhIoflUKcYptghklViAVbnpXOWt0dUvAI3/AHCcMQc5NdvZQ+VAoRQwGAPY1EddQqr2at1J0VBguvzY6dqeFGRIAMdhj9amjwuFc/UmkkdQMAjB7itLnIMTGBu49Ko38attUMSc9BVye48tSGTHYHPNVogScsQcnuMYp3BIRl8tRj5V7msacfa9TWIuCR82a17+YQW/Ofm4GPSsrRo9169xIPlA6596Gy4KybN3aqOoA6f4VjavKrPK8fOBwCe9bayK6SSlmxjHI61zFyrSyvnJQnAIp3FGJPokZ8sFjgtycity2AjDAkdcVV02AiFFYZA54rRaJcZAJIGSRTRMnqYepR4nPzADtiq6Ln7pAz1zRfSMt6FY9uKhvbqKzhkuJCqRxDLFjwB61FzZReiHvLFbwgyyLGGbgscZNcnr+p2UmofZHuU37d3l5/hrB+Iusw6np9uNMPnDzAQ6HIQ9e1czLpBurmzgWRpbrUHWIOxOVB+9x7DNOKuzrVFQhzzdj07wZpq3V1JrbxqFOYrU9Ts7t+NddMsh4CDAOBk4A/CrWm2EdrawwW64jiQIqr0AHvSzsA20gAE9fWtrnlSfM7k4cDJAOB0HpVO42lwmA6htzD0NXZVe2mMTDLAcN/eHY0hVHB+Uhz2HWuF9j2E1uVFfZOEVAAPmyK07SR1bBHHb3qnBArSKxBD9SP8APatO3RcAYz3pbim0kXo5QvBPJHekXMjEtgDtTUQORkHI4q3GiJncPoa0SbOKTUdiPYdpwhximNz/AA/XBq0pBALE8cA0yXB3FcZ7ircSFLUrxAKu3IPPapAvzbsZyKQR4G4dqQn5fp2xU7FPXYcR8v3QPWo32jG4fjTs4Xmmkgj1+vegaRGVHIwCuO4qB7ZRyv8A9arQ4GMDBpvAOCcj3pGkZNbFHyEIIK8kelUbmIxnO07c8EdjWw4Gd34VUmTeDxz6VLNoT1MDUYop4wt1AkjA4Ix0FY9xp6Qg/Y7hou5iPKGunnwuN8ZJx09qybiOMMxyYlIz8xzU8x0xVzl3vZ7TCzRRSK2W2k8D6Csy+hl1YoIrNYhIcI4TAz6ZrenttMW6U3Eoc5yAfWte0ImWMb9qA5UYwMUnUtsdEafVmbYeDoLe3RmUSSnB29hWiPDlmYJUaBGXofkGTWqyNkqxJCY+YE8CsxtdjLTvE8X7p9khzyMDvWV23dlxc5K0TiIvCUVpey/Yp5rO5d/3UolIjA7gjpWD4m8TslteaZNdJM1s+zz1GA/HJFb/AI08QJ/Z8zF0QD5mfPy4r5+vp5Ly5u9UmLCHJWFfUngcfrXTRp8+sgxOKdBLq+36lTV9RfULo4yIFyFHc+5r0T4IeAE8Z62TeM6WVuQzhf4vbNcj4C8E6z411IWmkQExKR505+5GPf39q+0fhz4Ms/BeixWVlh5QMyy9C7V2J2VkfO+0cm6k92b6WFvpnh9rOyiWOCOMhUXoKw7Mh4z1XJ6V0mqlv7KuMH5thrm7cbHVWA5XqT3oZy3bbbLYZk4LDAFLJcMsK71Pvjuaic7T854qrdzLFAXY4AGcdqQxuoSK0bNjG1ew61ztupjikJU5QdP5VJfXiywrIu5kIIIH+elYepayBC1tZDzZ/LKSODwPUfWnshxXM7Iqm+ikuXllJweCq8kD2qxaSrqDeTEpSEHBzwTWRpaCVFUW7qpbbk9c+hrrbew+zWwijY71G7J5wfesJyXQ9CFO246W2SwhB25J5OB2rkdQvW1bXoNNtdzIqF2cdh2BrW8Va4NP07y5ZR5zKcKOv/1q8l0rxNcaZLNLaKJZ5GA8xuQFHtWajfU76FOUl5nvHhvRVsbdAMcj5zjGTXVJCFAGDjofWvG/DXxQijGzV42jZTgsnIb3xXpdrr1tcwLIkh2MoZSRjINUmjjxOGrU3eaNmfai8kVX2/NlSOlUzeiZwqgAe/ekmkIX5SV9f/1VSZyuAj/vpsPuJ6cVeiUBRkcDjmshLsq5BIUZ4b1rStbtfKLBiR1xQDizP13dKwjjcYzjBqWwjNvbbQBk8mnbY7i5DNyO2eKm8vzJEwVAHXnpSH0sMuvktCBjcRWRaqrrmQhtxwQOMVoauwiG7JCAfeas/Tr62YFYpQQxyD1yad1cqMW43SNq2byoduSUP3aso5PUArjHB71lw3kAVkD57Fe9S+chiGw8D3qrozcX1MrVlLXyyDAzwK8e8d+JrmS9vNKtflAIQjGd49B7V7DrD/uXkVd2wZx0Jrw+w0yXWNaubthui89sO45XJ6D8qlNX1PRwsPtPoX/C+lTWGmu06FfNOXX29K1PBUX2r4hxyS5Elnaudg6DJwp+uK6CdVFltmBMigAnscd/pVL4SWwXWPEl8+SVmSBHP8WBmqpu7bJxUnyN9z1eGTyo13dWOMf3aozS4PK7iOh7/hStKGRVxhiTz2qpcYcqi4C+pPJrU8g6fWIg9sLpesIzx3XvWfA4ZQSQc81swgxfuZ/mQjAJ7j3rnGzBeXMEmFWFsD029q5J9z1aOq5TT5yzrjPvViBCG3eo71FBh1HoeCD3q0gB+oqEE3bQmQ7Rk4xipASfvHkVFwCMdDT1JP1q0zmaJi+AMsKhyCSQcAn1qKaZI8h3UcZJJxWNe+JNNt8KlzHLKVLBUbPA6nNDkXClKXwo3vM+XGRx3pfNGVAJrzrVPiDaJbK1pb3LiQ7Q2zp7/Sk0bxk0gke+deW+VQuGC/T+tT7Sx0LBVGr2PQyQy9aXySSCeB39q8+h+IEZlkAtm8tCevUYrr9I8Q22o2kcqyBHOAY24YH6UKcXuTUwtamr2NMqFALfd9ajLLnbwPb1rP1HUZ1LxwFVBUHzAu4jn09KxrmzvjLFcfbGBbGHU/KfYj0qZVLbBTw7lrJ2OqABOzgioZigBL8AfyqhDHKGVy8mMYePORn1BpZBuDec7AdpB0+hHrRz6AqdnuVLy5hMLmPc/UZ6gVzWoRy3ETCVX2nhgF4rpWQTzoHiwUH3h91qtpGkbgkKyHqG71nudkZqn0OKstAEMq4JeCThWdt2PbNdZHbWdrGqyjZIo7kEH6VA9xEqtFEVi+cjB5B+lZOq3gLFVfcE5z70rmj5qmj0RH4tut9t5FqxileIruU9Ca8NS3vdLvMRapPI1xlpvNGRvx39RXdeINSaZzHv27TuyDziuR1BkjR7q9kSGLG4yv2/z6VvSi+pspRpx9DN1HTjeqr6le+cEXzWUjbEo75HevPtdvk1K/WCxQmBG2QgA5ck9ce/arnifxLJqn+h2RZLEHvw0p9/b2r2f9nr4TXH2qHxN4ltCkMY3WlvIOWJ6OR/KuqOiPExWJVaTjD4er7/ANdD1L4C+DpPCPgiBbuPF/enz5x3XPRfwFeklASA2Me1OT0UYHtShgODwKqxwSld6EGpYOmz8cbelc264QYAJHYV0epf8g2bb/d4rnIULZAYe4xTZmtyaUBotygkdMGuZ8R34jURpw+eU7fnWtPdFTNGSAyDK++a4e9eS5viZhgREqATyc9aV+VXZpGDnJRQwQy30Xkh2iiX5iq9z/hUsHh22UjeWweSvPzH39auwBolCoVXj73Wrtk7NIfmB9Ae1czqSk9T0o0o017okekx26GWKM8YbOc5q2xjs0nkZslxuB7AY6VIoYvnJB/nWN4uMv8AZU4tmwwUnnp0pBG83ZnkXj/US0UjK5Jl6Anov9K5Pw/dNEBLGA0jZwJP5Yql4r1VpoDMxwY/3ew92r0L4daJbXXhy0zskuJJA0i919AP5mt5rlgd1GrGFTlfRalXR9DfVEQzx5G/f8q4JA7GvQrWxEtorbZU2jG1j90eg9q6qz0ZYyqbQiqoIIHU1JLYMXdNuFXovasDGrivabmJbTGyiV9xOOOTkEVoW2uWN1GUguBJMgyyoQSPrXm/xa1K40O1gtrXzGmupPLiVOuTxgfWtrwV4bm0PR41uQWvJvnnYdAT/CPpTs0rkSjTa1ep0V3fSKrP5Xy+uccVRTxT5d0kGwCHnc+7G3HbFT3qPFHl1wBwAeQR2rxPx7f3ja/aWdijPNPLsUJnJpxXNoJQjFc0tj6Lt7+Ga1WWKRXSQbgRxn6Ux9UjVWKyA4HbnHtXLaHplza6Xaw6hO0ksaBWXPGfSrlxGFildESNgvUDqKXMT7GNzhvHnj2cXhs7Byu0je5PUegq54d1galEk1qzQyxrgxKMgn1rxfxZdyzeMJrePAG/BwchhXp2h6jZ6HpEc8WSZOj5/XHrntVzhojpozjK8YrbQ3vE2q3Ok2fnSM0zk8lBgim+DfEuqTXmy7ImsGGM4AdD2z61yZvL7X5y021rdWDGMnGB612Wl6TJZ2ZmX5Xdc57gdqzemh0ypRjG00rs09Y1sRFomUvCwxu9O1Z+m2iWQt/LXfGTyRxuzVNYZNnlyyF+C/mN9ela1hJH9nIJOEOAcdPejoc8oqOxV8Vah9h02a6hO8Kp4I/Otb4bwNZ+DrSS5ytxeBrpwPVjwPyxXNapGPEWqW2ixMWW6bfclf4Il6n8cYr0a2t1aSOGJAsUagKoHAUdq3pq0Tz8ZPaBZR2KoFyrY5FKsOQWHzenHOamaOMSqAXbH3gOAPTNG7DsqkLnoOua0OA7ZYUnVkfvXD+L3m07WIodwIkQMHI4IGeDXaqTXIeP4Wkls5jyNpTPpzmuer8J6OEdqqT2ZY0++iaJN8igEcZNSy6vawsUe5XcPvDNcKITtQhmUq2QAe9Sta5YNgl2OAD3rl5mei8PBu7ZtXfjFYp5DHBuiHCvnqfTFYk/inXbgutgilkO5yR9wdhj1rRs9NhkuEQhlPPmFTkD6H1ratdFt0nY7SoPpxuoTYNUqfQ85u5dd1BZ51WVpVAxHKCF9x9KfpOg6nqc8NwsUMMSIEdWBAX1wO9en2uniFpUmYsrH5GJ6D0p91GYoV+zqpyeQOlGo/rK2ijJ/sZUiQzRxAKMIu3rSTaRaSw7oY41yMBXHQjtWpc3LLCflVsHoe1V7a9EyNhFWTPLLyPypWM1UnuZUOj2LhZY7aJJB98A8Ej+dJqUFnFcQ3Hls0pGBjpn3rSkhjjXcrEZ52kZrE8R6ra6dZ/aLy7t7VUGWMrgcew7/hTUGy/aa3b0NazD2sfnF9idSDzn2rRW4ikiMZ2sh6j0NeJ3fxv0aKUwJb3V7H3mjG1T+Dc1W/4XZo6RHydOv3kPclQPx5rRUJ9jmlXoyesj3QXXlAqG3qvBNMbUFWbG0sD3FfO138btQ3ldO06BIvSdix/TFRt8ZdeIJ/s6yRjzuCsK0+q1BKtRfU+h7nUP3eFyn9fwrIuNRkTLB8DHbtXgF58VvE043RQ2qg8fLEW/nWS3iXxxqrssL6g27+G3tyP5Cn9Un1Y1iqUdEme9XeqM6ZGGYelcdrHiSxsonXUdShhOfmTzNzfkOa85tfh/8QtcxJ/ZeqyBx96dyoP5muq0T9nXxZfOralcWOnxk5JZ/McD6CtI4eMd2ZVMwdrRjY5jWfiBbIzrpNq0zdFluOFH0XqfxrH0fRvFXxF1UR2ME94wPLY2wxf0H86+k/C37PPhfSWWfV5LjV51Gdkh2R5+g6/ia9X0qxsNItkttNs4rOBRhY4UAX9K0skcE60qvxO/keT/AAt+BGl+GZbbUvEDJqOqp8ypj9zE3sD1Pua9nOVwAvyj07VG8vAwefal3MSTuHXpRdGTu9wUnO4jI9u9SKOMNSEZOTxj0oXcSDjI9aEJlfWARpdwFGTt/rXNwvJHFv2gEcYzya6TVGxpk7EEHb0/Guemc+SirjcMGqZK3OQvJ5P7e1FD90QBxnv61hQM5UyOS2eTjqK3vFUEjS297AAu4GGYY7HpiueNzDH5gmVyqDcVXvisK70SO/Aw1ci0rSeWMNI5HICrn8KqwXlyl0iPBLEjHLFx0/Gr9rLMisWYEv0UDOwf1+tWIpJF3MrctznHX8K57HpKpvoa9hcK8RQvlgMnPOayvE9yE0q7Qf3CSewqtFfSRSIt0kaqxwJUGMH0b2965H4j3zWtg0AmYtM55HpjpVR1aREKN53PnfXLuS41OaFTmLzyyD619PfCDSDb2IzIGZcFgOiMR0/LFfLmrg2usPjHyMGHv3r69+G5EHha2uDF5Ut2omYdDkjj9MV01nZHnYaTcqqe9/8AM7GPcZwAw3DjOOvtRcXLJJtI3I2ckdqpPLLyyl844FJLeD7MHkJACnccVz3N+RnF6ha2+ufEzSkZd8OlRNdOOwkbhM/qa7mZVznaHIGfp9K858Da0jPqmoygCW8uSq7uojX5V/Dg/nXZW9y7KJAnzPxgNwPwo5raG9Wi1Z9CTUoUltSMHAGcYry3w/pCXfxbV1w0VlbPKWborNwMe9epX9wFtC6kjA+YMK5D4bQLJqGuatNjE8/kpjk4Xr+Gaae4oJqm7natbpkBjyDwTVTWLYJA4VSARgN61dmfMoPIGar38okhbP3R2HXNIzV7o+UtRit4viddRXsmLeOU72Uc4xk4rqtH0K91uSS6igNrYZPlh8n5c8AU+88PW2s/GLUTOrJbQhJmUcb2IHFe4WljCtokdvEI4QAFGOla1KmiS3NMI5Uuab6tnKaNo0UDwu0KqRjcSM5/H0rV8Q3yQWg27VUnHP8AKtWWAwjduG3vxxXBfEO8Vlsooid8lwqkY469axguaWp0TnzWNmPDQRfdKY9OKy769SxnljTLLKw2qD94+g96vpI6I4UKfl5z2qv4R0K41HV49XvTmxiZjb56SP03L7D1rSELmNSvGmrs3/B2hS6dby3F2qjUbrlwP+WS9QgPt3967WwgCoXz+8kx0XtRa2mE3PyemW71oeV93hRtGMAV0Hjzm5tyZUYxx7tzyEkewpqugg/dRkMSOg5qWeIhOFViD1qAR7QuCf8AdoJOrDAdxVbXbP8AtHS5YlQNIvzr7n0q3CYmG7h0Izx0NWFeBcgKRx2rO19GdHM4tNLVHk2wpIQwJOeQOw9K0Itsi7wvzAYYHt7flW94m0L94buxXIb7yeh9a5xMQyDeCxJ7enoa45U3F2PYp1lUjzI2rfyViAcFVJG0gYrVR0CMJCCMdR3rlrnUOOpBA4GOD70kNzIshlEgZSBuBON34UkiJQ5tzpfPidQoOM8kcHI9az7m5e3diAzp6Drj3rJF+UkMkcTZJ7nAx3P0qomqXOoXxg0i1jvLxh92J9yD3duij61ajcm3Jr0NF9Ss3jZnuQD33dvwrh9X+JPh/S72S3juZ7mcfKwtY9wH49DW9N8L9c1+Uy+KvEX2K2kOGsdOiwu308w9fyr0Xw14K8O+HbFLfStLtVCgAyOgeR8d2Y8k1vCgupz1MZGO2p82Xur+MPH1wLHwtpd7a2TNhp/mUkerP0X6CtW0/Z/1m9lDazrtqp7t80jfrivqFEVF2ooVR2AwKRkVvvKD9RW6hy6I5ZYtyex4npv7OvhGO3Iv7q+u5j0kSQRge2Bn9a35vgl4FaNEfR2XbxvjlYE49ea9KNvEeiAfTimi2UHKvIPo1P3jDnu73/A4/Rfhb4L0kiSz0K0Z87g8o8wg/jXUPo+mSJtfTrNlxjBgU8flVgWyq25WYN9af8w4cBh6ij1Jcm9mVItG0yH/AFWnWa4/uwqP6VaiiijGIokT2VQKkGOn6UtOxN31GFwOvWlDA9CDUZwmQenXAp0ew9CCR6Uk7jaHknsKZkA429PQU846EEg0YpiK7Rc5Vcn1pQhGAox7Gpifm+gpC2ACQeTU8qK5mRLuDYIOTnvUiuvCjH0pAqsQQPalYA/eUcdKFoDaZBqfz6fMPUf1rnZlCKDuCgnjPSuh1HK6dLjBIHf61zu4Mu09ffpQyVuYHiKEpYS+XtZWI6nvmuJ1NDDZPKpC4Zdw/EV6Hq9v5trMq8KVxtHrXFG2NxBLHvCscNzzjHNc9VbM9LAztdE8ZV/LU7Rnk47VrxRKy9B8w4b0rD0zS724uNrTRNtX+/yPrXRvpV1FAsyTQyA4Aw/f0NY2Z1TlFaXKF1bxGJldflK7eOteV/EiYyaDaTNnByN3rgV6lqEd7FZ3EgRR5cZb7wOfQV5T4+CR6HDbF2YJgDcuO2TVQ+JXOmgnyyaZ4vPbG78RWtszEmaSNCWPqQK+oL3WP7Puoo0yqLH5aqOgAGAf0r5ttXU+PtP3/cW5iHH1FfVVzo0F7qEK3MhWOGNZGRBgvk8A1pibtpI48ulTpyqymr62+4rQ+I2FnExidt5CEgdD/hV3X7sQ+Hb24dgGWFmA98VcTT7VlKwZRgMAg8/rXBeLLm7jk+xTuJLaSWOIuvGQTyCOx4rDVHZCNOvL3Va2pS+HWnOkkhll3RsoYKR0NelND5MEbxyCRQOdvrWTp2kA3C3KSywu+WMSgbFHYUawl5aQiRXQwDJ3AY2++O9Gu46041Z2TsQapqJuLV7ebAco2Rntil+HltHF4ZtEiBAYszE9yWJzWRqcDx291KzFsRNgY68dqv8AgKa4t/C1iLi3khZkGzuGHrmnHYmtBKFonTXamFtuRg89e9Z17N+6YbhuU8ds1bmkEke4AHP55rL1CRIrWQkDOwsSe2KOphBdzjPCEMVx8RNdmYKx2xLn04zXr9zFFDbARspJG7J6CvK/hrpM50W71l5C0t3du+3byUBwMe1dzcXjzR5J5A6Yq5aPUKi52lHoZ+sXRRWPIxy2On5V45r2srJrEVzKwEVu+Avdm7BR3Ndj471iOKylV5NiEfvGXOcen/1qf8Jfh9P9oh8R+IogZ2GbKzcf6hD0cj++R+VbUIWTkzDFV/ZRUY7s6TwT4Wv9cgivPEsTWtl96KwBw8g7GUjoP9kfjXfXEKvqEMMaKkcahVCDCqKvWcJSFgzOxUk5qGKMC65G7I6etanmuTk7smRIl+Xqc4HFWdiupPHAqr8pKgjnPHOKsryMEFe2O1Igz5OMgEYqFiZV5cAhuQFq3MgZc52kHgCqxj5JbGd3OTyT70xmhBbyWpzZybeclG5Vv8K1bTVIWby7lfJl/wBrofxrlrHVJ8iK5iKsOuOeK2PtEM67XHXjJHSsYyaO6pTUtzoxgqMYKn8qyb/QLS8cvgxMeuwDmqsJe3H+iTFF/unlfyrTstRWZhHMvlTdhnhvof6VpzRnozm5J0veizDbwgmSRddeOU7fnUP/AAhreapF4qRjqEi5H0JNdjRT9lDsH1ur3OYHgnSZEQX4nvSpJImkO1vYqMAj610FnaW1lAsFnBFbwqMLHEgVR+AqeirUUtjKU5S+JhUTQjkoSpPcVLRQ1clNojXcnDnI6AipAc9KRhkYqPayn5TxilsG5LRSDPfFLVCCiikIzQAtMcNj5fxFPNFICFHVmx8wI7GpGUH1B9RSMgfhhkU1Yyn3GOPQ0rFaBgqDtye2KVSGGGHTuaQnkb8oR0OeKcFIHBoD1FXGODkUjJ0xwfWk8vC4BP8AjQFk3Z3celAfMYMK3f6elS9hnmkZMt14PWkdT0Xilqg3K2sHGlzkHHA5/EVzC4cHhgO/pXRa8T/Y1wRwcD+YrlomxEu0nGfShiW5bg+RxkAHpk9DXLeJtIlsbgXlpkW8hySv/LNvT6GuwtYgyDP5EVcQKYyjqGiIwVYZzWclzaG1Ko6cuZHliOG3vOSHYcspyPxqyt4WOwOuByMDjNafivQJ7aM3WkWUl3APv28TgSL7qD1+lcLB4m0iGaWG9eawuE4ZLuFoiD+IwawdKfQ9OGJpT33Ox3hQPlU4JP1zXEfEKzjudDnLFQ8YDrkdOeefpVyTxn4ftLcudXtQg5OJNx/Ifyrxr4l/ElteMtlo6vFYkbWlcYeQd+OwqoUpNq6CeLp4dOTd/IwfAGkP4o+Imn2cbMBJceYXXsq85/QV9cWNzbwTyTXELyuyrGyp94FeDnNeOfsyeAtSbUT4qvY3t7FIyluWGDKT3Htx1r3XXfDs13vudJeCO+Y5dZshJfqR90+9bVo3tY8zB1eVS9ptLUq6he6Y8E1zEZreSNeImHLnsBjrXASacummwuNaJumnvY550Q8oScKB7DiuoOi+KoTk6PA/vDdKwI/4EBXN+JvDXjzXfs1tpujx6eY5kla7uLhGxtPQKM1j7OUmelTxNKinZ/5npc+mQzwtNYTQmQDO0N94f0rlb5H1C8/s9tyRAZuCMHav+JqPXNH8T6Zsli04amAo3SWEnlyZ7/K3b8a4vUfGd/o0bRz+EvECOSSQbfgn1JBOaHTk9kZQr04auR1HiWK3GnXMod1SONgPmxgAYrY8P3D/ANgWEDbZoFgUiNgABwPyryLS/FOv+JvENra3Xg/UZNDLfvooo28wjsSxwMD0r0+fVIrd/IsfDGv3Mw4CG32ov4k4NHs5xG8VRqRUU9h0c6+ZNuOFRz5fPauX1xb3XNRTRdLIN1d/Ix/55J/E5/CrWo6T4/1klNL0e20iJz/r76ZWcD2Rc1o+B/hNN4cvJ9Wn8S3txrsy7WlRR5a59j1/SnGk92OeMhB2grnTW9s2iaXb6PBB5kMKLHGRyTgc1zet3Eqy/Z4irXLkhbaFdz4/z3Nb/wDZfiqa4ZNV16zFkDjdZ2flzOvpuLED6gVo2Wm2umo6WNusUhADOfmd/ct1NV7O71ZhHEqOqWpx/h/wNvvYtS8Q7ZJUIaCyHKxn+85/if8AQV6DHAAd+SOwHSiKGRUBfqRz3p8oljAwmV6A4rbyOWc3N8zLMO5scjYfSoCoNy3OORwKfbknHykDpzUb4e5cqpznjmkQPAGV68nnHap2YKSTkjpzVQnBjXC9eeas5YYJG7PcDOaAIS4MZ+Ujnp61XZlVGPA9DmnyOWzwQPeqpIGSxLencCmBZdFdV3AHcOc0xXYW4AY9cc80UVznqF2J26Z4OKgmJMZyScGiigR0OiSvNp6NKxZskZNX6KK6Y7I86rpNhRRRVGYUUUUAFFFFAEY4Y4qSiikhsKKKKYgooooAKKKKAGScqAeh61WgYrcmMH5AOlFFZy3RrH4WXMdKKKK0MgooopAZ/iA40i4x6D/0IVyqMcLzRRSkCNSAnzm+gFWTxKB24oorMoEY+YxyeOlR6lp1lqkJh1K0guoiPuyxhv50UUPQDxX4j+AfC9numtdHt4ZCeShYfpmuB+GXhLQtR8bxwX2nRzwjnY7MR19M0UV1p3hqZtK59ZtGltGtvbosUEYCJGgwFX0ApEOCAOATRRXIaFggeXnHNMi+7RRTQhqE5Jzzmmzu37sFiQetFFIZmySOWYFjgdKmTJiGS33c9TRRTY0DE5YZ48vP405APLHH8INFFAircAMyAjIwaitlBlbI74/CiihDNTAC5AHFV7knb17UUUEkKgYY/wCxmo4FBKMQCx70UUxgEUmMkDP/ANenSMyTttJHy5ooo6gQT/N19qjgUYlOBkciiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine 1988; 67:40. Copyright &copy; 1988 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34929=[""].join("\n");
var outline_f34_7_34929=null;
var title_f34_7_34930="Ultrasound of osteogenesis imperfecta type 2";
var content_f34_7_34930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Ultrasound of osteogenesis imperfecta type 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) 24 weeks of gestation: two-dimensional ultrasound cross-section of the thorax demonstrates the \"bashed in\" appearance of the ribs at the lateral aspect of the thorax due to the elbows hitting the fragile rib bones resulting in fractures and angulation (arrows).",
"    <br>",
"     (B) Three dimensional ultrasound sagittal image of the wavy irregular contour of the ribs due to multiple fractures. Note the ribs are short and do not encircle the thorax.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34930=[""].join("\n");
var outline_f34_7_34930=null;
var title_f34_7_34931="Ecallantide: Patient drug information";
var content_f34_7_34931=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ecallantide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     see \"Ecallantide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9640246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kalbitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of the face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ecallantide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11665 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34931=[""].join("\n");
var outline_f34_7_34931=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9640246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030850\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030852\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030851\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030855\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030856\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030858\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030854\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030859\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030860\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=related_link\">",
"      Ecallantide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34932="Loratadine: Patient drug information";
var content_f34_7_34932=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Loratadine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     see \"Loratadine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/5/8278?source=see_link\">",
"     see \"Loratadine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alavert&reg; Allergy 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Alavert&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; Liqui-Gels&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; RediTabs&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Loradamed [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Loratadine&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg; Kids",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hives.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702410",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to loratadine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699323",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       RediTabs&reg;: After foil pouch is opened, use within 6 months. After the tablet is taken off the blister card, use it right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11781 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34932=[""].join("\n");
var outline_f34_7_34932=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190023\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190024\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017507\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017506\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017511\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017512\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017514\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017509\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017510\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017515\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017516\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=related_link\">",
"      Loratadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/5/8278?source=related_link\">",
"      Loratadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34933="Polyethylene glycol electrolyte solution: Patient drug information";
var content_f34_7_34933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Polyethylene glycol electrolyte solution: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     see \"Polyethylene glycol electrolyte solution: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=see_link\">",
"     see \"Polyethylene glycol electrolyte solution: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colyte&reg;;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-C;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-G;",
"     </li>",
"     <li>",
"      GaviLyte&trade;-N;",
"     </li>",
"     <li>",
"      GoLYTELY&reg;;",
"     </li>",
"     <li>",
"      MoviPrep&reg;;",
"     </li>",
"     <li>",
"      NuLYTELY&reg;;",
"     </li>",
"     <li>",
"      TriLyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Colyte&trade;;",
"     </li>",
"     <li>",
"      Klean-Prep&reg;;",
"     </li>",
"     <li>",
"      PegLyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12809003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean out the GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to polyethylene glycol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow-moving bowel tract or a block in the GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel disease such as Crohn's disease or ulcerative colitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697260",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart failure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         MoviPrep&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697330",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. This product (MoviPrep&reg;) has phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bloating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to drink the solution.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat solid food 2 to 4 hours before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chill the solution to make it taste better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not add flavorings.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Works best if you drink each part fast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Colyte&reg;; GaviLyte&trade;-C; GaviLyte&trade;-G; GaviLyte&trade;-N; GoLYTELY&reg;; NuLytely&reg;; Trilyte&trade;: Drink 1 glass every 10 minutes until all of the liquid is gone or your rectal fluid is clear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695478",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       MoviPrep&reg;: You may have clear liquids or plain yogurt for dinner. Finish 1 hour before starting this drug. Mix pouch A and pouch B in container that comes with it. Add warm water and mix solution. Repeat for a second dose. Finish drug and clear liquids 1 hour before the exam.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         MoviPrep&reg; Split dose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Evening dose: Drink 1 glass (8 ounces) of solution every 15 minutes until gone. Then drink 2 glasses (16 ounces) of clear fluid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Morning dose: Repeat the evening dose. Then drink 2 glasses (16 ounces) of clear liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         MoviPrep&reg; Full dose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694846",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Evening dose (6 PM): Drink 1 glass (8 ounces) of solution every 15 minutes until gone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       7:30 PM: Repeat 6 PM dose. Then drink 4 glasses (32 ounces) of clear liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store powder at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid Colyte&reg;, GaviLyte&trade;-C, GaviLyte&trade;-G, GaviLyte&trade;-N, GoLYTELY&reg;, NuLYTELY&reg;, and TriLyte&trade; in a refrigerator. Throw away any part not used after 2 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid MoviPrep&reg; in a refrigerator. Throw away any part not used after 1 day.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11260 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34933=[""].join("\n");
var outline_f34_7_34933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211123\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809003\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018377\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018376\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018381\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018382\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018384\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018379\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018380\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018385\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018386\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=related_link\">",
"      Polyethylene glycol electrolyte solution: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=related_link\">",
"      Polyethylene glycol electrolyte solution: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34934="Nitroglycerin (glyceryl trinitrate): Pediatric drug information";
var content_f34_7_34934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitroglycerin (glyceryl trinitrate): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"    see \"Nitroglycerin (glyceryl trinitrate): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/10/9382?source=see_link\">",
"    see \"Nitroglycerin (glyceryl trinitrate): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Minitran&trade;;",
"     </li>",
"     <li>",
"      Nitro-Bid&reg;;",
"     </li>",
"     <li>",
"      Nitro-Dur&reg;;",
"     </li>",
"     <li>",
"      Nitro-Time&reg;;",
"     </li>",
"     <li>",
"      Nitrolingual&reg;;",
"     </li>",
"     <li>",
"      NitroMist&reg;;",
"     </li>",
"     <li>",
"      Nitrostat&reg;;",
"     </li>",
"     <li>",
"      Rectiv&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Minitran&trade;;",
"     </li>",
"     <li>",
"      Mylan-Nitro Sublingual Spray;",
"     </li>",
"     <li>",
"      Nitro-Dur&reg;;",
"     </li>",
"     <li>",
"      Nitroglycerin Injection, USP;",
"     </li>",
"     <li>",
"      Nitrol&reg;;",
"     </li>",
"     <li>",
"      Nitrostat&reg;;",
"     </li>",
"     <li>",
"      Rho&reg;-Nitro Pump Spray;",
"     </li>",
"     <li>",
"      Transderm-Nitro&reg;;",
"     </li>",
"     <li>",
"      Trinipatch&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nitrate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator, Coronary",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited data exist; further studies needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous I.V. infusion: Initial: 0.25-0.5 mcg/kg/minute; titrate by 0.5-1 mcg/kg/minute every 3-5 minutes as needed; usual dose: 1-3 mcg/kg/minute; usual maximum dose: 5 mcg/kg/minute. In one clinical study of 16 pediatric patients &lt;24 months of age (median: 4.4 months, range: 3 days-23.7 months), a median dose of 1.8 mcg/kg/minute (range: 0.5-4 mcg/kg/minute) was reported following cardiac surgery with bypass (Williams, 1994); another trial describes a fixed dose of 1 mcg/kg/minute administered to 15 neonates (mean: 8 days of age) after cardiac surgery in conjunction with dopamine (Laitinen, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"      see \"Nitroglycerin (glyceryl trinitrate): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolerance to the hemodynamic and antianginal effects can develop within 24-48 hours of continuous use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Infants and Children: Continuous I.V. infusion: Initial: 0.25-0.5 mcg/kg/minute; titrate by 0.5-1 mcg/kg/minute every 3-5 minutes as needed; usual dose: 1-3 mcg/kg/minute; usual maximum dose: 5 mcg/kg/minute; doses up to 20 mcg/kg/minute may be used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anal fissure, chronic:",
"     </b>",
"     Intra-anal: 0.4% ointment: 1 inch (equals 1.5 mg of nitroglycerin) every 12 hours for up to 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Angina/coronary artery disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion:",
"     <b>",
"      Note:",
"     </b>",
"     Do",
"     <b>",
"      not",
"     </b>",
"     dose per kg; adult dose is in units of mcg/minute; Initial: 5 mcg/minute, increase by 5 mcg/minute every 3-5 minutes to 20 mcg/minute, then increase as needed by 10-20 mcg/minute every 3-5 minutes (generally accepted maximum dose: 400 mcg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2.5-6.5 mg 3-4 times daily (maximum dose: 26 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patch, transdermal: Initial: 0.2-0.4 mg/hour, titrate to 0.4-0.8 mg/hour; use a \"patch-on\" period of 12-14 hours per day and a \"patch-off' period of 10-12 hours per day to minimize tolerance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sublingual: 0.3-0.6 mg every 5 minutes for maximum of 3 doses in 15 minutes; may also use prophylactically 5-10 minutes prior to activities which may provoke an attack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Topical: 2% Ointment: Apply 0.5 inch upon rising and 0.5 inch 6 hours later; if necessary, the dose may be doubled to 1 inch and subsequently doubled again to 2 inches if response is inadequate. Doses of 0.5-2 inches were used in clinical trials. Recommended maximum: 2 doses/day; include a nitrate-free interval ~10-12 hours/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Translingual: 1-2 sprays into mouth onto or under tongue every 3-5 minutes for maximum of 3 sprays in 15 minutes; may administer 5-10 minutes before activities that may precipitate angina",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, translingual: 400 mcg/spray (4.1 g, 8.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NitroMist&reg;: 400 mcg/spray (8.5 g) [230 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 2.5 mg, 6.5 mg, 9 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitro-Time&reg;: 2.5 mg, 6.5 mg, 9 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 25 mg (250 mL) [100 mcg/mL]; 50 mg (500 mL) [100 mcg/mL]; 50 mg (250 mL) [200 mcg/mL]; 100 mg (250 mL) [400 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 5 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectiv&reg;: 0.4% (30 g) [contains propylene glycol; ~1.5 mg/inch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitro-Bid&reg;: 2% (1 g, 30 g, 60 g) [~15 mg/inch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal: 0.1 mg/hr (30s); 0.2 mg/hr (30s); 0.4 mg/hr (30s); 0.6 mg/hr (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minitran&trade;: 0.1 mg/hr (30s); 0.2 mg/hr (30s); 0.4 mg/hr (30s); 0.6 mg/hr (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitro-Dur&reg;: 0.1 mg/hr (30s); 0.2 mg/hr (30s); 0.3 mg/hr (30s); 0.4 mg/hr (30s); 0.6 mg/hr (30s); 0.8 mg/hr (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, translingual [spray]: 0.4 mg/spray (4.9 g, 12 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitrolingual&reg;: 0.4 mg/spray (12 g) [contains ethanol 20%; 200 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitrolingual&reg;: 0.4 mg/spray (4.9 g) [contains ethanol 20%; 60 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitrostat&reg;: 0.3 mg, 0.4 mg, 0.6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, infusion, injection, patch, solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intra-anal ointment: Using a finger covering (eg, plastic wrap, surgical glove, finger cot), place finger beside 1 inch measuring guide on the box and squeeze ointment the length of the measuring line directly onto covered finger. Insert ointment into the anal canal using the covered finger up to first finger joint (do not insert further than the first finger joint) and apply ointment around the side of the anal canal. If intra-anal application is too painful, may apply the ointment to the outside of the anus. Wash hands following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule (sustained release): Administer with a full glass of water on an empty stomach; swallow whole, do not crush or chew",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet: Place under tongue and allow to dissolve, do not swallow, chew, or crush; do not eat or drink while tablet dissolves",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Translingual spray: Do not shake container. Pump must be primed prior to first use by spraying 5 times (Nitrolingual&reg;) or 10 times (Nitromist&trade;); direct priming sprays into the air, away from patient and others; if pump is unused for 6 weeks, a single priming spray (Nitrolingual&reg;) or 2 priming sprays (Nitromist&trade;) should be completed. To administer dose, spray onto or under tongue with container as close to mouth as possible; close mouth after administration; do not inhale spray; avoid swallowing immediately after spray; do not expectorate or rinse mouth for 5-10 minutes after use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Continuous I.V. infusion: Dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to 50-100 mcg/mL; maximum concentration not to exceed 400 mcg/mL; prepare in glass bottles, EXCEL&reg; or PAB&reg; containers [adsorption occurs to soft plastic (eg, PVC)]; administer via controlled infusion device; special administration sets intended for nitroglycerin (nonpolyvinyl chloride) must be used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Place on hair-free area of skin; rotate patch sites;",
"     <b>",
"      Note:",
"     </b>",
"     Some products are a membrane-controlled system (eg, Transderm-Nitro&reg;); do",
"     <b>",
"      not",
"     </b>",
"     cut these patches to deliver partial doses; rate of drug delivery, reservoir contents, and adhesion may be affected; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (Lee, 1997 and see specific product labeling)",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 200",
"     <b>",
"      mcg",
"     </b>",
"     /mL, or 400",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F202155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, amphotericin B cholesteryl sulfate complex, argatroban, atracurium, bivalirudin, cisatracurium, clonidine, dexmedetomidine, diltiazem, dobutamine, dobutamine with dopamine, dobutamine with lidocaine, dobutamine with nitroprusside, dopamine, dopamine with lidocaine, dopamine with nitroprusside, drotrecogin alfa, epinephrine, eptifibatide, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, haloperidol, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, inamrinone, insulin (regular), labetalol, lidocaine, lidocaine with nitroprusside, linezolid, lorazepam, micafungin, midazolam, milrinone, morphine, nesiritide, nicardipine, nitroprusside, norepinephrine, pancuronium, propofol, ranitidine, remifentanil, tacrolimus, theophylline, thiopental, tirofiban, vasopressin, vecuronium, warfarin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, levofloxacin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Alteplase, furosemide, heparin, hydralazine, metoprolol, pantoprazole, tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. solution: Doses should be made in glass bottles, EXCEL&reg;, or PAB&reg; containers. Adsorption occurs to soft plastic (eg, polyvinyl chloride tubing). Nitroglycerin diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS in glass containers is physically and chemically stable for 48 hours at room temperature and 7 days under refrigeration. In D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS in EXCEL&reg;/PAB&reg; containers it is physically and chemically stable for 24 hours at room temperature. Premixed bottles are stable according to the manufacturer's expiration dating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual tablets, topical ointment, rectal ointment: Store in tightly closed containers at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); slow release capsules at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); translingual spray and transdermal patch at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); use rectal ointment within 8 weeks of opening.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of angina pectoris (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration: Treatment or prevention of angina pectoris; acute decompensated heart failure (especially when associated with acute myocardial infarction); perioperative hypertension (especially during cardiovascular surgery); induction of intraoperative hypotension (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intra-anal administration (Rectiv&trade; ointment): Treatment of moderate to severe pain associated with chronic anal fissure (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitroglycerin may be confused with nitrofurantoin, nitroprusside",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitro-Bid&reg; may be confused with Macrobid&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitroderm may be confused with NicoDerm&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitrol may be confused with Nizoral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitrostat&reg; may be confused with Nilstat, nystatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitrocor [Italy, Russia, and Venezuela] may be confused with Natrecor brand name for nesiritide [U.S., Canada, and multiple international markets]; Nutracort brand name for hydrocortisone in the [U.S. and multiple international markets]; Nitro-Dur [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F4040395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypotension, orthostatic hypotension, peripheral edema, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (common), dizziness, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting,  xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening): Allergic reactions, anaphylactoid reaction, application site irritation (patch), blurred vision, cardiovascular collapse, contact dermatitis (ointment, patch), crescendo angina, exfoliative dermatitis, fixed drug eruption (ointment, patch), methemoglobinemia (rare; overdose), pallor, palpitation, rash, rebound hypertension, restlessness, shock, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitroglycerin, organic nitrates, or any component (including adhesives in transdermal patches); severe anemia; increased ICP; concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (eg, sildenafil, tadalafil, or vardenafil); I.V. product is also contraindicated in hypotension, pericardial tamponade, restrictive cardiomyopathy, or constrictive pericarditis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13842072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intra-anal ointment: Use with caution when treating rectal anal fissures with nitroglycerin in patients with suspected or known significant cardiovascular disorders (eg, cardiomyopathies, heart failure, acute MI); intra-anal topical nitroglycerin administration may decrease systolic blood pressure and decrease arterial vascular resistance.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause severe hypotension; use with caution in hypovolemia, hypotension, and right ventricular infarctions. Transdermal patch may contain conducting metal (eg, aluminum) which may cause a burn to the skin during an MRI scan; remove patch prior to MRI; reapply patch after scan is completed. Due to the potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation. Rectal ointment and some I.V. preparations contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4039431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Nitroglycerin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alteplase: Nitroglycerin may decrease the serum concentration of Alteplase.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Nitroglycerin may diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of myocardial ischemia was reported for users of this combination in a meta-analysis.  Management: Consider alternatives to this combination when possible.  Rosiglitazone prescribing information states that the combination of rosiglitazone and a nitrate is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11313090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased fetal mortality has been observed in animal studies using isosorbide mononitrate and isosorbide dinitrate at doses much higher than those used in humans. Toxic effects were not observed in animal studies following topical administration of nitroglycerin. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate (continuously with I.V. use)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces cardiac oxygen demand by decreasing left ventricular end diastolic pressure and systemic vascular resistance; dilates coronary arteries and improves collateral flow to ischemic regions; vasodilates veins more than arteries",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Sublingual tablet: 1-3 minutes; Translingual spray: Similar to sublingual tablet; Sustained release: ~60 minutes; Topical: 15-30 minutes; Transdermal: ~30 minutes; I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peak effect: Sublingual tablet: 5 minutes; Translingual spray: 4-10 minutes; Sustained release: 2.5-4 hours; Topical: ~60 minutes; Transdermal: 120 minutes; I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Sublingual tablet: At least 25 minutes; Translingual spray: Similar to sublingual tablet; Sustained release: 4-8 hours; Topical: 7 hours; Transdermal: 10-12 hours; I.V.: 3-5 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass; metabolized hepatically to glycerol di- and mononitrate metabolites via liver reductase enzyme; subsequent metabolism to glycerol and organic nitrate; nonhepatic metabolism via red blood cells and vascular walls also occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excretion of inactive metabolites in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/10/9382?source=see_link\">",
"      see \"Nitroglycerin (glyceryl trinitrate): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause dizziness, headache; if no relief of chest pains after 3 sublingual doses, seek emergency care immediately. Remove patch while having MRI scan; can cause burns. Discard rectal ointment 8 weeks after first opening.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. preparations contain alcohol and/or propylene glycol; may need to use nitrate-free interval (10-12 hours/day) to avoid tolerance development; tolerance may possibly be reversed with acetylcysteine; gradually decrease dose in patients receiving NTG for prolonged period to avoid withdrawal reaction; lingual spray contains 20% alcohol, do not spray toward flames",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Elkayam U, &ldquo;Tolerance to Organic Nitrates: Evidence, Mechanisms, Clinical Relevance, and Strategies for Prevention,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 114(8):667-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34934/abstract-text/2003715 /pubmed\" id=\"2003715 \" target=\"_blank\">",
"        2003715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman WF and George BL, \"Treatment of Congestive Heart Failure by Altering Loading Conditions of the Heart,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 106(5):697-706.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34934/abstract-text/3923176/pubmed\" id=\"3923176\" target=\"_blank\">",
"        3923176",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laitinen P, Happonen JM, Sairanen H, et al, \"Amrinone Versus Dopamine-Nitroglycerin After Reconstructive Surgery for Complete Atrioventricular Septal Defect,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 1997, 11(7):870-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34934/abstract-text/9412887/pubmed\" id=\"9412887\" target=\"_blank\">",
"        9412887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laitinen P, Happonen JM, Sairanen H, et al, \"Amrinone Versus Dopamine and Nitroglycerin in Neonates After Arterial Switch Operation for Transposition of the Great Arteries,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 1999, 13(2):186-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34934/abstract-text/10230954/pubmed\" id=\"10230954\" target=\"_blank\">",
"        10230954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee HA and Anderson PO, &ldquo;Giving Partial Doses of Transdermal Patches,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(15):1759-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34934/abstract-text/9262751/pubmed\" id=\"9262751\" target=\"_blank\">",
"        9262751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams RS, Mickell JJ, Young ES, et al, \"Methemoglobin Levels During Prolonged Combined Nitroglycerin and Sodium Nitroprusside Infusions in Infants After Cardiac Surgery,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 1994, 8(6):658-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34934/abstract-text/7880995/pubmed\" id=\"7880995\" target=\"_blank\">",
"        7880995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12646 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34934=[""].join("\n");
var outline_f34_7_34934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054421\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675227\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054413\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202076\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202061\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054425\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472968\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202155\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054416\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054424\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202157\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4040395\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054429\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842072\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054412\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299768\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4039431\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202072\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11313090\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054420\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054411\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054427\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054428\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054418\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054430\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12646\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12646|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=related_link\">",
"      Nitroglycerin (glyceryl trinitrate): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/10/9382?source=related_link\">",
"      Nitroglycerin (glyceryl trinitrate): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34935="Maintenance and replacement fluid therapy in adults";
var content_f34_7_34935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maintenance and replacement fluid therapy in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34935/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34935/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34935/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34935/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34935/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/7/34935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical role of the kidneys is to maintain the effective circulating volume and plasma osmolality within relatively narrow limits, as well as to maintain electrolyte homeostasis. The normal homeostatic mechanisms that maintain the effective circulating volume and plasma osmolality are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Under normal circumstances, the kidneys can adjust to wide variations in dietary intake by appropriate variations in water and electrolyte excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/1\">",
"     1",
"    </a>",
"    ], which is particularly important when discussing maintenance fluid requirements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Water balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water losses lead to an increase in serum sodium and osmolality, resulting in stimulation of thirst and increased release of antidiuretic hormone (ADH). In normal individuals, these changes will lead to increased water intake and reduced water excretion, which will restore normal water balance. Thus, patients who are alert, have an intact thirst mechanism, and access to water will not become hypernatremic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On a normal diet, the minimum water intake is estimated at 500",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    (assuming there are no increased losses). This value is based upon the balance of total water intake and production and the minimum rate of urinary loss. Individuals who can concentrate their urine to 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    who excrete 600 mosmol of solute (sodium and potassium salts and urea) per day will have a minimum urine output of 500 mL (600 mosmol &divide; 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"   </p>",
"   <p>",
"    There are two other sources of water in addition to fluid ingestion: the water content of food (fruits and vegetables are almost 100 percent water by weight) and the water generated by oxidation of carbohydrates. There are also other sources of water loss in addition to the urine output: insensible losses and sweat.",
"   </p>",
"   <p>",
"    Normal adults are considered to have a minimal obligatory water intake or generation of approximately 1600 mL per day, composed of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ingested water &ndash; 500 mL",
"     </li>",
"     <li>",
"      Water in food &ndash; 800 mL",
"     </li>",
"     <li>",
"      Water from oxidation &ndash; 300 mL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sources of obligatory water output in normal adults are composed of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urine &ndash; 500 mL",
"     </li>",
"     <li>",
"      Skin &ndash; 500 mL",
"     </li>",
"     <li>",
"      Respiratory tract &ndash; 400 mL",
"     </li>",
"     <li>",
"      Stool &ndash; 200 mL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the water of oxidation and much of the water lost from the lungs during respiration are linked [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/2\">",
"     2",
"    </a>",
"    ]. The metabolic production of CO2 and water occur in a 1:1 proportion during the oxidation of carbohydrates and fatty acids and, if the arterial pCO2 is close to 40 mmHg, these two end-products are eliminated together in alveolar air in a 1:1 proportion. Water and CO2 are eliminated in parallel because the partial pressures of water vapor (47 mmHg) and CO2 (40 mmHg) are virtually equal in alveolar air, and because both CO2 and water are nearly absent in inspired air.",
"   </p>",
"   <p>",
"    Thus, the water of oxidation and most of the water normally lost from the lungs during respiration can probably be removed from estimates of water balance [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/2\">",
"     2",
"    </a>",
"    ]. In most patients, only the small amount of water evaporation from the upper respiratory tract results in a negative water balance. This does not apply to patients who are hyperventilating (which increases alveolar water losses) or are on a ventilator and inspiring humidified air warmed to body temperature (which decreases alveolar water losses).",
"   </p>",
"   <p>",
"    Evaporation of water from the skin as sweat (which usually has a sodium concentration of 15 to 30",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and is therefore mostly water) is required to dissipate heat. When additional heat loss is needed, there is an increase in evaporative water losses from the skin. On the other hand, these losses diminish during fasting and inactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sodium balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium intake and urinary sodium excretion are closely balanced. On a normal western diet, the 100 to 250 meq of sodium that are taken are excreted in the urine. However, the kidney can excrete urine that is virtually free of sodium. As an example, in the era before antihypertensive drugs were available, most patients maintained sodium balance on the Kempner rice diet, which contained less than 10 meq of sodium per day [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fluid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two components to fluid therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy replaces the ongoing losses of water and electrolytes under normal physiologic conditions via urine, sweat, respiration, and stool.",
"     </li>",
"     <li>",
"      Replacement therapy corrects any existing water and electrolyte deficits. These deficits can result from gastrointestinal, urinary, or skin losses, bleeding, and third-space sequestration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maintenance fluid therapy and repletion of mild fluid deficits will be reviewed here. The following discussion generally applies to patients with normal kidney function (and normal concentrating and diluting ability) and no underlying severe cardiac or hepatic dysfunction. Fluid and electrolyte balance are clearly different in patients with severe renal disease or an edematous state. The treatment of severe hypovolemia or hypovolemic shock is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MAINTENANCE FLUID THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of normal or near-normal kidney function, maintenance fluid therapy is usually undertaken when the patient is not expected to be able to eat or drink normally for a prolonged period of time (eg, perioperatively or on a ventilator). The goal of maintenance fluid therapy is to preserve water and electrolyte balance and to provide nutrition. Patients expected to have inadequate energy or fluid intake for more than one to two weeks should be considered for parenteral or enteral nutrition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum sodium concentration provides the best estimate of water balance in relation to solute. A normal serum sodium concentration implies that the patient is in water balance in relation to sodium but does not provide any information on volume status. Weighing the patient daily provides the best means for estimating net gain or loss of fluid, since gastrointestinal, urine, and insensible losses in hospitalized patients are unpredictable and difficult to monitor.",
"   </p>",
"   <p>",
"    The patient should also be monitored for clinical signs of either volume excess (edema) or volume depletion (eg, reduced skin turgor, fall in blood pressure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Water",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalized patients who are afebrile, not eating, and physically inactive require less than one liter of electrolyte (sodium and potassium)-free water as maintenance fluid. Maintenance water requirements can be increased or decreased by a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased water intake is required if the patient has fever, sweating, burns, tachypnea, surgical drains, polyuria, or ongoing significant gastrointestinal losses. As an example, water requirements increase by 100 to 150",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      for each degree of body temperature elevation over 37&ordm;C.",
"     </li>",
"     <li>",
"      Decreased water intake is required in a number of clinical settings, including oliguric renal failure, the use of humidified air, edematous states, and hypothyroidism. In addition, sick patients may be unable to excrete excess water due to the presence of nonosmotic stimuli for the release of antidiuretic hormone (ie, syndrome of inappropriate ADH secretion). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"       \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, the adequacy of water balance, as opposed to the adequacy of volume balance, is determined solely from the serum sodium concentration. A normal value means that the body has the proper amount of water for the amount of sodium but provides no information on volume balance. Because water deficits do not develop very rapidly in patients who do not have accelerated water losses, adjustment of the water prescription based upon frequent measurements of the serum sodium concentration is a logical strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of electrolyte losses (primarily sodium and potassium salts) are in the urine, with a lesser contribution from the skin and gastrointestinal tract. Electrolyte balance can be maintained over wide range of intakes due to appropriate changes in urinary electrolyte excretion. If, for example, there is an increase in sodium intake, the ensuing increase in extracellular fluid volume will reduce the activity of the renin-angiotensin-aldosterone system and increase the release of natriuretic peptides, resulting in an appropriate increase in sodium excretion.",
"   </p>",
"   <p>",
"    Since maintenance electrolyte-free water intake is less than one liter per day, a reasonable approach is to begin with two liters per day of one-half isotonic saline in 5 percent dextrose to which 20 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    is added per liter. This regimen provides 9 g of sodium chloride (3.4 g of sodium), which is similar to the sodium content of a hospital diet. The presence of dextrose in the solution does not alter its tonicity and infusion of two liters provides 400 calories, enough to suppress catabolism. Patients with gastrointestinal or third-space losses may require a higher rate of saline (or blood) administration to maintain volume balance.",
"   </p>",
"   <p>",
"    The original solution can be continued unless one of the following occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum sodium starts to fall, a more concentrated solution should be given (eg, isotonic saline in 5 percent dextrose).",
"     </li>",
"     <li>",
"      If the serum sodium starts to rise due, for example, to high fever leading to increased insensible losses, a more dilute solution should be given (eg, one-quarter isotonic saline in 5 percent dextrose).",
"     </li>",
"     <li>",
"      If the serum potassium starts to fall, more potassium should be added and, should it rise above normal, potassium should be eliminated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with normal or near normal renal function, hyperkalemia is a rare problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REPLACEMENT FLUID THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of replacement therapy is to correct existing abnormalities in volume status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum electrolytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Volume deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no formula that can be used to accurately estimate the total fluid deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/6\">",
"     6",
"    </a>",
"    ]. If pre- and post-deficit body weight is known, then weight loss provides a reasonable estimate of fluid losses. If the degree of weight loss is not known, then the fluid deficit cannot be estimated. Clinical and laboratory parameters can be used to assess the possible presence of volume depletion, including the blood pressure, jugular venous pressure, urine sodium concentration, urine output, and, if baseline values are available and bleeding has not occurred, the hematocrit.",
"   </p>",
"   <p>",
"    These parameters should be followed to assess the efficacy of volume repletion. If, for example, the urine sodium concentration remains below 15",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    then the kidney is sensing persistent volume depletion and more fluid should be given. Use of the urine sodium concentration does",
"    <strong>",
"     not",
"    </strong>",
"    apply to edematous patients with heart failure or cirrhosis in whom the urine sodium concentration is a marker of effective circulating volume depletion but not of the need for more fluid or more salt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathophysiology and etiology of edema in adults\", section on 'Renal sodium retention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rate of repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of correction of volume depletion depends upon its severity. With severe volume depletion or hypovolemic shock, at least 1 to 2 liters of isotonic saline are generally given as rapidly as possible in an attempt to restore tissue perfusion, Fluid repletion is continued at a rapid rate until the clinical signs of hypovolemia improve (eg, low blood pressure, low urine output,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired mental status). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Rate of fluid repletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, rapid fluid resuscitation is not necessary in patients with mild to moderate hypovolemia. To avoid worsening of the volume deficit, the rate of fluid administration must be greater than the rate of continued fluid losses, which is equal to the urine output plus estimated insensible losses (usually 30 to 50",
"    <span class=\"nowrap\">",
"     mL/h)",
"    </span>",
"    plus any other fluid losses (eg, gastrointestinal losses) that may be present. One regimen that we have used to induce positive fluid balance in such patients is the administration of fluid at a rate that is 50 to 100",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    greater than estimated fluid losses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choice of replacement fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The composition of fluid that is given is largely dependent upon the type of fluid that has been lost and any concurrent electrolyte disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/6\">",
"     6",
"    </a>",
"    ]. Most patients are treated with isotonic or one-half isotonic saline but the choice of therapy can be influenced by concurrent abnormalities in serum sodium or potassium or the presence of metabolic acidosis (",
"    <a class=\"graphic graphic_table graphicRef69195 \" href=\"UTD.htm?42/56/43916\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60477 \" href=\"UTD.htm?36/7/36988\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As examples, hypotonic solutions should be used in hypernatremia, isotonic or hypertonic saline should be used in hyponatremia, and isotonic saline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood should be used in patients with blood loss. Potassium or bicarbonate may need to be added in patients with hypokalemia or metabolic acidosis.",
"   </p>",
"   <p>",
"    Choosing a replacement fluid in patients with severe volume depletion, including a discussion about the use of crystalloid versus colloid, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Choice of replacement fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water deficits resulting in hypernatremia should almost always be corrected",
"    <strong>",
"     slowly",
"    </strong>",
"    , since overly rapid correction is potentially harmful. The preferred rate of correction and the supportive data are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hypernatremia\", section on 'Step two: choose a rate of correction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Avoidance of overly rapid correction can be achieved by calculating how much dilute fluid (eg, 5 percent dextrose in water) should be given to lower the sodium at the desired rate. Dextrose in water can be given alone in patients with diabetes insipidus who have lost only water, but will not correct all of the hypovolemia if there has also been salt and water loss due, for example, to concurrent diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hypernatremia\", section on 'Step one: estimate the water deficit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sodium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potassium can be added to the intravenous fluid as necessary to treat concurrent volume depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypokalemia (due, for example, to diarrhea). However, the addition of sodium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potassium decreases the amount of free water that is being given. If, for example, one-quarter isotonic saline is infused, then only three-quarters of the solution is free water. In this setting, approximately 1333 mL of isotonic saline must be given to provide 1000 mL of free water. If potassium is also added to the intravenous fluid, then even less free water is present and a further adjustment to the rate of infusion must be made. These adjustments are only estimates that are then guided by serial monitoring of the serum sodium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with hypernatremia, overly rapid correction of hyponatremia is potentially harmful if there has been time for adaptation to the electrolyte disturbance (greater than 48 hours). The administration of isotonic saline in hyponatremic patients will initially tend to raise the serum sodium, since it has a higher sodium concentration than the serum.",
"   </p>",
"   <p>",
"    If the cause of hyponatremia is a hypovolemic stimulus to antidiuretic hormone (ADH) secretion, then once the volume deficit is largely repaired, the stimulus to ADH secretion will be removed. This will result in the excretion of a maximally dilute urine and possible overly rapid correction of the hyponatremia that can lead to severe neurologic dysfunction.",
"   </p>",
"   <p>",
"    On the other hand, if the cause of hyponatremia is the syndrome of inappropriate ADH secretion (SIADH), the urine will remain concentrated and the sodium contained in the intravenous isotonic fluid will be excreted in the urine at a higher concentration than in the infused intravenous fluid. This &ldquo;desalination&rdquo; phenomenon will result in a net gain of electrolyte-free water that may cause the serum sodium to fall during the infusion of isotonic saline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Addition of potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent potassium replacement is indicated in patients who have developed potassium depletion as typically manifested by hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also settings in which potassium depletion is present but the serum potassium is normal or even increased. A classic example is diabetic ketoacidosis or nonketotic hyperglycemia in which both hyperosmolality and insulin deficiency promote potassium movement out of the cells, masking the presence of potassium depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum potassium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potassium is as osmotically active as sodium. Thus, the addition of 40 meq of potassium to one liter of one-half isotonic saline (containing 77",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of sodium) creates a solution that is essentially three-quarters isotonic saline and therefore contains less free water. This could be important in patients with an elevated plasma osmolality due to hypernatremia or uncontrolled diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Effect of potassium supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Addition of bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more complex solution may be required in patients with metabolic acidosis. In this setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    may be added, particularly if the acidemia is severe (arterial pH less than 7.15 to 7.20 or less than 7.0 in diabetic ketoacidosis) or bicarbonate losses persist (as with severe diarrhea). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Bicarbonate and metabolic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suppose a patient with diarrhea presents with mild hypernatremia, mild hypokalemia, and a serum bicarbonate concentration of 10",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    An appropriate dilute replacement fluid in this setting might be one-quarter isotonic saline in 5 percent dextrose (containing 38.5 meq of sodium chloride) to which 20 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    and 25 meq (one-half ampule) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    have been added. The total cation concentration is 83.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    roughly equivalent to one-half isotonic saline. It is important to add potassium to the intravenous fluid in hypokalemic patients since both the administration of bicarbonate and increased insulin secretion induced by dextrose will tend to drive potassium into the cells, which will further reduce the serum potassium concentration.",
"   </p>",
"   <p>",
"    An alternative regimen that can be used in patients with metabolic acidosis without hypokalemia is the addition of three ampules of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    (each containing 50 meq of sodium and 50 mL of water) to one liter of 5 percent dextrose in water, which results in a nearly isotonic solution with a sodium concentration of approximately 130",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In contrast, addition of the same three ampules of sodium bicarbonate to one-liter of half isotonic saline (containing 77",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of sodium), results in a hypertonic solution with a sodium concentration of 197",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which will tend to raise the serum sodium concentration. Such a solution should not be used unless the patient is hyponatremic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SALINE ALONE OR WITH DEXTROSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence that a dextrose-saline solution has any benefit or harm compared to a saline solution alone for most patients. However, there are some exceptions to this general rule:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dextrose-containing solutions",
"      <strong>",
"       should be used",
"      </strong>",
"      in patients with hypoglycemia or alcohol or fasting ketoacidosis, and should be given with insulin in patients with hyperkalemia and no hyperglycemia since insulin-mediated entry of potassium into cells will lower the serum potassium concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link&amp;anchor=H26#H26\">",
"       \"Management of hypoglycemia during treatment of diabetes mellitus\", section on 'Treatment of hypoglycemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment and prevention of hyperkalemia in adults\", section on 'Insulin with glucose'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=see_link&amp;anchor=H5#H5\">",
"       \"Alcoholic and fasting ketoacidosis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dextrose-containing solutions",
"      <strong>",
"       should not be used",
"      </strong>",
"      in patients with uncontrolled diabetes mellitus or hypokalemia. With respect to hypokalemia, the administration of dextrose stimulates the release of insulin, which promotes potassium entry into cells with possible worsening of the hypokalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820183#H3820183\">",
"       \"Clinical manifestations and treatment of hypokalemia\", section on 'Intravenous therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dextrose-induced hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of large volumes of dextrose-containing solutions to critically ill patients can promote the development of hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], which is in part mediated by both administering dextrose at a rate that exceeds the maximum rate of metabolism and by the counterregulatory hormone response (eg, increased epinephrine secretion) and perhaps cytokine responses [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies of patients without diabetes who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) or in normal individuals given glucose infusions, hyperglycemia is primarily seen when glucose is given at a rate exceeding 4 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute, a rate that exceeds the body's ability to metabolize glucose, even with maximum doses of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In a patient weighing 70 kg, a glucose dose of 4 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute translates into an infusion rate greater than 5.6 to 7.0",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (336 to 420",
"    <span class=\"nowrap\">",
"     mL/h)",
"    </span>",
"    with 5 percent dextrose solutions and greater than 0.8 to 1.0",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (48 to 60",
"    <span class=\"nowrap\">",
"     mL/h)",
"    </span>",
"    with the 25 to 35 percent glucose solutions that may be used in TPN.",
"   </p>",
"   <p>",
"    The usual safety of lower glucose infusion rates was demonstrated in a report of TPN in hematopoietic stem cell transplant recipients, who are typically highly stressed [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34935/abstract/11\">",
"     11",
"    </a>",
"    ]. The proportion of hyperglycemic days was not increased compared to patients not treated with TPN at an average glucose infusion rate of 2.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min (range 1.3 to 3.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of maintenance fluid therapy is to preserve water and electrolyte balance and to provide nutrition among patients who are not able to eat or drink.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalized patients who are afebrile, not eating, and physically inactive require less than one liter of electrolyte (sodium and potassium)-free water as maintenance fluid. Requirements are increased if there are increased fluid losses as with fever, surgical drains, or ongoing significant gastrointestinal losses. Water requirements are decreased by oliguric renal failure, the use of humidified air, edematous states, hypothyroidism, and the presence of nonosmotic stimuli for the release of antidiuretic hormone (ie, syndrome of inappropriate ADH secretion). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Maintenance fluid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require maintenance fluid and have normal or near-normal renal function and are otherwise stable, we suggest beginning with two liters per day of one-half isotonic saline in 5 percent dextrose to which 20 meq of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      is added per liter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Electrolytes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with gastrointestinal or third-space losses may require a higher rate of saline (or blood) administration to maintain volume balance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The original maintenance regimen can be continued unless one of the following occurs (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Electrolytes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the serum sodium starts to fall, a more concentrated solution should be given (eg, isotonic saline).",
"     </li>",
"     <li>",
"      If the serum sodium starts to rise, a more dilute solution should be given (eg, one-quarter isotonic saline).",
"     </li>",
"     <li>",
"      If the serum potassium starts to fall, more potassium should be added, and, if it rises above normal, potassium should be eliminated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of replacement therapy is to correct existing abnormalities in volume status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum electrolytes. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Replacement fluid therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The total fluid deficit can be estimated from pre- and post-deficit body weight. If the degree of weight loss is not known, then the fluid deficit cannot be estimated. Clinical and laboratory parameters can be used to assess the possible presence of volume depletion, including the blood pressure and urine sodium concentration. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Volume deficit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of correction of volume depletion depends upon its severity. For patients with severe volume depletion or hypovolemic shock, we recommend administration of 1 to 2 liters of isotonic saline as rapidly as possible in an attempt to restore tissue perfusion (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Fluid repletion is continued at a rapid rate until the clinical signs of hypovolemia improve (eg, low blood pressure, low urine output,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impaired mental status). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Rate of repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A less rapid rate of correction should be used in patients with mild to moderate hypovolemia. In such cases, the rate of fluid administration must be greater than the rate of continued fluid losses, which is equal to the urine output plus estimated insensible losses (usually 30 to 50",
"      <span class=\"nowrap\">",
"       mL/h)",
"      </span>",
"      plus any other fluid losses (eg, gastrointestinal losses) that may be present. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Rate of repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of replacement fluid is dependent upon the type of fluid that has been lost and any concurrent electrolyte disorders. Most patients are initially treated with isotonic or one-half isotonic saline. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of replacement fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypernatremia and hyponatremia should usually be corrected slowly, since overly rapid correction is potentially harmful. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypernatremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potassium replacement is indicated in patients with potassium depletion. This is typically manifested by hypokalemia, but may occur in the setting of a normal or even increased serum potassium in patients with diabetic ketoacidosis or nonketotic hyperglycemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Addition of potassium'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum potassium'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      may be required in patients with metabolic acidosis if the acidemia is severe (arterial pH less than 7.20) or bicarbonate losses persist (as with severe diarrhea). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Addition of bicarbonate'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"       \"Approach to the adult with metabolic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In general, there is little evidence that adding or omitting dextrose from saline has any benefit or harms. However, there are settings in which dextrose should or should not be used. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Saline alone or with dextrose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/2\">",
"      Shafiee MA, Bohn D, Hoorn EJ, Halperin ML. How to select optimal maintenance intravenous fluid therapy. QJM 2003; 96:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/3\">",
"      WATKIN DM, FROEB HG, HATCH FT, GUTMAN AB. Effects of diet in essential hypertension. II. Results with unmodified Kempner rice diet in 50 hospitalized patients. Am J Med 1950; 9:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/4\">",
"      MURPHY RJ. The effect of \"rice diet\" on plasma volume and extracellular fluid space in hypertensive subjects. J Clin Invest 1950; 29:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/5\">",
"      Sterns RH, Silver SM. Salt and water: read the package insert. QJM 2003; 96:549.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.441.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/7\">",
"      McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/8\">",
"      Rosmarin DK, Wardlaw GM, Mirtallo J. Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition dextrose. Nutr Clin Pract 1996; 11:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/9\">",
"      Schloerb PR, Henning JF. Patterns and problems of adult total parenteral nutrition use in US academic medical centers. Arch Surg 1998; 133:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/10\">",
"      Wolfe RR, Allsop JR, Burke JF. Glucose metabolism in man: responses to intravenous glucose infusion. Metabolism 1979; 28:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34935/abstract/11\">",
"      Sheean P, Braunschweig C. The incidence and impact of dextrose dose on hyperglycemia from parenteral nutrition (PN) exposure in hematopoietic stem cell transplant (HSCT) recipients. JPEN J Parenter Enteral Nutr 2006; 30:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2296 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34935=[""].join("\n");
var outline_f34_7_34935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Water balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sodium balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fluid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MAINTENANCE FLUID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REPLACEMENT FLUID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Volume deficit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rate of repletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choice of replacement fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Addition of potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Addition of bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SALINE ALONE OR WITH DEXTROSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dextrose-induced hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2296|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/56/43916\" title=\"table 1\">",
"      Common IV Solutions B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/7/36988\" title=\"table 2\">",
"      Common IV Solutions A",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=related_link\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34936="Metronidazole (systemic): Drug information";
var content_f34_7_34936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metronidazole (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19205?source=see_link\">",
"    see \"Metronidazole (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=see_link\">",
"    see \"Metronidazole (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8770965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8770969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flagyl&reg;;",
"     </li>",
"     <li>",
"      Flagyl&reg; 375;",
"     </li>",
"     <li>",
"      Flagyl&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8770970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metronidazole&reg;;",
"     </li>",
"     <li>",
"      Flagyl&reg;;",
"     </li>",
"     <li>",
"      Florazole&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8771005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Amebicide;",
"     </li>",
"     <li>",
"      Antibiotic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antiprotozoal, Nitroimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8771169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anaerobic infections (diverticulitis, intra-abdominal, peritonitis, cholangitis, or abscess):",
"     </b>",
"     Oral, I.V.: 500 mg every 6-8 hours, not to exceed 4 g/day;",
"     <b>",
"      Note:",
"     </b>",
"     Initial: 1 g I.V. loading dose may be administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Amebiasis:",
"     </b>",
"     Oral: 500-750 mg every 8 hours for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Antibiotic-associated pseudomembranous colitis:",
"     </b>",
"     IDSA Guidelines (Cohen, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate infection: Oral: 500 mg 3 times/day for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe complicated infection: I.V.: 500 mg 3 times/day with oral vancomycin (recommended agent) for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to the emergence of a new strain of",
"     <i>",
"      C. difficile",
"     </i>",
"     , some clinicians recommend converting to oral vancomycin therapy if the patient does not show a clear clinical response after 2 days of metronidazole therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Giardiasis:",
"     </b>",
"     500 mg twice daily for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection, complicated, community-acquired, mild-to-moderate (in combination with cephalosporin or fluoroquinolone):",
"     </b>",
"     I.V.: 500 mg every 8-12 hours",
"     <b>",
"      or",
"     </b>",
"     1.5 g every 24 hours for for 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peptic ulcer disease:",
"     </b>",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      eradication:",
"     </b>",
"     Oral: 250-500 mg with meals and at bedtime for 14 days; requires combination therapy with at least one other antibiotic and an acid-suppressing agent (proton pump inhibitor or H",
"     <sub>",
"      2",
"     </sub>",
"     blocker)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bacterial vaginosis or vaginitis due to",
"     </b>",
"     <b>",
"      <i>",
"       Gardnerella",
"      </i>",
"     </b>",
"     ,",
"     <b>",
"      <i>",
"       Mobiluncus",
"      </i>",
"     </b>",
"     : Oral: 500 mg twice daily (regular release) or 750 mg once daily (extended release tablet) for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pelvic inflammatory disease (unlabeled use):",
"     </b>",
"     Oral: 500 mg twice daily for 14 days (in combination with a cephalosporin and doxycycline) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Periodontitis treatment (monotherapy or combination) associated with presence of",
"     </b>",
"     <b>",
"      <i>",
"       Actinobacillus actinomycetemcomitans",
"      </i>",
"     </b>",
"     <b>",
"      (AA):",
"     </b>",
"     Oral: 250-500 mg every 8 hours for 8-10 days used in addition to scaling and root planing (Varela, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Trichomoniasis:",
"     </b>",
"     Oral: 250 mg every 8 hours for 7 days",
"     <b>",
"      or",
"     </b>",
"     375 mg twice daily for 7 days",
"     <b>",
"      or",
"     </b>",
"     2 g as a single dose",
"     <b>",
"      or",
"     </b>",
"     1 g twice daily for 2 doses (on same day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urethritis (unlabeled use):",
"     </b>",
"     Oral: 2 g as a single dose with azithromycin (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Surgical prophylaxis (colorectal):",
"     </b>",
"     I.V. 15 mg/kg 1 hour prior to surgery; followed by 7.5 mg/kg 6 and 12 hours after initial dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8771168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=see_link\">",
"      see \"Metronidazole (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anaerobic infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 15-35 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 30 mg/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colitis due to",
"     </b>",
"     <b>",
"      <i>",
"       Clostridium difficile",
"      </i>",
"     </b>",
"     : Oral: 30 mg/kg/day divided every 6 hours for 7-10 days; maximum dose: 2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amebiasis:",
"     </b>",
"     Oral: 35-50 mg/kg/day in divided doses every 8 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Trichomoniasis:",
"     </b>",
"     Oral: 15-30 mg/kg/day in divided doses every 8 hours for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8771170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use the lower end of the dosing recommendations for adults; do not administer as single dose as efficacy has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8771171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute (not on dialysis): Recommendations vary: To reduce possible accumulation in patients receiving multiple doses, consider reduction to 50% of dose or administer normal dose every 12 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Dosage reduction is unnecessary in short courses of therapy. Some references do not recommend reduction at any level of renal impairment (Lamp, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50% to 100%): 500 mg every 8-12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing regimen highly dependent on clinical indication (trichomoniasis vs",
"     <i>",
"      C. difficile",
"     </i>",
"     colitis) (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of thrice weekly, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH/CVVHD/CVVHDF: 500 mg every 6-12 hours (or per clinical indication; dosage reduction generally not necessary)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8771172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unchanged in mild liver disease; reduce dosage in severe liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8771210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 375 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flagyl&reg; 375: 375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic sodium chloride solution: 500 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flagyl&reg;: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flagyl&reg; ER: 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8770972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule, extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8771184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse intravenously over 30-60 minutes. Avoid contact of drug solution with equipment containing aluminum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be taken with food to minimize stomach upset. Extended release tablets should be taken on an empty stomach (1 hour before or 2 hours after meals).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8771128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amiodarone, anidulafungin, bivalirudin, caspofungin, cefepime, ciprofloxacin, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, dimenhydrinate, docetaxel, dopamine, doripenem, doxapram, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, fentanyl, fluconazole, foscarnet, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, labetalol, levofloxacin, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, methylprednisolone sodium succinate, midazolam, milrinone, morphine, nicardipine, oxytocin, palonosetron, piperacillin/tazobactam, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa, vasopressin, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, aztreonam, drotrecogin alpha, filgrastim, meropenem, pemetrexed.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, doxapram, pantoprazole, warfarin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8771015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible anaerobic bacterial and protozoal infections in the following conditions: Amebiasis, symptomatic and asymptomatic trichomoniasis; skin and skin structure infections, bone and joint infections, CNS infections, endocarditis, gynecologic infections, intra-abdominal infections (as part of combination regimen), respiratory tract infections (lower), systemic anaerobic infections; treatment of antibiotic-associated pseudomembranous colitis (AAPC); as part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence; surgical prophylaxis (colorectal); useful as single agent or in combination with amoxicillin, amoxicillin/clavulanic acid, or ciprofloxacin in the treatment of periodontitis associated with the presence of",
"     <i>",
"      Actinobacillus actinomycetemcomitans",
"     </i>",
"     (AA).",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8771017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Crohn's disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8770967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MetroNIDAZOLE may be confused with mebendazole, meropenem, metFORMIN, methotrexate, metoclopramide, miconazole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8771038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flattening of the T-wave, flushing, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aseptic meningitis, ataxia, confusion, coordination impaired, depression, dizziness, encephalopathy, fever, headache, insomnia, irritability, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythematous rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disulfiram-like reaction, dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (~12%), anorexia, abdominal cramping, constipation, diarrhea, epigastric distress, furry tongue, glossitis, pancreatitis (rare), proctitis, stomatitis, unusual/metallic taste, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis, darkened urine (rare), dyspareunia, dysuria, incontinence, libido decreased, pelvic pressure, polyuria, vaginal dryness, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia (reversible), thrombocytopenia (reversible, rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria, peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, pharyngitis, rhinitis, sinusitis, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, joint pains resembling serum sickness, moniliasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8771023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component of the formulation; pregnancy (first trimester)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8771024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenic:",
"     <b>",
"      [U.S. Boxed Warning]: Possibly carcinogenic based on animal data.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Aseptic meningitis, encephalopathy, seizures, and neuropathies (peripheral and optic) have been reported especially with increased doses and chronic treatment; monitor and consider discontinuation of therapy if signs/symptoms occur. Use with caution in patients with a history of seizure disorder; reduce doses with patients with CNS disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Candidiasis infection (known or unknown) may be more prominent during metronidazole treatment, antifungal treatment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Use with caution in patients with or history of blood dyscrasias; leukopenia has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use injection with caution in patients with heart failure, edema or other sodium retaining states.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe liver impairment due to potential accumulation; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      H. pylori",
"     </i>",
"     infection: If",
"     <i>",
"      H. pylori",
"     </i>",
"     is not eradicated in patients being treated with metronidazole in a regimen, it should be assumed that metronidazole-resistance has occurred and it should not again be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Consider dosage reduction in longer-term therapy with severe renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: The Infectious Disease Society of America (IDSA) recommends the use of oral metronidazole for initial treatment of mild-to-moderate",
"     <i>",
"      C. difficile",
"     </i>",
"     infection and the use of oral vancomycin for initial treatment of severe",
"     <i>",
"      C. difficile",
"     </i>",
"     infection with or without I.V. metronidazole depending on the presence of complications. May treat recurrent mild-to-moderate infection once with oral metronidazole; avoid use beyond first reoccurrence due to potential cumulative neurotoxicity (Cohen, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alcohol consumption:  Disulfiram-like reactions to ethanol have been reported with oral metronidazole; avoid alcoholic beverages during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8771042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8771043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: MetroNIDAZOLE (Systemic) may increase the serum concentration of Busulfan.  Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcineurin Inhibitors: MetroNIDAZOLE (Systemic) may decrease the metabolism of Calcineurin Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): MetroNIDAZOLE (Systemic) may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: MetroNIDAZOLE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives to concomitant therapy with these agents.  Monitor for increased INR/bleeding risk if metronidazole is initiated/dose increased, or decreased effects if metronidazole is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8771047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: The manufacturer recommends to avoid all ethanol or any ethanol-containing drugs (may cause disulfiram-like reaction characterized by flushing, headache, nausea, vomiting, sweating, or tachycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8771018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8771019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Metronidazole crosses the placenta and rapidly distributes into the fetal circulation. Although there have been a few reports of facial anomalies after",
"     <i>",
"      in utero",
"     </i>",
"     exposure, most studies have not found an increased risk of congenital abnormalities following maternal use of metronidazole during the first trimester of pregnancy. In studies that included women taking metronidazole during all trimesters of pregnancy, an increased risk of adverse fetal and neonatal outcomes has not been observed. Because metronidazole has been carcinogenic in some animal species, concern has been raised whether metronidazole should be used during pregnancy; however, a strong carcinogenic potential in humans has not been observed, including one study of prenatal exposure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients.  Bacterial vaginosis has been associated with adverse pregnancy outcomes (including preterm labor); metronidazole is recommended for the treatment of symptomatic bacterial vaginosis in pregnant patients. Vaginal trichomoniasis has been also associated with adverse pregnancy outcomes (including preterm labor). Treatment may relieve symptoms and prevent further sexual transmission; however, metronidazole has not resulted in reduced perinatal morbidity and should not be used solely to prevent preterm delivery.  Some clinicians consider deferring therapy in asymptomatic women until &gt;37 weeks gestation. Use of oral metronidazole is contraindicated during the first trimester (per the FDA approved labeling). Consult current CDC guidelines for appropriate use in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8771021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"of concern\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8771022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metronidazole and its active metabolite are measurable in the breast milk and infant plasma. Milk concentrations are similar to those in the maternal plasma and are highly variable.  Peak concentrations of metronidazole in breast milk occur ~2-4 hours after the oral dose. In studies, the calculated relative infant doses have ranged from 0.13% to 36% of the weight-adjusted maternal dose. Use of metronidazole in a lactating patient is not recommended by the manufacturer. If metronidazole is given, breast-feeding should be withheld for 12-24 hours after the dose (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8771183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach. Drug may cause GI upset; if GI upset occurs, take with food. Extended release tablets should be taken on an empty stomach (1 hour before or 2 hours after meals). Some products may contain sodium. The manufacturer recommends that ethanol be avoided during treatment and for 3 days after therapy is complete.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8771212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Flagyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375 mg (50): $325.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Metro Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/100 mL 0.74% (100 mL): $2.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (MetroNIDAZOLE in NaCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL 0.79% (100 mL): $2.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/100 mL 0.79 (100 mL): $2.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Flagyl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (30): $473.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Flagyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (50): $234.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $418.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (MetroNIDAZOLE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $43.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (500): $345.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amevan (EC);",
"     </li>",
"     <li>",
"      Anaerobex (AT);",
"     </li>",
"     <li>",
"      Anerobizol (PH);",
"     </li>",
"     <li>",
"      Ao Ke An (CL);",
"     </li>",
"     <li>",
"      Arilin (DE);",
"     </li>",
"     <li>",
"      Asiazole (TH);",
"     </li>",
"     <li>",
"      Biatron (ID);",
"     </li>",
"     <li>",
"      Camezol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Clont (DE);",
"     </li>",
"     <li>",
"      Clovizole (PH);",
"     </li>",
"     <li>",
"      Deflamon (IT);",
"     </li>",
"     <li>",
"      Dequazol Oral (PE);",
"     </li>",
"     <li>",
"      Dumozol (ID);",
"     </li>",
"     <li>",
"      Efloran (CZ);",
"     </li>",
"     <li>",
"      Elyzol (FI);",
"     </li>",
"     <li>",
"      Endazole (PH);",
"     </li>",
"     <li>",
"      Entizol (CZ);",
"     </li>",
"     <li>",
"      Farnat (ID);",
"     </li>",
"     <li>",
"      Fentiazol (PY);",
"     </li>",
"     <li>",
"      Fladex (ID);",
"     </li>",
"     <li>",
"      Flagesol (UY);",
"     </li>",
"     <li>",
"      Flagizole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Flagyl (AR, AU, BE, BG, BR, CH, CN, CO, EC, FR, GB, GR, HK, ID, IE, IL, IN, KP, NL, NO, NZ, PE, PH, PK, PT, RU, SG, TH, TR, TW, VE);",
"     </li>",
"     <li>",
"      Flasinyl (KP);",
"     </li>",
"     <li>",
"      Flazol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fogyl (MY);",
"     </li>",
"     <li>",
"      Frotin (HK, MY, TW);",
"     </li>",
"     <li>",
"      Fu Shu Da (CL);",
"     </li>",
"     <li>",
"      Gynoplix (HK);",
"     </li>",
"     <li>",
"      Helmizol (BR);",
"     </li>",
"     <li>",
"      Metazol (ZA);",
"     </li>",
"     <li>",
"      Metrogyl (AU);",
"     </li>",
"     <li>",
"      Metrolag (AE, BF, BH, BJ, CH, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Metrolex (TH);",
"     </li>",
"     <li>",
"      Metronidazole IV (AU, NZ);",
"     </li>",
"     <li>",
"      Metronide (AU);",
"     </li>",
"     <li>",
"      Metrozin (CO);",
"     </li>",
"     <li>",
"      Molazol (ID);",
"     </li>",
"     <li>",
"      Nalox (AR);",
"     </li>",
"     <li>",
"      Narobic (ZA);",
"     </li>",
"     <li>",
"      Novazole (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Patryl (PH);",
"     </li>",
"     <li>",
"      Protozol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Protozole (PH);",
"     </li>",
"     <li>",
"      Qualigyl (HK);",
"     </li>",
"     <li>",
"      Rodazid (PH);",
"     </li>",
"     <li>",
"      Ronazol (ID);",
"     </li>",
"     <li>",
"      Sharizole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Supplin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Trichex (AT);",
"     </li>",
"     <li>",
"      Trizele (KP);",
"     </li>",
"     <li>",
"      Trogiar (ID);",
"     </li>",
"     <li>",
"      Unigo (HK, TH);",
"     </li>",
"     <li>",
"      Vertisal (DO, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Zol (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8771129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     After diffusing into the organism, interacts with DNA to cause a loss of helical DNA structure and strand breakage resulting in inhibition of protein synthesis and cell death in susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8771131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To saliva, bile, seminal fluid, bone, liver, and liver abscesses, lung and vaginal secretions; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF:blood level ratio: Normal meninges: 16% to 43%; Inflamed meninges: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (30% to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Neonates: 25-75 hours; Others: 6-8 hours, prolonged with hepatic impairment; End-stage renal disease: 21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Immediate release: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 80% as unchanged drug); feces (6% to 15%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartlett JG and Perl TM, \"The New",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      - What Does it Mean?\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(23):2503-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/16322604/pubmed\" id=\"16322604\" target=\"_blank\">",
"        16322604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belliveau PP, Nightingale CH, and Quintilani R, &ldquo;Stability of Cefotaxime Sodium and Metronidazole in 0.9% Sodium Chloride Injection or in Ready-to-Use Metronidazole Bags,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(14):1561-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/7552904/pubmed\" id=\"7552904\" target=\"_blank\">",
"        7552904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodgen RN, Heel RC, Speight TM, et al, &ldquo;Metronidazole in Anaerobic Infections: A Review of Its Activity, Pharmacokinetics and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1978, 16(5):387-417.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/363399/pubmed\" id=\"363399\" target=\"_blank\">",
"        363399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cantu JM and Carcia-Cruz D, &ldquo;Midline Facial Defect as a Teratogenic Effect of Metronidazole,&rdquo;",
"      <i>",
"       Birth Defects",
"      </i>",
"      , 1982, 18:85-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen SH, Gerding DN, Johnson S, et al, &ldquo;Clinical Practice Guidelines for",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA),",
"      <i>",
"       Infect Control Hosp Epidemiol",
"      </i>",
"      , 2010, 31(5):431-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/20307191/pubmed\" id=\"20307191\" target=\"_blank\">",
"        20307191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Committee on Adolescence, American Academy of Pediatrics, &ldquo;Sexual Assault and the Adolescent,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 94(5):761-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/7936916/pubmed\" id=\"7936916\" target=\"_blank\">",
"        7936916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coronado BE, Opal SM, and Yoburn DC, &ldquo;Antibiotic-Induced D-Lactic Acidosis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 122(11):839-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/7741368/pubmed\" id=\"7741368\" target=\"_blank\">",
"        7741368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fekety R and Shah AB, &ldquo;Diagnosis and Treatment of",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Colitis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 269(1):71-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/8416409/pubmed\" id=\"8416409\" target=\"_blank\">",
"        8416409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freeman CD, Klutman NE, and Lamp KC, &ldquo;Metronidazole. A Therapeutic Review and Update,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 54(5):679-708.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/9360057/pubmed\" id=\"9360057\" target=\"_blank\">",
"        9360057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hampson JP, &ldquo;The Use of Metronidazole in the Treatment of Malodorous Wounds,&rdquo;",
"      <i>",
"       J Wound Care",
"      </i>",
"      , 1996, 5(9):421-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/8954436/pubmed\" id=\"8954436\" target=\"_blank\">",
"        8954436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Israel DM and Hassall E, &ldquo;Treatment and Long-Term Follow-up of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      -Associated Duodenal Ulcer Disease in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(1):53-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/8320625/pubmed\" id=\"8320625\" target=\"_blank\">",
"        8320625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly CP, Pothoulakis C, and LaMont JT, &ldquo;",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Colitis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(4):257-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/8043060/pubmed\" id=\"8043060\" target=\"_blank\">",
"        8043060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam S and Bank S, &ldquo;Hepatotoxicity Caused by Metronidazole Overdose,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 122(10):803.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lamp KC, Freeman CD, Klutman NE, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of the Nitroimidazole Antimicrobials,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1999,  36(5):353-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/10384859/pubmed\" id=\"10384859\" target=\"_blank\">",
"        10384859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau AH, Chang CW, and Sabatini S, &ldquo;Hemodialysis Clearance of Metronidazole and its Metabolites,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1986, 29(2):235-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/3717930/pubmed\" id=\"3717930\" target=\"_blank\">",
"        3717930",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorber B, \"Update in Infectious Diseases,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2006, 145:356-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ludwig E, Csiba A, Magyar T, et al, &ldquo;Age-Associated Pharmacokinetic Changes of Metronidazole,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther Toxicol",
"      </i>",
"      , 1983, 21(2):87-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/6840930/pubmed\" id=\"6840930\" target=\"_blank\">",
"        6840930",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ralph ED, &ldquo;Clinical Pharmacokinetics of Metronidazole,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8:43-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/6340904/pubmed\" id=\"6340904\" target=\"_blank\">",
"        6340904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smogyi A, Kong C, Sabto J, et al, &ldquo;Disposition and Removal of Metronidazole in Patients Undergoing Haemodialysis,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1983, 25:683-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/6662167/pubmed\" id=\"6662167\" target=\"_blank\">",
"        6662167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Diarrhea,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1989, 31(803):94-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/2796843/pubmed\" id=\"2796843\" target=\"_blank\">",
"        2796843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Varela VM, Heller D, Silva-Senem MX, et al, \"Systemic Antimicrobials Adjunctive to a Repeated Mechanical and Antiseptic Therapy for Aggressive Periodontitis: A 6-Month Randomized Controlled Trial,\"",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 2011, 82(8):1121-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/7/34936/abstract-text/21235333/pubmed\" id=\"21235333\" target=\"_blank\">",
"        21235333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9589 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D4E9CFABE8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34936=[""].join("\n");
var outline_f34_7_34936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770965\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770969\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770970\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771005\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771169\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771168\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771170\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771171\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771172\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771210\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770972\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771184\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771128\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771015\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771017\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770967\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771038\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771023\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771024\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771042\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771047\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771018\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771019\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771021\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771022\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771183\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771212\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961987\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771129\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771131\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9589|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19205?source=related_link\">",
"      Metronidazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=related_link\">",
"      Metronidazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13717?source=related_link\">",
"      Metronidazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=related_link\">",
"      Metronidazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23252?source=related_link\">",
"      Metronidazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34937="Prevention and management of complications from percutaneous endoscopic gastrostomy";
var content_f34_7_34937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and management of complications from percutaneous endoscopic gastrostomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34937/contributors\">",
"     Mark H DeLegge, MD, FACG, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34937/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34937/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34937/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34937/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/7/34937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since endoscopic insertion of a gastrostomy tube was first described in 1980 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/1\">",
"     1",
"    </a>",
"    ], a multitude of commercial kits and variations of the percutaneous endoscopic gastrostomy (PEG) technique have been introduced, including the push (Sachs-Vine), pull (Ponsky), introducer (Russell), and Versa (t-fastener). The most commonly performed are the push and pull techniques, which have been shown to have efficacy and safety in controlled trials. Approximately 100,000 to 125,000 PEG procedures are performed annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/2\">",
"     2",
"    </a>",
"    ]. Despite their overall safety, a number of complications can occur following PEG placement.",
"   </p>",
"   <p>",
"    The prevention and treatment of complications related to PEG will be reviewed here. The indications for PEG placement are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large prospective trials of PEG placement have evaluated the efficacy and safety of the procedure. The frequency of complications observed in the various reports depends upon the definitions used and the population under study [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, for example, complications were described in 70 percent of 97 patients of which 88 percent were considered to be minor, including tube dislodgement, peristomal wound leakage, and PEG wound infection [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A much lower rate of complications was observed in another report of 314 patients of whom 13 percent had minor and 3 percent had major complications, including gastric perforation, gastric bleeding, and hematoma development [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study with 484 patients, 85 patients (18 percent) died within two months of PEG placement [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/5\">",
"       5",
"      </a>",
"      ]. Excluding those who died, complications including abdominal pain, peristomal infection, diarrhea, and leakage were seen in 39 percent of patients at two weeks and in 27 percent of patients at two months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies have suggested that complications are more likely to occur in elderly patients with comorbid illnesses, particularly those with an infectious process or who have a history of aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MINOR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, complications from PEG tube placement can be classified as major or minor. Minor complications include wound infection, wound leakage, wound bleeding, cutaneous or gastric ulceration, pneumoperitoneum, temporary ileus, gastric outlet obstruction, and persistent gastric fistula post-PEG tube removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infection is more likely to occur when a PEG has been placed through a contaminated procedure field or with poor technique in debilitated patients and those who did not receive antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most PEG wound infections will respond to a first generation cephalosporin or a quinolone. Methicillin resistant Staphylococcus aureus has emerged as an important cause of PEG-site infections in some centers [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two studies found that nasopharyngeal decontamination of patients with MRSA (in addition to standard prophylactic antibiotics) significantly reduced the incidence of wound infections [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Another study found that administration of a third generation cephalosporin intravenously and a povidone-iodine spray to the abdominal wall pre-PEG procedure reduced wound infections compared with the intravenous cephalosporin or the povidone-iodine spray used separately [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study looked at treatment with sulfamethoxazole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    to prevent cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/15\">",
"     15",
"    </a>",
"    ]. A total of 234 patients were assigned to either a 20 mL solution of sulfamethoxazole 800 mg plus trimethoprim 160 mg given through the PEG immediately after placement or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    1.5 gm intravenously one hour before PEG placement. After 7 to 14 days of follow-up, there was no significant difference in the rate of wound infections between the patients in the sulfamethoxazole-trimethoprim group compared with the patients who received cefuroxime (9 versus 12 percent).",
"   </p>",
"   <p>",
"    Fungal-related PEG infectious complications occur, although much less commonly than bacterial infectious complications. These include fungal peristomal cellulitis, candidal peritonitis and intra-abdominal abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peristomal leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peristomal leakage usually occurs within the first few days after PEG placement. It is more likely to occur in malnourished patients and those with diabetes who may have poor tissue healing and are prone to wound breakdown. In addition, placement of the external bolster of the PEG tube too tightly against the external abdominal wall will lead to poor tissue blood flow, wound breakdown, and peristomal leakage.",
"   </p>",
"   <p>",
"    Treatment should include correction of comorbidities such as malnutrition and elevated blood sugar, loosening of the external bolster, and local measures to address skin breakdown (such as powdered absorbing agents or a skin protectant such as a paste of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    ). Placement of a larger size PEG tube through the same PEG tube tract will",
"    <strong>",
"     not",
"    </strong>",
"    solve the problem. Once the PEG tube tract has started to leak, placing larger gastrostomy tubes through the same tract will serve only to further distend and distort the tract and will not promote tissue growth or healing.",
"   </p>",
"   <p>",
"    As a treatment method in patients in whom the PEG tract has had time to mature (eg, several weeks after placement), the PEG tube can be removed for 24 to 48 hours, permitting the tract to close slightly; a replacement gastrostomy tube can then be placed through the same, partially closed tract [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/20\">",
"     20",
"    </a>",
"    ]. However, as a note of caution, different tracts will close at different rates and there is a chance that in some patients the tract may close after 24 hours. Leaving a guidewire in place may help maintain tract patency until a replacement PEG is inserted. This technique works well for patients whose PEG tube tract started to leak a month or more after initial insertion. It does not work as well for patients with early tract leakage since these patients are usually experiencing poor wound healing from comorbid disease processes.",
"   </p>",
"   <p>",
"    In many patients with a mature PEG tract and peristomal leakage, the PEG tube will need to be fully removed, allowing the tract to close completely. Another PEG tube can then be placed at a different location on the abdominal wall. In our experience, the new PEG tube can be placed when there is at least 50 percent closure of the old PEG tube tract, at which point the initiation of feedings will not have a significant impact on leakage or inhibition of tissue healing through the old PEG tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pneumoperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumoperitoneum is common post-PEG placement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/21\">",
"     21",
"    </a>",
"    ]. Its etiology is thought to be secondary to the insufflation of air associated with the endoscopic procedure and needle puncture of the gastric wall. In the absence of peritonitis it has no consequence and should",
"    <strong>",
"     not",
"    </strong>",
"    preclude feedings. However, pneumoperitoneum may cause confusion for clinicians in those patients where clinical features raise concern about a ruptured viscous. In these settings, a contrast radiology study should be obtained to confirm the position of the PEG tube within the stomach and to exclude a leak. A contrast CT scan of the abdomen is also beneficial in deciding if a pneumoperitoneum is associated with damage to any contiguous abdominal structure [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subcutaneous air has also been described after PEG placement. It occurs from air being introduced between the cutaneous and subcutaneous tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/23\">",
"     23",
"    </a>",
"    ]. In the absence of other findings, it is inconsequential and should not preclude feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ileus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop nausea and vomiting after PEG placement, which may be due to transient gastroparesis. In rare patients, an ileus develops, a complication that may be more likely in patients with significant pneumoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/24\">",
"     24",
"    </a>",
"    ]. After a gastric or duodenal perforation has been excluded, patients who develop an ileus should be treated with bowel rest and, if necessary, nasogastric decompression. These patients can be identified by the presence of post-procedure abdominal distention, vomiting, and absence of bowel sounds. Feedings should be held until the ileus resolves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage following PEG tube placement is rare. It is recommended that patients have normal coagulation parameters at the time of PEG tube placement and that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    be held for 7 to 10 days prior to PEG placement. In addition, there is evidence that the use of serotonin reuptake inhibitors (SRIs) may increase the risk of bleeding following PEG placement. In one study with 990 patients, patients taking SRIs had a significantly higher risk of post-procedure bleeding compared with patients not taking the medications (odds ratio 4.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/25\">",
"     25",
"    </a>",
"    ]. While there are no guidelines regarding whether to stop SRIs prior to PEG placement, the authors of the study suggested holding SRIs for 24 hours prior to the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\", section on 'Elective procedures in anticoagulated patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\", section on 'Thienopyridines (ticlopidine, clopidogrel)'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    There have been case reports of significant bleeding following PEG including an aortic perforation, gastric artery perforation, and a retroperitoneal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Most bleeding can be controlled by simple pressure over the abdominal wound. Appropriate measures should be taken to improve abnormal coagulation parameters. Gastric wall and rectus sheath hematomas have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/29\">",
"     29",
"    </a>",
"    ]. These have generally been self-contained lesions that did not require surgical intervention.",
"   </p>",
"   <p>",
"    Bleeding occasionally develops in the PEG tube tract itself. In such cases, we suggest tightening the external bumper against the abdominal wall, thereby pulling the internal bumper against the gastric mucosa and compressing the PEG tube tract. Compression should be released within 48 hours to avoid PEG tube tract wound breakdown. Only rarely will surgical intervention be necessary for PEG associated bleeding complications.",
"   </p>",
"   <p>",
"    One case of severe upper gastrointestinal bleeding has been reported following the use of T-fasteners to secure the stomach to the abdominal wall prior to PEG tube placement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/30\">",
"     30",
"    </a>",
"    ]. Six weeks after PEG placement, a retained metal T-fastener was found embedded in the abdominal wall at the site of a major arterial bleeding event. Bleeding did not respond to endoscopic intervention and ultimately required surgery.",
"   </p>",
"   <p>",
"    It is also necessary to attempt improvement of significantly abnormal blood coagulation parameters prior to traction removal of PEG tubes to prevent PEG tract hemorrhage. However, gastrostomy tube replacement devices with a balloon tip can be placed percutaneously safely in patients with abnormal blood coagulation parameters unless it is anticipated that the gastrostomy tube tract will require dilation prior to insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with longstanding PEG tubes, an ulcer may develop underneath the internal PEG tube bolster or on the gastric wall. This often responds to loosening of the external bolster, which allows the internal PEG tube bolster to be released from the gastric mucosa. In patients who have a rigid internal bolster, the PEG should be exchanged for one with a flexible internal bolster to reduce the potential for future gastric ulceration.",
"   </p>",
"   <p>",
"    Ulceration of the contralateral gastric wall from the site of the gastrostomy tube can occur with balloon gastrostomy replacement tubes. In some of these tubes, the tip of the PEG may extend out from the inflated balloon and act as a mechanical irritant. The balloon gastrostomy tube should be removed and replaced with a non-balloon replacement gastrostomy tube or a replacement gastrostomy tube in which the gastrostomy tube tip is contained within the inflated balloon [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clogging",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most common problems is tube dysfunction secondary to clogging from medications or the enteral formula. All medications should be dissolved in water or an appropriate liquid substance or delivered in liquid form, if available. A clinical pharmacist should be consulted if there are questions. Bulking agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    and resins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    should",
"    <strong>",
"     never",
"    </strong>",
"    be placed through the PEG tube. Patients and caregivers should be educated in the importance of flushing water through the PEG tube after all medication and enteral formula delivery. In the event of a PEG tube obstruction, flushing the tube with a 60 cc syringe is recommended.",
"   </p>",
"   <p>",
"    The best irrigant is warm water, which is superior to other liquids such as juices or colas [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/32\">",
"     32",
"    </a>",
"    ]. Pancreatic enzymes (dissolved in a bicarbonate solution and left to dwell within the PEG prior to water flushing) can also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/33\">",
"     33",
"    </a>",
"    ]. If this technique fails, the gastrostomy tube can be cleared with a specially designed gastrostomy tube declogging brush.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tube dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, one of the most common causes of tube dysfunction is clogging from medications or the enteral formula. Another common cause is deterioration of the PEG tube. Deterioration can be recognized by the presence of pitting, ballooning, and a characteristic smell. Although this presents no real risk to the patient, the tube can develop leaks and break, which makes tube feedings difficult or impossible. Microscopic examinations have demonstrated that tube deterioration is caused by yeast implantation into the wall of the tube [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/34\">",
"     34",
"    </a>",
"    ]. A randomized controlled trial suggested that deterioration leading to tube dysfunction was significantly more common with silicone compared with polyurethane PEG tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No preventative measures have been established as being effective for preventing this problem. In my own practice, I recommend flushing the tube daily with 3 to 5 cc of ethanol in an attempt to \"sterilize\" the tube lumen. There is no absolute time period after which PEG tubes should be removed and exchanged to prevent tube dysfunction. The standard of care is to permit the tubes to remain in place until tube dysfunction, such as clogging or deterioration, prevents adequate feedings or medication.",
"   </p>",
"   <p>",
"    Another aspect of gastrostomy tube failure is the early deflation of the balloon, which serves as the internal bolster. This is usually encountered with the use of balloon gastrostomy replacement tubes. There are no prospective data comparing one manufacturer's gastrostomy tube balloon to another manufacturer's gastrostomy tube balloon. Evaluation of PEG tube materials suggest that balloons constructed of polyurethane may be more durable than balloons constructed of silicone [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/36\">",
"     36",
"    </a>",
"    ]. There are commercially available gastrostomy replacement tube devices where a flexible bolster, rather than a balloon, serves as the internal bolster. The internal bolster is distended with a rigid stylet and passed through the PEG ostomy site. This resolves the balloon deflation issue. However, the stylet can cause damage to the existing PEG tube tract on insertion if not placed properly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastric outlet obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;PEG tubes can migrate forward into the duodenum and cause gastric outlet obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/37\">",
"     37",
"    </a>",
"    ]. This occurs if the external bolster on the PEG tube is allowed to migrate away from the abdominal wall, allowing the PEG tube to slide forward through the gastrostomy tract and into the duodenum. A similar problem has been reported with balloon gastrostomy tubes, where the inflated balloon is allowed to migrate through the pylorus resulting in an obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/38\">",
"     38",
"    </a>",
"    ]. This complication can be avoided by making sure the external bolster remains at the same centimeter mark on the gastrostomy tubes after initial proper positioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link\">",
"     \"Gastric outlet obstruction in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Post-PEG removal persistent gastric fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;A PEG tube may be removed permanently in patients who recovered from their original disease process. As a general rule, the PEG tract fistula closes within 24 to 72 hours of PEG tube removal but on occasion a fistula persists. A persistent gastrocutaneous PEG fistulas (PGPF) has been described in 2 to 44 percent of children who underwent a PEG in various pediatric reports [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/39\">",
"     39",
"    </a>",
"    ]. The only factor that demonstrated any correlation with the development of PGPF in these pediatric populations was that the PEG tube (the original tube or a replacement tube) was in place for greater than eight months. PGPF has also been reported in the adult literature although no incidence data exist.",
"   </p>",
"   <p>",
"    There are a number of case reports and small series documenting approaches to the closure of a PGPF. One series documented closure of a PGPF in 7 of 13 cases by the use of gastric acid suppression with a histamine antagonist after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    ablation of the actual PEG tract lining to disrupt any epithelialization and to encourage tract closure. The same premise of PEG tract lining disruption before using a number of closure techniques (argon plasma coagulation [APC], fibrin glue, and endoclipping) has been reported in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. There have also been some reports of PGPF closure using an endoclip closure technique alone without pre-procedure fistula tract lining disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/43\">",
"     43",
"    </a>",
"    ]. Our center uses the technique of tract lining disruption with either a brush or an APC catheter with subsequent gastric mucosal endoclipping. This technique has recently been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MAJOR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major complications of percutaneous endoscopic gastrostomy (PEG) include necrotizing fasciitis, esophageal perforation, gastric perforation, colocutaneous fistula, buried bumper syndrome, and inadvertent PEG removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Necrotizing fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing fasciitis (necrosis of the fascia layers) is a rare complication of PEG placement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Patients with diabetes, wound infections, malnutrition, and a poor immune system are at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traction and pressure on the PEG wound can predispose to the development of necrotizing fasciitis. One study demonstrated that patients who had their PEG tube external bolster set directly against the abdominal wall were more likely to develop wound infection, peristomal drainage, and fasciitis compared with patients whose external PEG bolster was left 3 cm from the abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/46\">",
"     46",
"    </a>",
"    ]. It was hypothesized that the distant placement of the external bumper prevented compression of the tissue in the PEG tube tract and wound breakdown. This hypothesis was confirmed in a study in dogs in which gastric mucosal histology showed severe inflammation when the PEG tube external bolsters were placed directly against the abdominal wall compared with external bolsters that were left 4 cm from the abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of necrotizing fasciitis is imperative since treatment requires large surgical debridement, antibiotics, and extensive hospital support. It is important to allow the external bolster of the PEG tube to \"free-float\" 1 to 2 cm from the abdominal wall after PEG placement to prevent this complication. Loose apposition of the bolster to the abdominal wall does not result in peritoneal leakage since an early PEG tube tract forms as a result of tissue edema and associated tissue secretions.",
"   </p>",
"   <p>",
"    It is also important to make at least a 1 cm skin incision prior to PEG placement to avoid creating too tight a PEG tube tract wound once the PEG tube is pulled through the wound following PEG placement. However, there is some controversy with this practice. A controlled trial randomly assigned 50 patients to PEG placement with and without an abdominal wall incision [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/48\">",
"     48",
"    </a>",
"    ]. There was no difference in wound healing between the two groups at seven days. Twelve percent of the no abdominal wall incision group ultimately required an abdominal wall incision for the PEG tube procedure to be completed.",
"   </p>",
"   <p>",
"    Wound care is important following PEG tube placement. As with any other surgical procedure, less manipulation is better with regard to tampering with a fresh wound. There are no prospective evaluations supporting the use of topical antibiotics as a preventative measure for wound infection following PEG placement. It is my practice to simply clean the wound with full strength",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    and to cover the wound with gauze dressing. The gauze dressing is changed and the PEG wound is cleansed with hydrogen peroxide daily for seven days. Following this, the wound can be cleaned with simple soap and water. The gauze dressing can be eliminated unless there is leakage around the PEG tube that is soiling a patient's clothing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Esophageal and gastric perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric and esophageal perforation with upper endoscopy are known, but rare complications. There are no large reports from which to derive estimates of how frequently these occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Buried bumper syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buried bumper syndrome is a long-term consequence of tight apposition of the external bolster of the PEG tube against the abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/49\">",
"     49",
"    </a>",
"    ]. The internal bolster of the PEG tube slowly erodes into the gastric wall as tension is created on the PEG tube tract, which ultimately causes pain and the inability to infuse feedings. The diagnosis can be confirmed on endoscopy, which will demonstrate the internal bumper buried within the gastric mucosa.",
"   </p>",
"   <p>",
"    The treatment of buried bumper syndrome depends upon the type of PEG tube [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/50\">",
"     50",
"    </a>",
"    ]. If the internal bolster is collapsible, as it is on externally removable PEG tubes, the PEG tube can be removed by simple external traction. In a modification of this technique, the buried bumper PEG tube can be cut short and a guidewire is passed through the stump into the gastric cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/50\">",
"     50",
"    </a>",
"    ]. The guidewire is snared and pulled out of the oral cavity and attached to a new PEG. The guidewire at the abdominal surface is pulled, dragging the new PEG into the gastric cavity. The dilating portion of the new PEG engages the buried bumper on the old PEG. As the new PEG is pulled through the abdominal wall, the old PEG is pushed out of the abdominal wall and removed.",
"   </p>",
"   <p>",
"    In contrast, if the internal bumper on the PEG tube is rigid, as it is on endoscopic only removable PEG tubes, the PEG tube may have to be removed by PEG wound tract cut-down or the push-pull T-technique [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/51\">",
"     51",
"    </a>",
"    ]. The push-pull T-technique requires the PEG tube to be cut 3 cm from the abdominal wall. The patient is endoscoped and a snare is passed through the PEG tube opening in the gastric wall to the outside through the PEG tube. An additional short piece of PEG tube is cut from the excess PEG tubing. The snare is opened and this short piece of tubing is grasped and pulled back against the PEG tube creating a T-shape. A Kelly clamp is placed across the T-shape. The endoscopist slowly removes the endoscope, snare, and PEG tube orally as a second operator pushes the Kelly clamp and PEG tube into the gastric lumen. This combined procedure frees the internal bumper from the gastric wall. Once the PEG tube is removed, a new PEG tube can be placed back through the existing PEG tract using direct endoscopic visualization. A standard PEG tube placement technique should be used to permit the PEG tube dilator to re-expand the partially closed PEG tube tract.",
"   </p>",
"   <p>",
"    Prevention of the buried bumper syndrome requires good nursing care and patient instruction. As mentioned above, the external bolster of the PEG tube should be left 1 to 2 cm from the abdominal wall. Gauze pads should be placed over the external bolster,",
"    <strong>",
"     not",
"    </strong>",
"    underneath, which would create pressure on the PEG tube tract. In addition, the gastrostomy tube itself should be pushed forward into the wound slightly and rotated during daily nursing care. This will ensure that the internal bumper does not become buried into the gastric mucosa. After rotation, the PEG should be placed back into its original position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Colocutaneous fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;A colocutaneous fistula is a rare complication associated with PEG placement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/52\">",
"     52",
"    </a>",
"    ]. It occurs as a result of interposition of bowel, usually the splenic flexure, between the anterior abdominal wall and the gastric wall. The PEG tube is placed directly through the bowel into the stomach.",
"   </p>",
"   <p>",
"    Patients in whom this complication has occurred are often asymptomatic, except for transient fever or ileus. The problem is usually discovered months after initial PEG tube placement when the original PEG tube is removed for gastrostomy tube replacement. As the replacement gastrostomy tube is passed blindly at the bedside, it is pushed through the PEG tract opening in the abdominal wall and into the colon, but cannot find its way back into the stomach. Once the tube feedings are restarted, the patient develops diarrhea from colonic tube feedings and dehydration from not receiving fluids or nutrition.",
"   </p>",
"   <p>",
"    This complication can often be treated by removing the PEG tube to allow the fistula to close [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/53\">",
"     53",
"    </a>",
"    ]. However, surgery is sometimes necessary to correct the internal gastric-bowel fistula.",
"   </p>",
"   <p>",
"    Prevention of this complication is related to the initial PEG tube procedure. Relying on the combination of transillumination and finger palpation of the abdominal wall in choosing an appropriate PEG tube site rather than one of these techniques alone will assure a safe PEG tube entrance site. In questionable situations, an 18 or 22 gauge needle should be passed through the PEG tube site prior to PEG tube placement. The needle should be withdrawn slowly with an attached syringe creating back pressure. The presence of a sudden bolus of air or stool within the syringe suggests passage through the bowel. However, this technique has not been subjected to a prospective evaluation. Some endoscopists place the PEG with the patient in reverse Trendelenburg to allow gravity to \"lower\" the colon away from the anterior gastric wall. In questionable situations where a safe access site cannot be determined, ultrasound or CAT scan guidance can assist in delineating a safe location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Inadvertent PEG tube removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadvertent PEG tube removal is a common complication, usually occurring in combative or confused patients who pull on the tube. Many PEG tubes today are designed to be externally removed with 10 to 14 pounds of external pull pressure.",
"   </p>",
"   <p>",
"    PEG tubes that are inadvertently removed within the first four weeks of PEG tube placement should",
"    <strong>",
"     not",
"    </strong>",
"    be replaced blindly at the bedside. Because the PEG tube tract may not have matured adequately, the gastric wall and the abdominal wall may have separated, leaving a rent in the gastric wall. Thus, blind replacement of the PEG tube at the bedside may result in its placement in the peritoneal cavity.",
"   </p>",
"   <p>",
"    If the PEG tube is removed early (prior to four weeks after initial placement) the patient can immediately be brought back to the endoscopy suite for repeat PEG tube placement through the same PEG tube site [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients should be treated with intravenous antibiotics, and monitored for signs of peritonitis, which would require surgical intervention. If there is ever a concern about the possibility of a replacement gastrostomy tube being positioned into the peritoneal cavity, a water soluble contrast study through the gastrostomy tube should be obtained to confirm proper position prior to the initiation of feedings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other intra-abdominal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of intra-abdominal complications have been described in case reports. Although rare, they must be recognized by the interventional endoscopist.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small bowel obstruction from a small bowel wall hematoma following PEG placement [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/55\">",
"       55",
"      </a>",
"      ]. The hematoma was on a jejunal loop of bowel near the stomach. An operative procedure allowed evacuation of the hematoma and resolution of the small bowel obstruction.",
"     </li>",
"     <li>",
"      Intrahepatic placement of a PEG tube [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/56\">",
"       56",
"      </a>",
"      ]. The originally inserted PEG tube malfunctioned and was replaced with a balloon gastrostomy tube two and one-half years after placement. The replacement tube was difficult to push back through the PEG fistula site. A contrast study showed that the balloon gastrostomy tube was inflated within the liver. Contrast from the tube entered the portal venous system. A fistula tract had developed between the liver and the stomach. Subsequent surgical exploration allowed the tube to be removed safely with resection of the gastrohepatic fistula tract, argon plasma coagulation of the liver bed to prevent bleeding, and replacement of the PEG with a Stamm gastrostomy. Two additional reports of transhepatic PEG placement resulted in very different outcomes. One case required emergency surgery and repair of the liver laceration [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/57\">",
"       57",
"      </a>",
"      ]. The second case resulted in the PEG tube being left in place for three months, at which time the tube was removed endoscopically [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Herniation of the stomach through a PEG tube fistula site [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/59\">",
"       59",
"      </a>",
"      ]. The patient was noted to have a leaking PEG site one year following PEG tube insertion. A bulge was noted at the PEG tube site on the abdominal wall when the patient coughed. A CAT scan demonstrated that a portion of the stomach had herniated through the PEG site. The PEG was removed, but the PEG fistula remained open. Surgical repair of the fistula was suggested. However, the patient died of aspiration pneumonia prior to definitive surgical therapy.",
"     </li>",
"     <li>",
"      Abdominal wall pain can occur and persist after PEG placement. Work-up should include a full examination to rule out infection of the abdominal wall. This may include a CT scan to rule out an abdominal wall abscess. In some cases the pain will be consistent with neuropathic pain, in which case the remedy is often removal of the PEG and insertion at a different site. Abdominal wall injection with an anesthetic agent may also be helpful.",
"     </li>",
"     <li>",
"      Peritonitis has been reported from leakage of gastric contents from the gastrostomy site into the peritoneal cavity with the PEG tube in situ [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/60\">",
"       60",
"      </a>",
"      ]. In addition, infusion of tube feeding formula can lead to a combination of a chemical and bacterial peritonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/4\">",
"       4",
"      </a>",
"      ]. It is hypothesized that peritonitis develops when the introducer needle enters the stomach tangentially rather than directly through the abdominal wall, leading to a long laceration along the greater curvature, which allows for escape of gastric contents.",
"     </li>",
"     <li>",
"      PEG tract tumor seeding &mdash; Patients with proximal GI tract cancers, such as head and neck and esophageal cancers are at risk of tumor seeding from the tumor site to the PEG tube tract by mechanical transfer [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. The PEG tube can transfer tumor cells as it is pushed or pulled by the tumor into its final position across the gastric and abdominal wall. The use of an overtube across the proximal GI tract tumor site should allow the PEG tube to be placed through the overtube without the risk of PEG tube tract seeding. There are currently no prospective studies comparing overtube versus no overtube PEG placements in patients with proximal GI tract cancers as a mechanism for preventing PEG tube tract tumor seeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PEG VERSUS SURGICAL GASTROSTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies comparing surgical gastrostomy to PEG have shown no difference in morbidity or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/63\">",
"     63",
"    </a>",
"    ]. However, PEGs are less expensive and save time. Thus, it seems prudent to reserve surgical gastrostomy for patients who are already going to the operating room for another surgical procedure or for patients in whom an endoscopy cannot be performed or where an anatomical aberration prevents a safe percutaneous approach for PEG placement.",
"   </p>",
"   <p>",
"    An alternative to surgery in patients in whom a PEG cannot be placed for anatomical reasons is a combination endoscopic and radiologic approach in which a CT scan or ultrasound is used to determine a safe site to access the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/64\">",
"     64",
"    </a>",
"    ]. An interventional radiologist can also place a gastrostomy tube using similar radiographic assistance to locate a safe access site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EARLY VERSUS DELAYED FEEDING AFTER PEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;PEG feedings have traditionally been delayed for several hours to overnight after PEG placement because of concern that earlier feeding would increase the risk of peritoneal leakage or aspiration. However, several studies have suggested that early feeding (&le;4 hours after PEG placement) may be as safe as later feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/65\">",
"     65",
"    </a>",
"    ]. A meta-analysis of six studies that compared early versus delayed or next day feeding (with a total of 467 patients) found no statistically significant differences in patient complications or death [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/65\">",
"     65",
"    </a>",
"    ]. By contrast, a statistically significant increase in gastric residual volumes during day one was noted in the early group, the clinical significance of which was unclear.",
"   </p>",
"   <p>",
"    However, the relatively small number of patients included leaves uncertainty about this practice. This was reflected in the 95 percent confidence interval for the risk of death within 72 hours in the above meta-analysis, which ranged from an 80 percent decrease in the risk with early feeding to as much as a 75 percent increase in the risk. Thus, more studies are needed before such a practice can be confidently adopted. At our institution, we begin with water and medications through the PEG tube on the same day as PEG placement, often four hours post-procedure. Tube feedings are initiated the following day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SPECIAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of settings may be encountered in which placement of a PEG is riskier, or that require modification of the standard technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prior abdominal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had prior abdominal surgery can undergo placement of a PEG. However, extra care needs to be taken to avoid passing the tube through interposed bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/66\">",
"     66",
"    </a>",
"    ]. In these settings, PEG placement should never be performed without confirming a safe access site by both finger palpation and transillumination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult to transilluminate the abdominal wall in patients who are obese or have a thick abdominal wall. In such patients, an adequate percutaneous access site can usually be palpated. A larger bedside incision can be made, and the fat tissue spread until the anterior rectus fascia is reached, after which standard PEG tube can be placed using conventional technique [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/67\">",
"     67",
"    </a>",
"    ]. The external wound should be closed with sutures or clips.",
"   </p>",
"   <p>",
"    Use of a spinal needle (9 cm long) as the introducer needle has been described in patients who are markedly obese (BMI &gt;40",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/68\">",
"     68",
"    </a>",
"    ]. In most instances abdominal wall transillumination could not be obtained, but finger palpation could be seen on the gastric mucosa with the endoscope. As the spinal needle was advanced, continuous aspiration on the needle was maintained to monitor for entry into the colon or small intestine. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Colocutaneous fistula'",
"    </a>",
"    above.) A 0.025 cm guidewire was required to fit through the spinal needle. This technique has been reported with success and without complications in six patients with a BMI &gt;60",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have demonstrated safe percutaneous approaches in women as late as 26 weeks of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/70\">",
"     70",
"    </a>",
"    ]. The risk of conscious sedation must be weighed against the need for nutritional support in these patients. An anesthesia consult can assist in delivering safe sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of ascites in the abdominal cavity is often a contraindication to PEG placement because of the fear of abdominal fluid leakage and peritonitis. However, case reports have demonstrated that large volume paracentesis before and for the first week after PEG placement combined with use of broad spectrum antibiotics has been associated with good patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34937/abstract/71\">",
"     71",
"    </a>",
"    ]. There have been no prospective trials confirming the safety of this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite their overall safety, a number of complications can occur following percutaneous endoscopic gastrostomy (PEG) tube placement. Most studies have suggested that complications are more likely to occur in elderly patients with comorbid illnesses, particularly those with an infectious process or who have a history of aspiration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minor complications include wound infection, wound leakage, wound bleeding, cutaneous or gastric ulceration, pneumoperitoneum, temporary ileus, and gastric outlet obstruction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Minor complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major complications include necrotizing fasciitis, esophageal perforation, gastric perforation, major gastrointestinal bleeding, colocutaneous fistula, buried bumper syndrome, and inadvertent PEG removal. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Major complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of intra-abdominal complications have been described in case reports. Although rare, they must be recognized by the interventional endoscopist. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other intra-abdominal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of settings may be encountered in which placement of a PEG is riskier, or that require modification of the standard technique. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Special settings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/1\">",
"      Gauderer MW, Ponsky JL, Izant RJ Jr. Gastrostomy without laparotomy: a percutaneous endoscopic technique. J Pediatr Surg 1980; 15:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/2\">",
"      Duszak R Jr, Mabry MR. National trends in gastrointestinal access procedures: an analysis of Medicare services provided by radiologists and other specialists. J Vasc Interv Radiol 2003; 14:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/3\">",
"      Taylor CA, Larson DE, Ballard DJ, et al. Predictors of outcome after percutaneous endoscopic gastrostomy: a community-based study. Mayo Clin Proc 1992; 67:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/4\">",
"      Larson DE, Burton DD, Schroeder KW, DiMagno EP. Percutaneous endoscopic gastrostomy. Indications, success, complications, and mortality in 314 consecutive patients. Gastroenterology 1987; 93:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/5\">",
"      Blomberg J, Lagergren J, Martin L, et al. Complications after percutaneous endoscopic gastrostomy in a prospective study. Scand J Gastroenterol 2012; 47:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/6\">",
"      Raha SK, Woodhouse K. The use of percutaneous endoscopic gastrostomy (PEG) in 161 consecutive elderly patients. Age Ageing 1994; 23:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/7\">",
"      Keung EZ, Liu X, Nuzhad A, et al. In-hospital and long-term outcomes after percutaneous endoscopic gastrostomy in patients with malignancy. J Am Coll Surg 2012; 215:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/8\">",
"      Sharma VK, Howden CW. Meta-analysis of randomized, controlled trials of antibiotic prophylaxis before percutaneous endoscopic gastrostomy. Am J Gastroenterol 2000; 95:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/9\">",
"      Ahmad I, Mouncher A, Abdoolah A, et al. Antibiotic prophylaxis for percutaneous endoscopic gastrostomy--a prospective, randomised, double-blind trial. Aliment Pharmacol Ther 2003; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/10\">",
"      Jafri NS, Mahid SS, Minor KS, et al. Meta-analysis: antibiotic prophylaxis to prevent peristomal infection following percutaneous endoscopic gastrostomy. Aliment Pharmacol Ther 2007; 25:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/11\">",
"      Chaudhary KA, Smith OJ, Cuddy PG, Clarkston WK. PEG site infections: the emergence of methicillin resistant Staphylococcus aureus as a major pathogen. Am J Gastroenterol 2002; 97:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/12\">",
"      Horiuchi A, Nakayama Y, Kajiyama M, et al. Nasopharyngeal decolonization of methicillin-resistant Staphylococcus aureus can reduce PEG peristomal wound infection. Am J Gastroenterol 2006; 101:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/13\">",
"      Thomas S, Cantrill S, Waghorn DJ, McIntyre A. The role of screening and antibiotic prophylaxis in the prevention of percutaneous gastrostomy site infection caused by methicillin-resistant Staphylococcus aureus. Aliment Pharmacol Ther 2007; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/14\">",
"      Radhakrishnan NV, Shenoy AH, Cartmill I, et al. Addition of local antiseptic spray to parenteral antibiotic regimen reduces the incidence of stomal infection following percutaneous endoscopic gastrostomy: A randomized controlled trial. Eur J Gastroenterol Hepatol 2006; 18:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/15\">",
"      Blomberg J, Lagergren P, Martin L, et al. Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomised controlled trial. BMJ 2010; 341:c3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/16\">",
"      Patel AS, DeRidder PH, Alexander TJ, et al. Candida cellulitis: a complication of percutaneous endoscopic gastrostomy. Gastrointest Endosc 1989; 35:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/17\">",
"      Murugasu B, Conley SB, Lemire JM, Portman RJ. Fungal peritonitis in children treated with peritoneal dialysis and gastrostomy feeding. Pediatr Nephrol 1991; 5:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/18\">",
"      Bell SC, Elborn JS, Campbell IA, Shale DJ. Candida albicans infection complicating percutaneous gastrostomy in cystic fibrosis. Br J Clin Pract 1995; 49:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/19\">",
"      Alkartha A, Kawji AS, Alder DG. First reported case of Candida galbrata perihepatic abscess as a complication of percutneous endoscopic gastrostomy tube placement. J Clin Gastro 2007; 41:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/20\">",
"      Tsang TK, Eaton D, Falconio MA. Percutaneous ostomy dilation: a technique for dilating the closed percutaneous endoscopic gastrostomy sites and reinserting gastrostomies. Gastrointest Endosc 1989; 35:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/21\">",
"      Wiesen AJ, Sideridis K, Fernandes A, et al. True incidence and clinical significance of pneumoperitoneum after PEG placement: a prospective study. Gastrointest Endosc 2006; 64:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/22\">",
"      Blum CA, Selander C, Ruddy JM, Leon S. The incidence and clinical significance of pneumoperitoneum after percutaneous endoscopic gastrostomy: a review of 722 cases. Am Surg 2009; 75:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/23\">",
"      Stathopoulos G, Rudberg MA, Harig JM. Subcutaneous emphysema following PEG. Gastrointest Endosc 1991; 37:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/24\">",
"      Dulabon GR, Abrams JE, Rutherford EJ. The incidence and significance of free air after percutaneous endoscopic gastrostomy. Am Surg 2002; 68:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/25\">",
"      Richter JA, Patrie JT, Richter RP, et al. Bleeding after percutaneous endoscopic gastrostomy is linked to serotonin reuptake inhibitors, not aspirin or clopidogrel. Gastrointest Endosc 2011; 74:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/26\">",
"      Lau G, Lai SH. Fatal retroperitoneal haemorrhage: an unusual complication of percutaneous endoscopic gastrostomy. Forensic Sci Int 2001; 116:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/27\">",
"      Schurink CA, Tuynman H, Scholten P, et al. Percutaneous endoscopic gastrostomy: complications and suggestions to avoid them. Eur J Gastroenterol Hepatol 2001; 13:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/28\">",
"      Chong C, Derigo L, Brown D. Massive gastric bleeding: a rarely seen subacute complication of percutaneous endoscopic gastrostomy. Intern Med J 2007; 37:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/29\">",
"      Ubogu EE, Zaidat OO. Rectus sheath hematoma complicating percutaneous endoscopic gastrostomy. Surg Laparosc Endosc Percutan Tech 2002; 12:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/30\">",
"      Mackenzie SH, Fang JC, Kuwada SK. Severe upper-GI bleeding in a patient with PEG tube placement by the radiologic push method. Gastrointest Endosc 2007; 65:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/31\">",
"      Kazi S, Gunasekaran TS, Berman JH, et al. Gastric mucosal injuries in children from inflatable low-profile gastrostomy tubes. J Pediatr Gastroenterol Nutr 1997; 24:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/32\">",
"      Metheny N, Eisenberg P, McSweeney M. Effect of feeding tube properties and three irrigants on clogging rates. Nurs Res 1988; 37:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/33\">",
"      Sriram K, Jayanthi V, Lakshmi RG, George VS. Prophylactic locking of enteral feeding tubes with pancreatic enzymes. JPEN J Parenter Enteral Nutr 1997; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/34\">",
"      Iber FL, Livak A, Patel M. Importance of fungus colonization in failure of silicone rubber percutaneous gastrostomy tubes (PEGs). Dig Dis Sci 1996; 41:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/35\">",
"      Blacka J, Donoghue J, Sutherland M, et al. Dwell time and functional failure in percutaneous endoscopic gastrostomy tubes: a prospective randomized-controlled comparison between silicon polymer and polyurethane percutaneous endoscopic gastrostomy tubes. Aliment Pharmacol Ther 2004; 20:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/36\">",
"      DeLegge RL, DeLegge MH. Percutaneous endoscopic gastrostomy evaluation of device materials: are we \"failsafe\"? Nutr Clin Pract 2005; 20:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/37\">",
"      Fischer LS, Bonello JC, Greenberg E. Gastrostomy tube migration and gastric outlet obstruction following percutaneous endoscopic gastrostomy. Gastrointest Endosc 1987; 33:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/38\">",
"      Chong VH. Gastric outlet obstruction caused by gastrostomy tube balloon. Indian J Gastroenterol 2004; 23:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/39\">",
"      Jsanik TA, Hendrickson RJ, Janik JS, et al. Analysis of factors affecting the spontaneous closure of a gastrocutaneous fistula. J Ped Surg 2006; 39:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/40\">",
"      Gonz&aacute;lez-Ojeda A, Avalos-Gonz&aacute;lez J, Muci&ntilde;o-Hern&aacute;ndez MI, et al. Fibrin glue as adjuvant treatment for gastrocutaneous fistula after gastrostomy tube removal. Endoscopy 2004; 36:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/41\">",
"      Hameed H, Kalim S, Khan YI. Closure of a nonhealing gastrocutanous fistula using argon plasma coagulation and endoscopic hemoclips. Can J Gastroenterol 2009; 23:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/42\">",
"      Teitelbaum JE, Gorcey SA, Fox VL. Combined endoscopic cautery and clip closure of chronic gastrocutaneous fistulas. Gastrointest Endosc 2005; 62:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/43\">",
"      Peter S, Geyer M, Beglinger C. Persistent gastrocutaneous fistula after percutaneous gastrostomy tube removal. Endoscopy 2006; 38:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/44\">",
"      Cave DR, Robinson WR, Brotschi EA. Necrotizing fasciitis following percutaneous endoscopic gastrostomy. Gastrointest Endosc 1986; 32:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/45\">",
"      Martindale R, Witte M, Hodges G, et al. Necrotizing fasciitis as a complication of percutaneous endoscopic gastrostomy. JPEN J Parenter Enteral Nutr 1987; 11:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/46\">",
"      Chung RS, Schertzer M. Pathogenesis of complications of percutaneous endoscopic gastrostomy. A lesson in surgical principles. Am Surg 1990; 56:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/47\">",
"      DeLegge MH, Lantz G, Kazacos R, et al. Effects of external bolster tension on PEG tube tract formation (abstract). Gastrointest Endosc 1996; 43:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/48\">",
"      Sedlack RE, Pochron NL, Baron TH. Percutaneous endoscopic gastrostomy placement without skin incision: results of a randomized trial. JPEN J Parenter Enteral Nutr 2006; 30:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/49\">",
"      Klein S, Heare BR, Soloway RD. The \"buried bumper syndrome\": a complication of percutaneous endoscopic gastrostomy. Am J Gastroenterol 1990; 85:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/50\">",
"      Venu RP, Brown RD, Pastika BJ, Erikson LW Jr. The buried bumper syndrome: a simple management approach in two patients. Gastrointest Endosc 2002; 56:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/51\">",
"      Boyd JW, DeLegge MH, Shamburek RD, Kirby DF. The buried bumper syndrome: a new technique for safe, endoscopic PEG removal. Gastrointest Endosc 1995; 41:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/52\">",
"      Saltzberg DM, Anand K, Juvan P, Joffe I. Colocutaneous fistula: an unusual complication of percutaneous endoscopic gastrostomy. JPEN J Parenter Enteral Nutr 1987; 11:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/53\">",
"      Berger SA, Zarling EJ. Colocutaneous fistula following migration of PEG tube. Gastrointest Endosc 1991; 37:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/54\">",
"      Galat SA, Gerig KD, Porter JA, Slezak FA. Management of premature removal of the percutaneous gastrostomy. Am Surg 1990; 56:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/55\">",
"      Williams E, Sabol DA, Delegge M. Small bowel obstruction caused by bowel wall hematoma after PEG. Gastrointest Endosc 2003; 57:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/56\">",
"      Chaer RA, Rekkas D, Trevino J, et al. Intrahepatic placement of a PEG tube. Gastrointest Endosc 2003; 57:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/57\">",
"      Fyock CJ, Kethu SR. PEG placement causing liver perforation. J Clin Gastroenterol 2009; 43:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/58\">",
"      Shaw J, Casey K. A PEG tube through the liver. Am J Gastroenterol 2009; 104:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/59\">",
"      Chuang CH, Chen CY. Gastric herniation through PEG site. Gastrointest Endosc 2003; 58:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/60\">",
"      Honjo S. A mother's complaints of overeating by her 25-month-old daughter: a proposal of anorexia nervosa by proxy. Int J Eat Disord 1996; 20:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/61\">",
"      Khurana V, Singh T. Percutaneous endoscopic gastrostomy site metastasis in esophageal cancer. Gastrointest Endosc 2005; 62:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/62\">",
"      Mincheff TV. Metastatic spread to a percutaneous gastrostomy site from head and neck cancer: case report and literature review. JSLS 2005; 9:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/63\">",
"      Stiegmann GV, Goff JS, Silas D, et al. Endoscopic versus operative gastrostomy: final results of a prospective randomized trial. Gastrointest Endosc 1990; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/64\">",
"      Vogt W, Messmann H, Lock G, et al. CT-guided PEG in patients with unsuccessful endoscopic transillumination. Gastrointest Endosc 1996; 43:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/65\">",
"      Bechtold ML, Matteson ML, Choudhary A, et al. Early versus delayed feeding after placement of a percutaneous endoscopic gastrostomy: a meta-analysis. Am J Gastroenterol 2008; 103:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/66\">",
"      Foutch PG, Talbert GA, Waring JP, Sanowski RA. Percutaneous endoscopic gastrostomy in patients with prior abdominal surgery: virtues of the safe tract. Am J Gastroenterol 1988; 83:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/67\">",
"      Bender JS. Percutaneous endoscopic gastrostomy placement in the morbidly obese. Gastrointest Endosc 1992; 38:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/68\">",
"      Karhadkar AS, Naini P, Dutta SK. PEG-tube placement in a patient with extreme obesity: overcoming the technical challenges. Gastrointest Endosc 2007; 65:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/69\">",
"      Bochicchio GV, Guzzo JL, Scalea TM. Percutaneous endoscopic gastrostomy in the supermorbidly obese patient. JSLS 2006; 10:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/70\">",
"      Shaheen NJ, Crosby MA, Grimm IS, Isaacs K. The use of percutaneous endoscopic gastrostomy in pregnancy. Gastrointest Endosc 1997; 46:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34937/abstract/71\">",
"      Kynci JA, Chodash HB, Tsang TK. PEG in a patient with ascites and varices. Gastrointest Endosc 1995; 42:100.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2552 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34937=[""].join("\n");
var outline_f34_7_34937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MINOR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Wound infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peristomal leakage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pneumoperitoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ileus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clogging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tube dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastric outlet obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Post-PEG removal persistent gastric fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MAJOR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Esophageal and gastric perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Buried bumper syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Colocutaneous fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Inadvertent PEG tube removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other intra-abdominal complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PEG VERSUS SURGICAL GASTROSTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EARLY VERSUS DELAYED FEEDING AFTER PEG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SPECIAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prior abdominal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=related_link\">",
"      Gastric outlet obstruction in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34938="Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract";
var content_f34_7_34938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34938/contributors\">",
"     George D Demetri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Jeffrey Morgan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Chandrajit P Raut, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/7/34938/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/7/34938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract are divided into two groups. The most common are neoplasms that are collectively referred to as gastrointestinal stromal tumors (GISTs). They are most often located in the stomach and proximal small intestine, but can occur in any portion of the alimentary tract and occasionally in the omentum, mesentery, and peritoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A far less common group of mesenchymal GI tract neoplasms is comprised of a spectrum of tumors that are identical to those that might arise in the soft tissues throughout the rest of the body. These include lipomas, liposarcomas, leiomyomas, leiomyosarcomas, desmoid tumors, schwannomas, and peripheral nerve sheath tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local treatment options for GIST, leiomyomas, and leiomyosarcomas of the GI tract will be discussed here. The epidemiology, classification, molecular pathogenesis, clinical presentation, and diagnostic workup of GISTs, leiomyomas, and leiomyosarcomas of the GI tract, and the use of tyrosine kinase inhibitors (TKIs), both in the adjuvant and neoadjuvant setting, and for patients with metastatic GIST, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL SURGICAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of GISTs, leiomyomas, and leiomyosarcomas involving the GI tract depends upon the confidence in the preoperative diagnosis, tumor location and size, extent of spread, and clinical presentation (eg, whether there is evidence of tumor obstruction, perforation, or uncontrolled hemorrhage). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some general surgical principles apply to these tumors regardless of location:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative biopsy or endoscopic ultrasound (EUS)-guided fine needle aspiration biopsy (FNA) may not be necessary if a mesenchymal GI tumor is strongly suspected, it appears to be resectable, and the patient is otherwise operable. However, a biopsy is preferred to confirm the diagnosis if metastatic disease is suspected or if preoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      is considered prior to attempted resection in a patient who has a large locally advanced lesion thought to represent a GIST. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H26#H26\">",
"       \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Necessity of preoperative biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All GISTs &ge;2 cm in size should be resected. However, there is no consensus on the management of smaller GISTs ; guidelines from the National Comprehensive Cancer Network (",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      ), European Society of Medical Oncology (ESMO) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/7\">",
"       7",
"      </a>",
"      ], and the Canadian advisory Committee on GIST [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/8\">",
"       8",
"      </a>",
"      ] differ.",
"      <br/>",
"      <br/>",
"      The natural history of these and other GISTs between 1 and 2 cm, including their growth rate and metastatic potential, remains unknown. Although these small GISTs may be followed endoscopically until they grow or become symptomatic, the optimal frequency of follow-up and specific risks of this strategy is uncertain. Successful endoscopic resection is reported, but it remains controversial because of the risk of positive margins, tumor spillage, and perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/9\">",
"       9",
"      </a>",
"      ]. Because GISTs are submucosal, standard techniques of endoscopic mucosal resection do not necessary extend deep enough into the submucosal tissue to guarantee removal of all the deep tissue.",
"      <br/>",
"      <br/>",
"      An algorithmic approach to management of gastric GISTs based upon size and endoscopic ultrasound (EUS) appearance has been proposed (",
"      <a class=\"graphic graphic_algorithm graphicRef66521 \" href=\"UTD.htm?12/35/12861\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/10\">",
"       10",
"      </a>",
"      ]. This approach has been adopted by the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      for gastric GISTs but not those at other sites in the GI tract. When endoscopic assessment is not possible, excision is the standard approach. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'GIST and leiomyoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Surgical resection is the treatment of choice for potentially resectable tumors; however, initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      may be preferred if a tumor is borderline resectable, or if resection would necessitate extensive organ disruption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link&amp;anchor=H8#H8\">",
"       \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Neoadjuvant therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goal of surgical treatment is complete gross resection with an intact pseudocapsule, if possible. Segmental resection of the stomach or intestine should be performed with the goal of achieving negative resection margins. Wider resection of uninvolved tissue is of no additional benefit. However, peritumoral as opposed to segmental resection should be avoided, as there is a higher risk of local recurrence, particularly with leiomyosarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/11\">",
"       11",
"      </a>",
"      ]. Routine lymphadenectomy is unnecessary because nodal metastases are rare.",
"      <br/>",
"      <br/>",
"      Although they may appear ominous on CT, GISTs often project extraluminally from the stomach or small intestine and displace rather than invade adjacent organs. They can often be lifted away from surrounding structures, although in some cases, en bloc resection is necessary because of dense adhesions.",
"      <br/>",
"      <br/>",
"      At laparotomy, the abdomen should be thoroughly explored, with particular attention to the peritoneal surfaces and liver to exclude metastatic spread. The tumor should be handled carefully to avoid rupture, which markedly increases the risk of a disease recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link&amp;anchor=H3#H3\">",
"       \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Estimation of recurrence risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The necessity of achieving negative microscopic margins is uncertain with large (&gt;10 cm) GISTs. The management of a positive margin according to the final pathology report is not well defined and depends on whether the surgeon believes the finding accurately reflects the surgical procedure that was undertaken [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/9,12\">",
"       9,12",
"      </a>",
"      ]. Although patients who undergo a microscopically incomplete resection may be at greater risk for a locoregional recurrence, other factors such as tumor grade and size may play a more significant role in determining the risk of recurrence. The risks and benefits of reexcision versus initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      must be carefully considered [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link\">",
"       \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laparoscopic resection of gastric GISTs is safe and effective [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/13-18\">",
"       13-18",
"      </a>",
"      ] but should only be performed by surgeons with expertise in the laparoscopic management of cancer. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stomach'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There is less experience with laparoscopic resection of small bowel GISTs [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Small intestine'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete resection is possible in the majority of localized GISTs, but only about one-half remain recurrence-free for five or more years [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. Data from the landmark ACOSOG Z9001 trial provide good evidence that one year of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy is effective in reducing GIST recurrence within the first year of therapy, and imatinib is approved by the Food and Drug Administration in the United States for adjuvant treatment of completely resected GISTs &ge;3 cm in size. In practice, we risk stratify patients for consideration of adjuvant imatinib. The European regulatory body, the European Medicines Agency, recommended adjuvant imatinib for patients with a resected primary GIST at a significant risk of relapse. They specified that patients with very",
"    <span class=\"nowrap\">",
"     low/low",
"    </span>",
"    risk GISTs should not get adjuvant imatinib. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Adjuvant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Staging and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis is influenced by size and mitotic rate, tumor site (small intestine worse than stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]) and the completeness of resection [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/22,30-35\">",
"     22,30-35",
"    </a>",
"    ]. A comparison of outcomes for different primary sites from an AFIP (Armed Forces Institute of Pathology) series of 1055 gastric, 629",
"    <span class=\"nowrap\">",
"     jejunal/ileal",
"    </span>",
"    and 144 duodenal, and 111 rectal GISTs with long-term follow-up, and stratified by tumor size and mitotic rate is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Largely based upon data from the AFIP [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/28,36\">",
"     28,36",
"    </a>",
"    ], a TNM (tumor-node-metastasis) staging system for GIST was developed by the American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC), and published in the 2010 7th edition of the cancer staging manual (",
"    <a class=\"graphic graphic_table graphicRef51606 \" href=\"UTD.htm?8/35/8766\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/37\">",
"     37",
"    </a>",
"    ]. Although the T and N designations are similar for all disease sites, there are separate stage groupings for",
"    <span class=\"nowrap\">",
"     gastric/omental",
"    </span>",
"    and small",
"    <span class=\"nowrap\">",
"     bowel/esophageal/colorectal/mesenteric",
"    </span>",
"    primaries. Rates of disease progression for gastric and small bowel GISTs, stratified by stage at diagnosis, are presented in the tables (",
"    <a class=\"graphic graphic_table graphicRef78594 \" href=\"UTD.htm?10/1/10268\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54480 \" href=\"UTD.htm?10/14/10476\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTATION AND MANAGEMENT AT SPECIFIC SITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenchymal tumors are most common in the mid to distal third of the esophagus. They are usually small and asymptomatic, but occasionally grow to enormous size and produce dysphagia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Leiomyomas and leiomyosarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare elsewhere in the GI tract, the majority of mesenchymal tumors affecting the esophagus are leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/38\">",
"     38",
"    </a>",
"    ]. Leiomyosarcomas are far less common [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leiomyomas are more common in men, and often detected incidentally on a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow or endoscopy performed for other reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The tumors appear as rounded submucosal lesions with intact overlying mucosa and feel rubbery when gently palpated with the endoscope. Ulceration or bleeding is uncommon.",
"   </p>",
"   <p>",
"    The histologic distinction between well-differentiated leiomyosarcoma and leiomyoma can be difficult. Endoscopic resection of all small submucosal tumors has been suggested to firmly establish their benignity. In one series of 62 patients with submucosal tumors of the esophagus, tumors less than 2 cm that were polypoid or had at least a round protrusion with moderate elevation were selected for endoscopic snare polypectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/39\">",
"     39",
"    </a>",
"    ]. Larger tumors, or those having only mild elevation, were treated by complete stripping of the overlying mucosa followed by enucleation using an electrocautery snare and a coagulation electrode. Tumors were completely resected in all but one patient, and there were no serious complications. Histologically, there were 56 leiomyomas, four granular cell tumors, one neurogenic tumor, and one cyst.",
"   </p>",
"   <p>",
"    Despite these encouraging results, no malignant tumors were encountered in this series (with the exception of the granular cell tumors, which can be malignant), and the risk of complications is uncertain. The safety of this technique depends upon the endoscopist's experience.",
"   </p>",
"   <p>",
"    A more conservative approach for small asymptomatic lesions that lack features suggesting malignancy is to perform follow-up examinations using endoscopic ultrasound (EUS). Follow-up studies consist of repeat EUS at six and 12 months. If no changes occur within one year, the follow-up intervals can be lengthened. Surgical removal should be performed if the tumor becomes symptomatic, enlarges to &gt;1 cm, or shows structural changes. Snare polypectomy should be reserved for lesions with mucosal elevations that meet the previously described criteria. Surgical resection also is indicated in any case in which a malignancy is suspected.",
"   </p>",
"   <p>",
"    Stable lesions that are &gt;2 cm or that produce dysphagia should be treated with appropriate surgical resection.",
"   </p>",
"   <p>",
"    Complete resection of a small leiomyosarcoma can often be accomplished through local excision [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/40\">",
"     40",
"    </a>",
"    ]. However, based upon the size of the tumor, resection may require a total or partial esophagectomy. Esophagectomy may also be needed for adequate treatment of giant esophageal leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five-year survival rates of approximately 30 to 40 percent are reported in patients with surgically resected leiomyosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/42\">",
"     42",
"    </a>",
"    ], although less favorable results are reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/38\">",
"     38",
"    </a>",
"    ]. Individual survival is strongly influenced by tumor differentiation and size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     GIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal GISTs are rare; this site accounts for only 1 percent of all GISTs reported in the Surveillance, Epidemiology and End Results (SEER) registry [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/43\">",
"     43",
"    </a>",
"    ]. Esophageal GISTs have a similar clinical, endoscopic and radiographic appearance as leiomyomas, although they are FDG-avid and can be reliably identified preoperatively by EUS-guided FNA [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/44\">",
"     44",
"    </a>",
"    ]. All well-circumscribed submucosal esophageal lesions that are &gt;2 cm, enlarging, or FDG-avid should undergo preoperative EUS with FNA, as these are not typical features of a leiomyoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Diagnostic work-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal GISTs are more difficult to manage than are GISTs arising in serosa-lined intraabdominal organs because of the lack of tumor confinement by a serosal layer, and the relative contraindication to segmental resection given the blood supply of the esophagus. Although local resection of small tumors confined to the wall of the distal esophagus is reasonable if negative resection margins can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], an open en bloc esophagectomy is recommended for tumors &ge;2 cm and for those involving the GE junction.",
"   </p>",
"   <p>",
"    The optimal management of esophageal GISTs &lt;2 cm in size is controversial. ESMO guidelines recommend endoscopic ultrasound and follow-up, reserving excision only for those esophageal nodules that increase in size [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/7\">",
"     7",
"    </a>",
"    ]. Canadian guidelines suggest that all GISTs, even those &lt;1 cm, be excised because of the risk of metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/8\">",
"     8",
"    </a>",
"    ]. An algorithmic approach to management of gastrointestinal GISTs &le;2 cm based upon size and EUS appearance has been proposed (",
"    <a class=\"graphic graphic_algorithm graphicRef66521 \" href=\"UTD.htm?12/35/12861\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/10\">",
"     10",
"    </a>",
"    ]; however, this approach has not been prospectively validated. It has been adopted by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    for small gastric GISTs but not those at other sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of soft tissue tumors arising in the stomach are GISTs, followed by leiomyomas; leiomyosarcomas are rare. As an example, in a series of 262 smooth muscle neoplasms seen over an 11-year period at a single German center, there were only three true leiomyosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stomach is the most frequent site for GISTs, and they account for 1 to 3 percent of all stomach neoplasms (",
"    <a class=\"graphic graphic_picture graphicRef52275 \" href=\"UTD.htm?9/22/9570\">",
"     picture 1",
"    </a>",
"    ). They may arise anywhere but are most common in the fundus (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"UTD.htm?4/45/4817\">",
"     figure 1",
"    </a>",
"    ). Gastric GISTs usually occur after the age of 50, but they can affect a broad age range and are disproportionately more common in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    \"Carney's triad\" is a rare syndrome reported in young women that includes mainly gastric GISTs (originally referred to as \"leiomyosarcomas\"), paraganglioma, and pulmonary chondroma. GISTs arising in this setting can be relatively indolent even if metastatic, especially in children and young adults aged 12 to 18 years.",
"   </p>",
"   <p>",
"    A familial syndrome consisting of multicentric paragangliomas and multifocal GIST tumors with an autosomal dominant pattern of inheritance also has been described in young men and women that is distinct from the Carney's triad and referred to as Carney-Stratakis syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Familial GIST'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     GIST and leiomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both leiomyomas and gastric GISTs may be &le;0.5 cm or as large as 20 cm. Both tumors may grow both inwardly and outwardly to form a dumbbell shape, although leiomyomas are more likely to grow intraluminally (endogastric) (",
"    <a class=\"graphic graphic_picture graphicRef58068 \" href=\"UTD.htm?11/11/11440\">",
"     picture 2",
"    </a>",
"    ). In contrast, GISTs (and leiomyosarcomas) grow and expand in a predominantly extragastric fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/47\">",
"     47",
"    </a>",
"    ]. Multiple small leiomyomas (microleiomyomas) are found in 16 to 38 percent of resected stomachs.",
"   </p>",
"   <p>",
"    Leiomyomas are typically asymptomatic, even when large in size. While most small GISTs are asymptomatic, large lesions ulcerate, and up to 60 percent present with bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/36,48\">",
"     36,48",
"    </a>",
"    ]. Other symptoms include anorexia, weight loss, nausea, vomiting, and pain; gastric perforation is uncommon.",
"   </p>",
"   <p>",
"    Endoscopic ultrasound (EUS)-guided fine needle aspiration biopsy has emerged as an important method to secure the diagnosis of a gastric GIST. However, a preoperative diagnosis may not be possible if there is insufficient material to perform immunohistochemistry. &nbsp;",
"   </p>",
"   <p>",
"    The treatment approach varies according to size. All nodules &ge;2 cm should be excised. Submucosal lesions &lt;1 cm with EUS findings suggestive of benignity may be followed conservatively, using a similar protocol as for esophageal leiomyomas. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Leiomyomas and leiomyosarcomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The management of lesions between 1 and 2 cm is controversial, and guidelines from expert groups differ in their recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/7,8,49\">",
"     7,8,49",
"    </a>",
"    ]. Some clinicians will resect tumors between 0.5 and 1.0 cm in size by endoscopic snare polypectomy, but there is a risk of perforation. If the decision is made to remove them, we prefer that these and other larger tumors be surgically resected (preferably by a laparoscopic approach, if feasible), because of the increased frequency of complications and the difficulty in excluding malignancy preoperatively. Even 1 cm GISTs are likely to have a KIT mutation, and the risk of growth and progression to malignancy is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General surgical principles'",
"    </a>",
"    above.) Furthermore, these tumors are submucosal, so an endoscopic snare polypectomy may conceivably leave tumor tissue behind.",
"   </p>",
"   <p>",
"    Whether all gastric GISTs &lt;2 cm need to be removed is controversial. The prognosis of gastric GISTs is better than those arising elsewhere in the intestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General surgical principles'",
"    </a>",
"    above.) Larger tumor size and high mitotic rate correlate with a relative rather than absolute risk of malignant behavior (",
"    <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"     table 1",
"    </a>",
"    ). Nevertheless, even lesions &lt;2 cm in diameter with &lt;1 mitosis per 10 HPFs occasionally metastasize to the liver, peritoneum, or lung [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/36,48\">",
"     36,48",
"    </a>",
"    ]. Canadian guidelines suggest that even small GISTs &lt;1 cm should be excised because of the risk of metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An algorithmic approach to management of gastric GIST based upon size and EUS appearance has been proposed (",
"    <a class=\"graphic graphic_algorithm graphicRef66521 \" href=\"UTD.htm?12/35/12861\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/10\">",
"     10",
"    </a>",
"    ]. Although not prospectively validated, this approach was adopted by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    in their revised 2010 guidelines for management of gastric GISTs (but not those at other GI sites). Complete surgical resection is recommended for small gastric GISTs &lt;2 cm at high risk of recurrence based upon EUS appearance (irregular borders, cystic spaces, ulceration, echogenic foci, or heterogeneity in appearance). For tumors that lack these features, endoscopic surveillance is an option. However, many clinicians limit endoscopic resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surveillance to patients who are at higher risk for surgical complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Leiomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric leiomyosarcomas are rare. Symptoms include nausea, vomiting, pain, weight loss, bleeding, or a palpable mass [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These tumors may be large at presentation (median 10 cm in one report of 15 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/50\">",
"     50",
"    </a>",
"    ]), and there may be local invasion of adjacent organs. Areas of necrosis produce an inhomogeneous pattern on EUS and on contrast-enhanced CT [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Ninety percent of tumors are located in the fundus and body. Hematogenous dissemination may occur to liver and lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local resection with an adequate margin is the treatment of choice in the absence of invasion to adjacent structures [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. En bloc resection is needed if adjacent organs are invaded. Nodal dissection is unnecessary since nodal metastases are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, outcomes are less favorable than for gastric GIST. In a report of 15 cases of gastric leiomyosarcoma treated between 1981 and 1998 (median tumor size 10 cm), the three- and five-year survival rates following resection were 53 and 22 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/50\">",
"     50",
"    </a>",
"    ]. Others report markedly better outcomes in patients with gastric \"leiomyosarcoma\" (five-year disease-specific survival 93 percent), but it is likely that many of the patients included in this series would likely be classified as GIST by modern methods [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small intestine is the second most frequent site for smooth muscle tumors. Tumors are most commonly found in the jejunum, followed by the ileum and then duodenum [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/28,53-55\">",
"     28,53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common type of intestinal sarcoma is a GIST, accounting for 83 to 86 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The majority of previously classified leiomyosarcomas in older studies are in fact GIST tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\", section on 'Sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small intestinal mesenchymal tumors are often large at diagnosis, and they commonly present with ulceration and bleeding, which can be massive (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53060 \" href=\"UTD.htm?41/2/42017\">",
"     image 1",
"    </a>",
"    ). Other common presenting symptoms of small bowel sarcomas include pain, weight loss, perforation, or a palpable mass [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/41\">",
"     41",
"    </a>",
"    ]. Because they tend to enlarge extraluminally, obstruction is rare and typically a late presenting symptom. In contrast, small bowel leiomyomas, which typically grow into the lumen, may obstruct the small bowel (",
"    <a class=\"graphic graphic_picture graphicRef60327 \" href=\"UTD.htm?43/19/44337\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Surgical treatment for a localized, potentially resectable GIST and a leiomyosarcoma of the small bowel is similar and consists of en bloc segmental resection with tumor-free margins. Peritumoral as opposed to segmental resection should be avoided, as it is associated with a high risk of local recurrence. Unlike adenocarcinoma and carcinoid, sarcomas infrequently metastasize to regional mesenteric lymph nodes, and mesenteric lymphadenectomy is neither necessary nor beneficial. For duodenal GISTs, local resection is appropriate when feasible, and pancreaticoduodenectomy should be reserved for lesions that are not amenable to local resection (eg, involvement of the papilla of Vater) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of small intestine GISTs depends upon the adequacy of resection, tumor size, mitotic activity, and location within the small bowel (",
"    <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/28,31,54,55\">",
"     28,31,54,55",
"    </a>",
"    ]. In a series of 70 patients, five-year disease-free and overall survival rates were 67 and 87 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/54\">",
"     54",
"    </a>",
"    ]. There were no recurrences or deaths in patients with tumor size less than 5 cm, and no deaths in patients with a tumor mitotic rate less than 5 per 50 high-power fields (hpf).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Colon and rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smooth muscle tumors are uncommon in the colon and rectum, and especially rare in the appendix [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/62\">",
"     62",
"    </a>",
"    ]. In the rectum, the great majority of smooth muscle tumors are GISTs [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/63\">",
"     63",
"    </a>",
"    ], and they usually present as small, hard nodules &lt;1 cm in diameter found incidentally during a clinical examination. Large tumors can ulcerate and mimic a rectal adenocarcinoma, with rectal bleeding, constipation, and abdominal discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the colon, GISTs are more common than leiomyosarcomas, and they are typically transmural, with frequent intramural and outward bulging components [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/65\">",
"     65",
"    </a>",
"    ]. In one report, none of the ten patients with incidentally found small tumors (two with tumor size larger than 1 cm and minimal mitotic activity), and nearly all patients with tumors &gt;1 cm and more than five mitoses per HPF died of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/65\">",
"     65",
"    </a>",
"    ]. In contrast, two of seven patients with leiomyosarcoma had long-term survival despite high mitotic activity.",
"   </p>",
"   <p>",
"    Lesions in which a malignancy cannot be excluded should be resected surgically, regardless of size. Although leiomyomas could theoretically be enucleated, a standard colectomy based on the blood supply to the bowel, as is done for adenocarcinomas, is technically easier, and the complication rate should be comparable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADJUVANT AND NEOADJUVANT IMATINIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before 2001, surgery was the only available treatment for GISTs. In approximately one-half of patients, complete resection was not possible, and median survival ranged from 10 to 23 months [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/22\">",
"     22",
"    </a>",
"    ]. Dramatic improvements occurred with the recognition that mutational activation of the KIT or PDGFRA genes stimulated the growth of these cancer cells. This led to the development of effective systemic therapies in the form of small molecule tyrosine kinase inhibitors (TKIs) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Following the introduction of imatinib, the median survival of advanced GIST was 60 months in the trial with the longest follow-up to date [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H2#H2\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Efficacy of imatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2687282\">",
"    <span class=\"h2\">",
"     Adjuvant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of these agents in the setting of advanced disease prompted interest in their use as adjuvant treatment for patients at high risk of recurrence after complete resection. Largely based upon a trial conducted by the American College of surgeon's Oncology Group (ACOSOG), which demonstrated a marked decrease in recurrence with one year of adjuvant treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is approved in the United States for use as adjuvant therapy for any primary GIST &ge;3 cm. Subsequently, significantly better outcomes (including survival) were demonstrated with three as compared to one year of adjuvant imatinib in the Scandinavian SSGXVIII-AIO trial. However, a number of clinical questions remain, including long-term benefit of such therapy, optimal disease risk stratification, and the optimal duration of adjuvant treatment. The subject of adjuvant imatinib for GISTs is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Adjuvant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2687275\">",
"    <span class=\"h2\">",
"     Neoadjuvant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high response rates seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in advanced disease has prompted interest in starting imatinib prior to locoregional therapy. The goals of preoperative treatment are to reduce the size of the tumor, thereby facilitating surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increasing the likelihood of organ preservation. Although there is no consensus as to the indications for neoadjuvant imatinib, patients with an unresectable or borderline resectable locally advanced tumor, or a potentially resectable tumor that requires extensive organ disruption could be considered for initial therapy with imatinib. Another circumstance in which neoadjuvant treatment might be beneficial is in patients with a GIST arising in the esophagus, esophagogastric junction, duodenum, or distal rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/67\">",
"     67",
"    </a>",
"    ]. Preoperative treatment might shrink the tumor and permit a more conservative local excision to be performed rather than radical surgery.",
"   </p>",
"   <p>",
"    The usual therapeutic schema includes a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (typically from 6 to 12 months, less if the treatment effect plateaus) with frequent imaging studies and periodic reevaluation for surgery. The decision as to how long to continue the imatinib and when to operate (ie, at first resectability versus after achieving maximal response) must be individualized. Referral to a multidisciplinary team experienced in the treatment of GIST is recommended in such cases. This subject is covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link&amp;anchor=H8#H8\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Neoadjuvant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ROLE OF SURGERY IN PATIENTS WITH METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although therapy with TKIs has become the first-line treatment for metastatic GIST, there are several reasons to consider surgical resection in patients who are receiving these drugs for metastatic disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While TKIs control tumor growth in over 80 percent of patients, complete responses are only rarely achieved [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/35,68,69\">",
"       35,68,69",
"      </a>",
"      ]. Even tumor masses that appear nonviable by metabolic imaging (eg, with PET scans) usually contain viable cancer cells [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most patients who initially respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      eventually acquire resistance via additional mutations in the KIT gene. The median time to progression is approximately two years. Thereafter, the therapeutic alternatives are limited. Only a minority of patients will benefit from escalating the imatinib dose or from switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      . In principle, resection of residual disease might delay or prevent the development of resistant clones by reducing tumor burden. In some, this may prolong the time to disease progression.",
"     </li>",
"     <li>",
"      The liver and peritoneum are the most common metastatic sites, and about 25 to 30 percent of patients who present with",
"      <span class=\"nowrap\">",
"       recurrent/metastatic",
"      </span>",
"      disease have potentially resectable disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two trials addressing this question were begun in",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00956072\">",
"     Europe",
"    </a>",
"    and in China, but both failed to recruit quickly enough to meet target accrual. However, in the absence of randomized trials, whether survival is altered by resecting residual disease (as opposed to just continuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    without surgical resection) is unknown. Single institution retrospective studies document long-term disease control following resection for selected patients with limited metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/71-79\">",
"     71-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, resection appears to benefit responding patients (ie, those who have a partial response, stable disease, or focal progression, and possibly those with isolated sites of progression) but has little to offer those who experience generalized disease progression while receiving a TKI. Furthermore, resection, even if complete, does not eliminate the need for continued treatment with TKI therapy. Progression-free survival is significantly shorter in patients who discontinue treatment as compared to those who continue the drug after resection.",
"   </p>",
"   <p>",
"    These issues can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 69 consecutive patients who underwent surgery for advanced GIST while receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      therapy, the 12 month progression-free survival rates were 80, 33, and 0 percent for patients with",
"      <span class=\"nowrap\">",
"       stable/responsive",
"      </span>",
"      disease,",
"      <span class=\"nowrap\">",
"       limited/focal",
"      </span>",
"      progression, or",
"      <span class=\"nowrap\">",
"       generalized/multifocal",
"      </span>",
"      as the best response to initial imatinib [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/73\">",
"       73",
"      </a>",
"      ]. All patients but one resumed therapy with a TKI postoperatively.",
"     </li>",
"     <li>",
"      Similar findings were noted in a preliminary report of 113 patients undergoing surgery for histologically confirmed GIST after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/80\">",
"       80",
"      </a>",
"      ]. The operative procedure included hepatic resection (n = 13), abdominoperineal",
"      <span class=\"nowrap\">",
"       excision/anterior",
"      </span>",
"      resection (n = 27), multivisceral resection (n = 73) or peritoneal debulking (n = 31). A complete (R0) resection was achieved in 72 percent of patients with a partial response to imatinib compared to only 26 percent with progressive disease. The corresponding median progression-free survival durations after R0 resection in these two groups were 16 versus 7 months, respectively. Despite an R0 resection, eight of 14 patients who discontinued imatinib postoperatively recurred.",
"     </li>",
"     <li>",
"      In another series of 40 patients with metastatic GIST, two-year progression-free and overall survival rates among the 20 patients undergoing surgery while responding to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      were 61 and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/75\">",
"       75",
"      </a>",
"      ]. Of the 13 patients with focal resistance (ie, one tumor growing), all progressed after surgery at a median of 12 months, and the two-year overall survival was 36 percent. All seven patients with multifocal resistance progressed within three months of surgery and the median survival was 11 months. Four of the seven patients who progressed did not resume TK inhibitor therapy immediately after surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, surgery may be considered as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    response permits. If there are signs of isolated progression (ie, one or two lesions growing out of proportion to other sites of responding disease), surgical excision of such lesions is a reasonable approach, although it is not clear if survival is prolonged compared to if systemic therapy were changed. For patients with more generalized progression of disease, surgery is not helpful, and other systemic options should be pursued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H15#H15\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Management of refractory or intolerant patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Timing of surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate timing of surgical intervention is unknown. Some propose that patients be treated for six to nine months with a TK inhibitor and then considered for surgery if the disease appears completely grossly resectable [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/75\">",
"     75",
"    </a>",
"    ]. While it has been shown that tumor load continues to decrease even after one year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , the median time to best response is 3.5 months, and there is little incremental tumor shrinkage after nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients treated with neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    should resume TKI therapy postoperatively, typically with the same agent and dose. In theory, this maximizes the potential benefit derived from the TK inhibitor by extending the time each patient is on that drug prior to proceeding to the next line of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hepatic resection for liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the site of recurrence in as many as 67 percent of patients with relapsed GIST [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/22\">",
"     22",
"    </a>",
"    ]. Prior to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    era, these patients were treated like other soft tissue sarcomas metastatic to the liver, with resection when technically feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The available data on GIST liver metastases suggest five-year survival rates from 27 to 34 percent in patients undergoing resection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with isolated liver metastases, hepatic resection combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    provides the greatest opportunity for long-term disease control [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/85,87-89\">",
"     85,87-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A course of preoperative therapy (ie, three to nine months) is preferred in most cases, as it not only has the potential to reduce the extent of needed surgery, but it also permits the \"biologic selection\" of the best candidates for surgery, particularly if extensive procedures are planned. As an example, in the setting of multiple bilateral lesions (which are common with GIST), a two-staged approach may be needed, with or without portal vein embolization to increase the volume of the future liver remnant prior to hepatic resection [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H1061867819#H1061867819\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Portal vein embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important component of periodic response assessment during neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is the understanding that a response to therapy consists less often of a change in tumor size or diameter, and more often of changes in density (ie, the development of cystic structures) and vascularity. This renders size-based tumor response criteria such as the RECIST (Response Evaluation Criteria in Solid Tumor) criteria (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"UTD.htm?41/48/42764\">",
"     table 5",
"    </a>",
"    ) less useful. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H3#H3\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Assessing response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other sites of metastatic disease, resection following neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    appears to benefit responding patients (ie, those who have a partial response, stable disease, or focal progression) but has little to offer those who experience generalized disease progression while receiving imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/73\">",
"     73",
"    </a>",
"    ]. The optimal timing of attempted surgical resection (ie, at the time of maximal response to imatinib or at the first suggestion of local progression) is unclear, but the best response to imatinib is observed with three to nine months of therapy, with little change thereafter, suggesting this is a reasonable time to consider resection.",
"   </p>",
"   <p>",
"    As with other sites of metastatic disease, hepatic resection, even if complete, does not eliminate the need for continued treatment with a tyrosine kinase inhibitor (TKI). Progression-free survival is significantly shorter in patients who discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    as compared to those who continue the drug after resection [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Existing clinical practice guidelines from the National Comprehensive Cancer Network (",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    ) and ESMO [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/7\">",
"     7",
"    </a>",
"    ] recommend the indefinite administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for patients with resected metastases in the liver or peritoneum, even if the resection was complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other local therapy options for liver metastases",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119647927\">",
"    <span class=\"h4\">",
"     Hepatic arterial embolization and chemoembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with isolated liver metastases, hepatic resection combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    provides the greatest opportunity for long-term disease control, but many patients are ineligible because they have multifocal bilobar disease. Few data are available on the long-term benefit of hepatic artery embolization or chemoembolization for patients with isolated unresectable liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. The largest series consisted of 110 patients who underwent the procedure (using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with or without an embolic agent) for liver metastases from GIST, 38 of whom had extrahepatic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/90\">",
"     90",
"    </a>",
"    ]. Sixty-two were treated in the pre-imatinib era.",
"   </p>",
"   <p>",
"    The number of sessions per patient ranged from one to seven; 62 percent had two or more treatments. Most patients developed a temporary postembolization syndrome (abdominal pain, fever, nausea, vomiting), which was effectively managed with supportive care alone. Moderate to severe adverse events (death, respiratory distress, myelosuppression, cholecystitis, sepsis, pulmonary embolism, symptomatic pleural effusion, and hyponatremia-induced seizures) developed in 25 (12 percent).",
"   </p>",
"   <p>",
"    Among the 85 patients who could be assessed, 12 had a partial radiologic response (14 percent, according to RECIST criteria) and 74 percent had stable disease. The median liver progression-free survival was 8.2 months, a value which is comparable to that reported in other smaller series (8 and 10 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Median overall survival was 17.2 months, but the contribution of chemoembolization to this value could not be ascertained because of the use of other therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , after disease progression. Concomitant imatinib prolonged survival time.",
"   </p>",
"   <p>",
"    In a later analysis by this group of 14 patients who underwent hepatic artery embolization or chemoembolization for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -refractory disease, the progression-free survival rates in the liver were 31 percent at both one and three years, and the median progression-free and overall survival times were 7 and 9.7 months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest a possible therapeutic role for hepatic arterial embolization in patients with unresectable but isolated liver metastases from GISTs. However, the benefit of chemoembolization over bland embolization alone is unclear. Furthermore, the place of embolization in the therapeutic armamentarium remains uncertain, particularly in view of the approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , a multitargeted TK inhibitor, for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H17#H17\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our general practice is to consider embolization if there is multifocal disease progression despite use of available systemic therapeutic options, although each patient must be considered individually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119647951\">",
"    <span class=\"h4\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of thermal ablation to produce necrosis in focal hepatic malignancies has been established in patients who are not otherwise candidates for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28234?source=see_link\">",
"     \"Nonsurgical local treatment strategies for colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have explored the efficacy of RFA in patients with liver metastases from GIST [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/83,85\">",
"     83,85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report included nine patients with metastatic GIST who had RFA for a single or limited number of sites of progressive disease after a median 25 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (eight for liver metastases) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/83\">",
"       83",
"      </a>",
"      ]. In a preliminary report (median 4.2 months), all lesions were completely ablated, and four remained stable on continued imatinib. Longer-term follow-up of this cohort has not been reported.",
"     </li>",
"     <li>",
"      A second series included 31 patients who underwent intraoperative RFA for sarcoma metastatic to liver (36 of the entire series of 66 patients had GIST) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/85\">",
"       85",
"      </a>",
"      ]. For 13 patients, RFA was the sole modality for tumors in unresectable locations, the remainder had resection of large lesions combined with RFA of smaller lesions deemed unresectable [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/85\">",
"       85",
"      </a>",
"      ]. Patients who were treated with RFA alone or as a combined modality with resection had a significantly shorter disease-free interval than did those undergoing resection alone. The contribution of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      to RFA outcomes was not addressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest a possible therapeutic role for RFA in patients with advanced GIST who develop focal progression of liver metastases during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy and who are not otherwise candidates for surgical resection. Both lesion size and proximity to large blood vessels (which serve as a heat sink) impact on the feasibility of RFA as a therapeutic option.",
"   </p>",
"   <p>",
"    However, as with hepatic arterial embolization, the place of RFA in the therapeutic armamentarium remains uncertain, particularly in view of the approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , a multitargeted TK inhibitor, for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H17#H17\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment follow-up is not required for a leiomyoma. While there is no proof that any schedule of follow up for any sarcoma changes clinical outcomes (ie, survival), posttreatment surveillance is usually carried out for early detection of recurrent disease that may be amenable to additional treatment. For GIST and leiomyosarcoma, the recommendations differ slightly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6016720\">",
"    <span class=\"h2\">",
"     GIST",
"    </span>",
"   </p>",
"   <p>",
"    There are no evidence-based guidelines on what constitutes appropriate follow-up after treatment of a GIST, and there is no consensus on this issue.",
"   </p>",
"   <p>",
"    Guidelines from the National Comprehensive Cancer Network (",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    ) suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a completely resected GIST tumor, history and physical examination every three to six months for five years, then annually. A CT scan is recommended every three to six months for three to five years, then annually.",
"     </li>",
"     <li>",
"      For patients with more locally advanced or metastatic disease who are receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , history and physical examination as well as abdominopelvic CT scan are recommended every three to six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, guidelines from the European Society of Medical Oncology (ESMO) suggest that the posttreatment surveillance strategy be tailored to the risk of disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For intermediate- or high-risk patients (who generally relapse early at a median of two years after resection), history, physical examination, and imaging every three to four months for three years, every six months for years three to five, then annually. However, surveillance beyond five years may not be necessary, as two studies of patients undergoing resection for high-risk tumors with long-term follow-up have shown very few recurrences after five years [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/23,95\">",
"       23,95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with small low-risk tumors, which have been known to recur as late as ten years following resection [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/96\">",
"       96",
"      </a>",
"      ], the follow-up can be at longer intervals, such as every six months, for five years, then annually thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6016736\">",
"    <span class=\"h2\">",
"     Leiomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus-based guidelines for posttreatment followup for intraabdominal or retroperitoneal sarcomas are available from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    and include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33146?source=see_link&amp;anchor=H35#H35\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\", section on 'Posttreatment follow-up'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For completely resected tumors: physical examination with",
"      <span class=\"nowrap\">",
"       abdominal/pelvic",
"      </span>",
"      imaging every three to six months for two to three years, and then annually; &ldquo;consider&rdquo; chest imaging.",
"     </li>",
"     <li>",
"      For sarcomas resected with positive margins: physical examination with",
"      <span class=\"nowrap\">",
"       abdominal/pelvic",
"      </span>",
"      imaging every three to six months for two to three years, then every six months for the next two years, and then annually; &ldquo;consider&rdquo; chest imaging.",
"     </li>",
"     <li>",
"      In either case, no specific recommendation is made for periodic chest imaging. However, given the higher rate of lung metastases with retroperitoneal and visceral leiomyosarcomas (as compared to other histologies), we recommend imaging of the chest in addition to the abdomen and pelvis on a regular schedule in these cases. Some clinicians routinely perform surveillance chest imaging for all patients with large, high-grade tumors, regardless of histology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal neoplasm affecting the GI tract. They differ clinically and pathogenetically from true leiomyosarcomas (which are very rare in the GI tract and predominantly found in the stomach) and leiomyomas, which occur predominantly in the esophagus, colon and rectum. The majority of mesenchymal tumors of the stomach are GISTs while the majority of smooth muscle tumors in the esophagus are leiomyomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"       \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gastrointestinal stromal tumors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The molecular hallmark of a GIST is a mutation in the KIT protooncogene that leads to constitutive activation of KIT, a receptor tyrosine kinase (RTK). A subset of GISTs lacking KIT gene mutations has activating mutations in a related RTK, platelet-derived growth factor receptor-alpha (PDGFRA). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical behavior of GISTs is variable, although with prolonged follow-up, it appears that virtually all GISTs have the potential to behave in a malignant fashion. Tumor size, mitotic count, and site of origin form the foundation of risk stratification (",
"      <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"       table 1",
"      </a>",
"      ). As an alternative to the risk-classification systems that stratify patients into discrete categories, others have quantified the risk of disease recurrence after complete resection as a continuous variable though the use of a",
"      <a class=\"external\" href=\"file://www.mskcc.org/cancer-care/adult/gastrointestinal-neuroendocrine-tumors/prediction-tools\">",
"       GIST tumor nomogram",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?34/7/34938/abstract/97\">",
"       97",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"       \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend resection for all localized GISTs &ge;2 cm in size (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). There is no consensus on the management of incidentally encountered smaller GISTs, and their management must be individualized. Guidelines for treatment of intraabdominal sarcomas from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      do not differentiate between tumors that are &ge;2 cm and smaller ones. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General surgical principles'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For potentially resectable gastric and intestinal GISTs, segmental (rather than peritumoral) visceral resection is preferred; regional lymphadenectomy is unnecessary. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Presentation and management at specific sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a nonmetastatic locally advanced or borderline resectable GIST, we suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      rather than attempted resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Another circumstance in which neoadjuvant treatment might be beneficial is in patients with a GIST arising in the esophagus, esophagogastric junction, duodenum, or distal rectum, where preoperative treatment might shrink the tumor and permit a more conservative local excision to be performed rather than radical surgery.",
"      <br/>",
"      <br/>",
"      The decision as to how long to continue the imatinib and when to operate (ie, at first resectability versus after achieving maximal response) must be individualized. Aggressive cytoreductive surgery may be offered only to patients whose disease is stable or responding to TK inhibitor therapy or who have only focal progression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link&amp;anchor=H8#H8\">",
"       \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Neoadjuvant therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Referral to a multidisciplinary team experienced in the treatment of GIST is recommended. If possible, such patients should be enrolled on a clinical trial.",
"      <br/>",
"      <br/>",
"      The FDA recommends three years of adjuvant imatinib following resection of KIT-positive GISTs with a high risk of recurrence (as defined in the SSGXVII-AIO phase III trial entry criteria).",
"     </li>",
"     <li>",
"      For patients with potentially resectable metastatic GIST (including liver and peritoneal metastases), we suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      rather than initial attempted resection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who develop extensive disease progression while on neoadjuvant imatinib gain little from surgery, and we recommend that it not be attempted (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Surgery may be reconsidered in patients who become resectable after initial imatinib and for those with primary imatinib resistance who become resectable after therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Role of surgery in patients with metastatic disease'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Cytoreductive surgery in this setting often requires extensive potentially morbid procedures such as gastrectomy, hepatectomy, pancreatic resection, and should be carried out in centers of excellence. All patients should resume therapy with a TK inhibitor for an indefinite period of time after resection of metastatic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There may be some therapeutic benefit from hepatic arterial embolization in patients with unresectable but isolated liver metastases from GISTs, and from RFA in patients with focal progression of liver metastases during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      who are not candidates for surgical resection. However, the place of embolization and RFA in the therapeutic armamentarium remains uncertain, particularly in view of the approval of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , a multitargeted TK inhibitor, for imatinib-resistant disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H17#H17\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Sunitinib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Leiomyosarcoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leiomyosarcomas are very rare in the GI tract and predominantly found in the stomach. We recommend local resection with an adequate margin in the absence of invasion to adjacent structures (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). En bloc resection is needed if adjacent organs are invaded. As with GISTs, nodal dissection is not necessary because of the rarity of nodal metastases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stomach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Leiomyoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leiomyomas are benign smooth muscle tumors that occur predominantly in the esophagus, colon and rectum. All well-circumscribed submucosal esophageal lesions that are &gt;2 cm, enlarging, or FDG-avid should undergo preoperative EUS with FNA, as these are not typical features of a leiomyoma. Surgical removal is indicated if the tumor becomes symptomatic, enlarges to &gt;1 cm or shows structural changes during surveillance, and in any case in which malignancy is suspected. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Leiomyomas and leiomyosarcomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/1\">",
"      Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/2\">",
"      Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/3\">",
"      Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/4\">",
"      Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/5\">",
"      Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889.",
"     </a>",
"    </li>",
"    <li>",
"     Atlas of Tumor Pathology: Tumors of the esophagus and stomach. Electronic fascicle v2.0b, Armed Forces Institute of Pathology, Washington DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/7\">",
"      Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/8\">",
"      Blackstein ME, Blay JY, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/9\">",
"      Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: optimal management of patients with gastrointestinal stromal tumor (GIST)- Update of NCCN Clinical Practice Guidelines. J Natl Comp Cancer Net 2007; 5(2 suppl):S-1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/10\">",
"      Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 2009; 6:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/11\">",
"      Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004; 30:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/12\">",
"      Everett M, Gutman H. Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique. J Surg Oncol 2008; 98:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/13\">",
"      Huguet KL, Rush RM Jr, Tessier DJ, et al. Laparoscopic gastric gastrointestinal stromal tumor resection: the mayo clinic experience. Arch Surg 2008; 143:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/14\">",
"      Nishimura J, Nakajima K, Omori T, et al. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection. Surg Endosc 2007; 21:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/15\">",
"      Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 2006; 243:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/16\">",
"      Tabrizian P, Nguyen SQ, Divino CM. Laparoscopic management and longterm outcomes of gastrointestinal stromal tumors. J Am Coll Surg 2009; 208:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/17\">",
"      Karakousis GC, Singer S, Zheng J, et al. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Ann Surg Oncol 2011; 18:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/18\">",
"      Melstrom LG, Phillips JD, Bentrem DJ, Wayne JD. Laparoscopic versus open resection of gastric gastrointestinal stromal tumors. Am J Clin Oncol 2012; 35:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/19\">",
"      Nguyen SQ, Divino CM, Wang JL, Dikman SH. Laparoscopic management of gastrointestinal stromal tumors. Surg Endosc 2006; 20:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/20\">",
"      Oida Y, Motojuku M, Morikawa G, et al. Laparoscopic-assisted resection of gastrointestinal stromal tumor in small intestine. Hepatogastroenterology 2008; 55:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/21\">",
"      Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/22\">",
"      DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/23\">",
"      Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/24\">",
"      Akwari OE, Dozois RR, Weiland LH, Beahrs OH. Leiomyosarcoma of the small and large bowel. Cancer 1978; 42:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/25\">",
"      McGrath PC, Neifeld JP, Lawrence W Jr, et al. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987; 206:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/26\">",
"      Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/27\">",
"      Wieczorek TJ, Faquin WC, Rubin BP, Cibas ES. Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcoma. Cancer 2001; 93:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/28\">",
"      Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/29\">",
"      Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/30\">",
"      Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003; 90:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/31\">",
"      Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/32\">",
"      Langer C, Gunawan B, Sch&uuml;ler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/33\">",
"      Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003; 134:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/34\">",
"      Besana-Ciani I, Boni L, Dionigi G, et al. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg 2003; 92:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/35\">",
"      Carboni F, Carlini M, Scardamaglia F, et al. Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience. J Exp Clin Cancer Res 2003; 22:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/36\">",
"      Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer. American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/38\">",
"      Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/39\">",
"      Hyun JH, Jeen YT, Chun HJ, et al. Endoscopic resection of submucosal tumor of the esophagus: results in 62 patients. Endoscopy 1997; 29:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/40\">",
"      Rocco G, Trastek VF, Deschamps C, et al. Leiomyosarcoma of the esophagus: results of surgical treatment. Ann Thorac Surg 1998; 66:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/41\">",
"      Rijcken E, Kersting CM, Senninger N, Bruewer M. Esophageal resection for giant leiomyoma: report of two cases and a review of the literature. Langenbecks Arch Surg 2009; 394:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/42\">",
"      Pesarini AC, Ernst H, Ell C, et al. [Leiomyosarcoma of the esophagus. Clinical aspects, diagnosis and therapy based on an individual case]. Med Klin (Munich) 1997; 92:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/43\">",
"      Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/44\">",
"      Blum MG, Bilimoria KY, Wayne JD, et al. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg 2007; 84:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/45\">",
"      Lee HJ, Park SI, Kim DK, Kim YH. Surgical resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg 2009; 87:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/46\">",
"      Agaimy A, W&uuml;nsch PH. True smooth muscle neoplasms of the gastrointestinal tract: morphological spectrum and classification in a series of 85 cases from a single institute. Langenbecks Arch Surg 2007; 392:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/47\">",
"      Davis GB, Blanchard DK, Hatch GF 3rd, et al. Tumors of the stomach. World J Surg 2000; 24:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/48\">",
"      Igwilo OC, Byrne MP, Nguyen KD, Atkinson J. Malignant gastric stromal tumor: unusual metastatic patterns. South Med J 2003; 96:512.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/50\">",
"      Hsieh CC, Shih CS, Wu YC, et al. Leiomyosarcoma of the gastric cardia and fundus. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/51\">",
"      Pannu HK, Hruban RH, Fishman EK. CT of gastric leiomyosarcoma: patterns of involvement. AJR Am J Roentgenol 1999; 173:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/52\">",
"      Katai H, Sasako M, Sano T, Maruyama K. Surgical treatment for gastric leiomyosarcoma. Ann Chir Gynaecol 1998; 87:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/53\">",
"      Blanchard DK, Budde JM, Hatch GF 3rd, et al. Tumors of the small intestine. World J Surg 2000; 24:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/54\">",
"      Huang CC, Yang CY, Lai IR, et al. Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg 2009; 33:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/55\">",
"      Yang WL, Yu JR, Wu YJ, et al. Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics, and surgical prognosis. J Surg Oncol 2009; 100:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/56\">",
"      Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/57\">",
"      Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/58\">",
"      Tien YW, Lee CY, Huang CC, et al. Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol 2010; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     Duffaud F, Ray-Coquard IL, Blesius A, et al. Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts) (abstract 10057). J Clin Oncol 2011; 29:619s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=81877 (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/60\">",
"      Johnston FM, Kneuertz PJ, Cameron JL, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis. Ann Surg Oncol 2012; 19:3351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/61\">",
"      Colombo C, Ronellenfitsch U, Yuxin Z, et al. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. Ann Surg Oncol 2012; 19:3361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/62\">",
"      Miettinen M, Sobin LH. Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 2001; 25:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/63\">",
"      Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/64\">",
"      Manouras A, Pappas A, Katergiannakis V, et al. Gastrointestinal stromal tumors of the rectum: report of five cases. Acta Gastroenterol Belg 2009; 72:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/65\">",
"      Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/66\">",
"      Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006; 139:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/67\">",
"      Gronchi A, Raut CP. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol 2012; 19:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/68\">",
"      Chac&oacute;n M, Roca E, Huertas E, et al. CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 2005; 23:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/69\">",
"      Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005; 117:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/70\">",
"      Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/71\">",
"      Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/72\">",
"      Bonvalot S, Eldweny H, P&eacute;choux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/73\">",
"      Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/74\">",
"      Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/75\">",
"      DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/76\">",
"      Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/77\">",
"      Al-Batran SE, Hartmann JT, Heidel F, et al. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer 2007; 10:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/78\">",
"      Yeh CN, Chen TW, Tseng JH, et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/79\">",
"      Mussi C, Ronellenfitsch U, Jakob J, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21:403.",
"     </a>",
"    </li>",
"    <li>",
"     Hohenberger P, Langer C, Pistorius S, et al. Indications and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) (abstract). J Clin Oncol 2006; 24:520s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/81\">",
"      Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/82\">",
"      Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am 2009; 23:115.",
"     </a>",
"    </li>",
"    <li>",
"     Dileo P, Randdhawa R, vanSonnenberg E, et al. Safety and effiacy of percutaneous radio-frequency ablation (RFA) in patients with metastatic gastrointestinal stromal tumor (GIST) with cloan evolution of lesions refractory to imatinib mesylate (IM) (abstract). J Clin Oncol 2004; 22:820a. (abstract 9024).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/84\">",
"      DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/85\">",
"      Pawlik TM, Vauthey JN, Abdalla EK, et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006; 141:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/86\">",
"      Nunobe S, Sano T, Shimada K, et al. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol 2005; 35:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/87\">",
"      Rutkowski P, Nyckowski P, Grzesiakowska U, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 2003; 50:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/88\">",
"      Xia L, Zhang MM, Ji L, et al. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 2010; 40:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/89\">",
"      Turley RS, Peng PD, Reddy SK, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer 2012; 118:3571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/90\">",
"      Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 2006; 107:2833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/91\">",
"      Mavligit GM, Zukwiski AA, Ellis LM, et al. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995; 75:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/92\">",
"      Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/93\">",
"      Kobayashi K, Szklaruk J, Trent JC, et al. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Am J Clin Oncol 2009; 32:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/94\">",
"      Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/95\">",
"      Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/96\">",
"      Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am 2009; 89:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/7/34938/abstract/97\">",
"      Gold JS, G&ouml;nen M, Guti&eacute;rrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10:1045.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7727 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34938=[""].join("\n");
var outline_f34_7_34938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL SURGICAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Staging and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTATION AND MANAGEMENT AT SPECIFIC SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Leiomyomas and leiomyosarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - GIST and leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Leiomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Small intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADJUVANT AND NEOADJUVANT IMATINIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2687282\">",
"      Adjuvant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2687275\">",
"      Neoadjuvant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ROLE OF SURGERY IN PATIENTS WITH METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Timing of surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hepatic resection for liver metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other local therapy options for liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H119647927\">",
"      Hepatic arterial embolization and chemoembolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H119647951\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6016720\">",
"      GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6016736\">",
"      Leiomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Leiomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7727\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7727|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/35/12861\" title=\"algorithm 1\">",
"      Proposed GIST management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7727|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/2/42017\" title=\"diagnostic image 1\">",
"      Small bowel leiomyoma CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7727|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/45/4817\" title=\"figure 1\">",
"      Parts of the stomach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7727|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/22/9570\" title=\"picture 1\">",
"      Gastrointestinal stromal tumor CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/11/11440\" title=\"picture 2\">",
"      Gastric leiomyoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/19/44337\" title=\"picture 3\">",
"      Jejunal leiomyoma Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7727|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/23/36220\" title=\"table 1\">",
"      GIST progn site size mit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/35/8766\" title=\"table 2\">",
"      TNM staging GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/1/10268\" title=\"table 3\">",
"      Dis prog gastric GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/14/10476\" title=\"table 4\">",
"      Dis prog small int GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42764\" title=\"table 5\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=related_link\">",
"      Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=related_link\">",
"      Epidemiology, clinical features, and types of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28234?source=related_link\">",
"      Nonsurgical local treatment strategies for colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_7_34939="Aspirin NSAID and asthma";
var content_f34_7_34939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonsteroidal antiinflammatory drugs (NSAIDs) in aspirin-induced asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Potent inhibitors of cyclooxygenase 1&nbsp;&nbsp;- can induce asthma in sensitive patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nabumetone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diclofenac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indomethacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naproxen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflunisal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketoprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piroxicam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etodolac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketorolac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulindac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fenoprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meclofenamate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolmetin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurbiprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mefanamic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Little to no inhibition of cyclooxygenase 1&nbsp;- generally safe in aspirin-induced asthma except for extremely sensitive patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choline magnesium trisalicylate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylsalicylic acid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34939=[""].join("\n");
var outline_f34_7_34939=null;
var title_f34_7_34940="Differential diagnosis BL";
var content_f34_7_34940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of Burkitt lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Entity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunophenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic features/other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burkitt lymphoma",
"       </td>",
"       <td>",
"        Monomorphic, medium-sized cells with round nuclei, multiple nucleoli, basophilic cytoplasm, prominent cytoplasmic lipid vacuoles, and a \"starry-sky\" pattern. Ki-67+ fraction approaching 100 percent.",
"       </td>",
"       <td>",
"        Express surface IgM and B-cell-associated antigens (CD19, CD20, CD22, CD79a), as well as CD10, HLA-DR, and CD43. They lack CD5, bcl-2, and typically lack CD23.",
"       </td>",
"       <td>",
"        Strongly (but not uniformly) associated with a translocation between the long arm of chromosome 8, the site of the c-MYC oncogene (8q24), and one of three locations on Ig genes: t(8;14), t(2;8), or t(8;22). No evidence of t(14;18).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diffuse large B-cell lymphoma",
"       </td>",
"       <td>",
"        Large, transformed B-cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation (Ki-67+) fraction.",
"       </td>",
"       <td>",
"        Generally express pan B-cell antigens (CD19, CD20, CD22, CD79a).",
"       </td>",
"       <td>",
"        The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. A subset will have c-MYC rearrangements.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Precursor T-cell lymphoblastic leukemia/lymphoma",
"       </td>",
"       <td>",
"        Varied morphology, but may resemble Burkitt lymphoma but have intermediate sized oval or round nuclei, more dispersed chromatin, several distinct nuclei, and more abundant cytoplasm.",
"       </td>",
"       <td>",
"        Express TdT and are of T-cell phenotype typically positive for CD7 and either surface or cytoplasmic CD3, and variably express CD2, CD5, CD1a, CD4 and/or CD8.",
"       </td>",
"       <td>",
"        No single cytogenetic change is typical or diagnostic.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Precursor B-cell lymphoblastic leukemia/lymphoma",
"       </td>",
"       <td>",
"        Varied morphology, but may resemble Burkitt lymphoma but have intermediate sized oval or round nuclei, more dispersed chromatin, several distinct nuclei, and more abundant cytoplasm.",
"       </td>",
"       <td>",
"        Lack expression of surface immunoglobulin. Express TdT and variably express the B-cell markers CD19, CD22, CD20, and CD79a, leukocyte common antigen CD45 and common acute lymphoblastic leukemia antigen CD10 (CALLA).",
"       </td>",
"       <td>",
"        No single cytogenetic change is typical or diagnostic. May have either or both immunoglobulin heavy chain and T-cell receptor gamma or beta chain gene rearrangements, or may lack rearrangements.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mantle cell lymphoma, blastoid variant",
"       </td>",
"       <td>",
"        Intermediate-sized cells with dispersed chromatin, irregular nuclear contours, and scant cytoplasm with a high mitotic rate.",
"       </td>",
"       <td>",
"        Express high levels of surface IgM and IgD and express pan-B cell antigens (CD19, CD20), CD5, and FMC7. Rare cases lack CD5 or express CD23. Nuclear staining for cyclin D1 present in 95 percent of cases.",
"       </td>",
"       <td>",
"        Not seen in children. Strongly associated with t(11;14)(q13;q32).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34940=[""].join("\n");
var outline_f34_7_34940=null;
var title_f34_7_34941="Gram stain CSF 4 with answer";
var content_f34_7_34941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Group B streptococcus in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and gram-positive coccobacilli.",
"    <em>",
"     Streptococcus agalactiae",
"    </em>",
"    (group B streptococcus) grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34941=[""].join("\n");
var outline_f34_7_34941=null;
var title_f34_7_34942="Distal tibia stress fracture";
var content_f34_7_34942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stress fracture of distal tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Periosteal reaction is evident at the site of this stress fracture (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl B Fields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34942=[""].join("\n");
var outline_f34_7_34942=null;
var title_f34_7_34943="Frank breech presentation";
var content_f34_7_34943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frank breech presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 479px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both hips are flexed and both knees are extended.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_7_34943=[""].join("\n");
var outline_f34_7_34943=null;
